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Skin cancer comprises different entities and is generally divided in two groups: melanoma and non-
melanoma skin cancer (NMSC). Malignant melanoma arises from melanocytes and is the most 
aggressive type. Basal- and squamous cell carcinomas are the majority of non-melanoma skin cancers 
and originate from keratinocytes. Other more rare NMSC are among others Merkel cell carcinoma, 
Kaposi sarcoma and cutaneous T- and B-cell lymphomas. When reference is made to skin cancer in 
this thesis, these three most common forms of skin cancer are referred to: malignant melanoma 
(MM), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC).  
Epidemiology 
Skin cancer epidemic 
In 2013, melanoma represented 1.8% of all new cancer diagnoses and 0.7% of all cancer deaths 
worldwide.1 Annually 272 000 new melanoma cases are diagnosed. The crude incidence rates of MM 
and NMSC however strongly depends on the latitude of the geographic location and ethnicity. In 
countries at low latitude where Caucasians historically migrated, the incidence rate of MM and NMSC 
is strikingly higher (BCC and melanoma incidence in Australia respectively >1 000 and 49 per 100 000 
person-years versus Africa < 1 per 100 000 person-years).2 Melanoma is the 5th most frequent cancer 
in Australia and New Zeeland after NMSC, prostate-, colon- and breast cancer, and the 9th most 
frequent in Belgium, France and the United Kingdom. The lowest incidence rates of melanoma are 
seen in Asia (Japan, Singapore and South Korea).1  
It is well known that the incidence of melanoma and NMSC is rapidly increasing in white populations. 
Over the last 25 years the absolute number of confirmed BCC increased with 700% in the Netherlands, 
currently 1 in every 5 men and 6 women will develop a BCC for the age of 85 years.3 Melanoma 
incidence rates have tripled in Europe during the last four decades, similar to increases in the United 
States.4,5 The rising trend is argued to be a result of increased exposure to ultraviolet (UV); due to 
increased travel and outdoor activities, changes in clothing style and use of sunbeds; aging of the 
population, ozone depletion and host factors. In addition, increased surgical treatment for NMSC and 
thus histological confirmation, as well as increased registration and awareness contributes to the 
rising incidence. Lastly, perhaps also overdiagnosis contributes, as supported by the observed 
increased proportion of early melanomas. Though this last point is the subject of major debates in the 
research field today.6–8  
Skin cancer risk increases with advanced age, on the other hand melanoma affects young and middle-




cancer diagnoses worldwide, resulting in important premature mortality and morbidity.1,9 Few cancer 
registries comprehensively record data on NMSC, nonetheless a recent study in the Netherlands 
showed that in 2009 more people were diagnosed with BCC than any other type of cancer.10 
Compared to other age groups, women younger than 40 years showed the most pronounced increase 
in BCC incidence.10–12  
Belgian situation 
The cumulative incidence of developing melanoma before the age of 75 years is currently 1.3% in 
males and 1.9% in females. The mean age at diagnosis is respectively 60 and 55 years. Melanoma 
represents almost 10% of all skin cancers in Belgium. MM results in an estimated 400 deaths per 
year.13  BCC represents the majority of skin cancers (69.6%) and its cumulative incidence is estimated 
at 8.1% in Belgium. Although mortality is very low (metastasis is reported in 0,003%)14 it can cause 
significant morbidity. SCC represents 20% of the skin cancer burden and has a cumulative incidence of 
2.2% in males and exactly half in females.13 The other forms of NMSC are rare and represent less than 
1% of all skin cancers.15 MM and NMSC together are by far the most frequent diagnosed cancers in 
Belgium in males and females, before prostate- and breast cancer (Figure 1). Figure 2 illustrates the 
evolution in incidence of melanoma in Belgium from 2005-2013. In the Netherlands mortality and the 
incidence of thick melanomas increased up to 2009.16 In the rest of Europe melanoma mortality 
remained more or less stable over the last two decades.17,18 In Belgium a small increase in melanoma 















Figure 1. The ten most frequent occurring tumors in Belgium in 2012 (adapted from the Belgian Cancer registry13). BCC is the most frequent tumor 
 in males and females. SCC is the 5th most frequent diagnosed cancer. Melanoma is for both males and females in the top ten of most commonly 








Figure 2. Total number of new melanoma diagnoses annually in males and females for all ages 
(adapted from the Belgian Cancer registry13). Stages according to the AJCC 2009 classification. Stage X: 
melanoma diagnosis without information concerning the stage.  
 
 
Figure 3. Annual number of melanoma deaths in Belgium (adapted from the Belgian Cancer registry13). 
Overall a stable or slightly increasing absolute mortality is seen the last years. More males than 


















































































Ultraviolet radiation and carcinogenesis 
Ultraviolet rays are the main environmental risk factor for the development of skin cancer. The 
International Agency for Research on Cancer defined solar UV as a group 1 carcinogen in 2009.19 UV 
radiation is classified as UVA (400-315 nm), UVB (315-280 nm) or UVC (280-200 nm) based on their 
specific wavelengths.20 The sun naturally emits the full UV spectrum, however no UVC reaches the 
earth surface since the atmosphere filters out wavelengths shorter than 280 nm. UVB absorption 
mainly depends on the thickness of the ozone layer. Other factors influencing the sun UV intensity are 
the season and time of day, latitude, altitude, presence of clouds and reflection of the radiation.  
Sunbeds are artificial sources of UV radiation and emit relatively more UVA than UVB, some up to 5 
times the dose of UVA compared to maximum exposition at midday.21 Skin pigmentation following UV 
exposition is a result of pyrimidine dimers formation and increased activation of the p53 protein. 
Consequently, transcription of the pro-opiomelanocortin, endotheline-1 and other pro-inflammatory 
genes is induced. In contrary to the protective effect of a high constitutional skin type by the presence 
of eumelanin, UV induced pigmentation protects in the range of sun protection factor (SPF) 2. UV 
induced pigmentation is only present following DNA damage (i.e. formation of pyrimidine dimers).22  
A p53 mutation has a key role in tumor initiation in the majority of sporadic BCC.23 Loss-of-function 
mutations in the patched gene (PTCH) and smoothened genes are a cause of hereditary predisposition 
i  patie ts ith e oid asal ell ar i o a Gorli s  s dro e a d sporadi  BCCs.24 In cutaneous 
melanoma the BRAF gene is most frequently mutated (50–70%),25 and part of the familial melanomas 
are characterized by a CDKN2A mutation.26 The genetic predisposition accounts for 10% of melanoma 
cases.27 Exposure to UV light is a well-established risk factor for the development of cutaneous 
melanoma by direct DNA damage or epigenetic events.28 In SCC an UV induced p53 mutation is also a 
key factor, in addition to a viral induced carcinogenesis caused by human papilloma virus (HPV).29 
Risk factors 
UVA and UVB exposure is associated with the development of skin cancer; however the pattern of 
exposure is different for the type of skin cancer. Based on epidemiological data, it seems that short 
intense periods of sun exposure early in life increases the risk for developing subsequent melanoma.30 
Some postulate that chronic UV exposure could have a protective effect.31–33 In case of BCC the 
associated risk ratio for chronic UV is fairly low, and seems to be associated with acute sunburns and 
intermittent sun exposure.33–36 SCC is related to chronic and cumulative UV exposure.33,33,37 Table 1 




Awareness for UV radiation and carcinogenicity has increased exponentially the last 20 years. An 
exposure limit has been defined by the International Commission on Non-Ionizing Radiation Protection 
of maximum 30 J/m² or 0.3 of the standard erythemal dose daily.38 Occupational UV radiation is 
acknowledged as a hazard for the development of NMSC (odds ratio (OR) SCC 1.77 (1.40–2.22) and OR 
BCC 1.43 (1.23-1.66)).39,40 A French outdoor worker population has a yearly median exposure dose 
between 77 kJ/m² and 116 kJ/m², depending on the body site.41 Road workers, construction workers 
and gardeners were most exposed. In Germany, SCC and multiple actinic keratoses (AK) of the skin 
caused by natural UV radiation was recently classified as an occupational disease.42 In Denmark and 
France, skin cancer is acknowledged as work-related, though no financial compensation has been 
provided for these patients up to now.43 
 
Table 1. Risk factors associated with the development of malignant melanoma, basal cell carcinoma 
and squamous cell carcinoma 
  MM BCC SCC 
Intrinsic Male gender  ++ 44,45 +++ 24,25 
 Age + ++ 44,45 +++ 46,47 
 Fitzpatrick skin type (I-II) +++ 48 +++ 49 +++ 50 
 Number of nevi +++ 51 + 52  
 Presence of atypical nevi +++ 51 +  
 Positive history of NMSC ++ 53 +++ 53 +++ 53 
 Positive history of MM +++ 54,55 +++ 55,56 ++ 55,56 
 Genetic predisposition +++ +++ 57 +++ 58 
External Actinic keratoses + 59 +++ + 
 Smoking   ++60 
 Ionizing radiation  ++ 61,62 ++ 61,62 
 Human papilloma virus (HPV)   + 63 
 Immunesupression + 64 ++ 65–67 +++ 68–70 
UV exposure33 Total  (cumulative) + + +++ 
 Non-occupational or intermittent ++ ++ + 
 Acute ++ ++  
Categorized relative risks; + relative risk of 1.0 -1.4, ++ relative risk of 1.5-5.0, +++ relative risk > 5.0.  








Melanoma frequently presents as a pigmented skin lesion with brown, red to grey color variation. On 
the other hand, some melanomas have complete absence of pigment. The ABCD rule (asymmetry, 
irregular border, color variation and diameter) can aid the diagnosis. BCC has no precursor lesion and 
presents as a small grayish or skin-colored nodule or induration with telangiectases. SCC develops 
mainly on chronically UV-exposed skin such as the face, ears, lower lip and back of the hand. They 
have a wide clinical variety and can present as indurated, hyperkeratotic papules, plaques, or nodules 
with or without ulceration.  
Dermoscopy 
This technique is used for the clinical diagnosis of skin cancer, and has shown to significantly increase 
the diagnostic accuracy for skin cancer detection in experienced users. A meta-analysis demonstrated 
an overall improvement in diagnostic accuracy for MM of 49% compared to naked-eye examination 
(NEE).71 In case of NMSC, the diagnostic accuracy increased from 84% up to 91%, and from 58% to 
84% for BCC in specific.72,73 Dermoscopy is a non-invasive magnifying optical tool that visualizes 
several structures correlated to the histopathology of the lesion. Over 200 dermoscopic structures 
have currently been described. These are not visible to the naked eye, since dermoscopy inhibits the 
light reflection in the stratum corneum using liquid immersion (non-polarized dermoscopy) or light 
polarization (polarized dermoscopy, Figure 4).  
 
Figure 4. Polarized dermoscopic images of a melanoma in situ (left panel) and basal cell carcinoma 








A melanoma in situ is located intra-epidermal. In case atypical melanocytes are growing trough the 
basal membrane into the dermis the diagnosis of an invasive melanoma is made (Figure 5). A radial 
and vertical growth phase can be identified during this process. Breslow thickness is used to express 
the extend of invasion of atypical melanocytes. In addition, the presence of microscopic ulceration and 
the mitotic index are important prognostic factors (Table 2). Superficial spreading melanoma, nodular 
melanoma, lentigo maligna and acral lentiginous melanoma are the 4 major types.  
Basal cell carcinoma  
BCC is a slow growing tumor arising from the basal layer of the epidermis or the pilosebaceous adnexa 
(Figure 5). BCC is most frequently on sun exposed body areas such as the head, neck, lower arms and 
back, but can occur anywhere on the skin that contains hair follicles.3 BCC has no clear clinical 
precursor lesion, in contrast to SCC.  A range of variants have been identified according to the growth 
and pigmentation pattern. Histology most often shows large globules of basaloid cells confined to the 
dermis, or tumor cells infiltrating in to the subcutis in case of infiltrating BCC. The World Health 
Organization (WHO) proposed a histologic classification in 2006 consisting of 8 types 74: 
I. Superficial basal cell carcinoma, 
II. Nodular basal cell carcinoma (solid, adenoid and cystic), 
III. Micronodular basal cell carcinoma, 
IV. Infiltrating basal cell carcinoma (non-sclerosing, sclerosing), 
V. Fibroepithelial basal cell carcinoma, 
VI. Basal cell carcinoma with adnexal differentiation (follicular, apocrine, eccrine), 
VII. Basosquamous carcinoma, 
VIII. Keratotic basal cell carcinoma. 
 
Squamous cell carcinoma 
Actinic keratoses are intraepithelial lesions that occur on chronic UV-exposed areas. Morbus Bowen 
and AK can be a precursor lesion of invasive SCC with a transition probabilities for AK ranging from 
0.06% to 16%.75–77 Actinic keratoses are seen as a marker of UV exposure and significantly increase the 
lifetime risk of developing a SCC, BCC and MM (Table 1).78 The tumor cells in well-differentiated SCC, 




Keratinocytic skin tumors are classified according to the WHO in 6 histologic subtypes74: 
I. Acantholytic squamous cell carcinoma, 
II. Spindle-cell squamous cell carcinoma, 
III. Verrucous squamous cell carcinoma, 
IV. Pseudovascular squamous cell carcinoma, 
V. Adenosquamous squamous cell carcinoma, 













The staging of malignant melanoma and SCC is based on the TNM staging categories according to the 
American Joint Committee on Cancer (AJCC) classification. These comprise the main prognostic factors 
and are tabulated below. Because of the low metastatic potential of BCC the tumor-node-metastasis 
(TNM) classification is less applicable in daily practice to determine prognosis and treatment. The 
National Comprehensive Cancer Network proposed a clinically relevant classification to determine the 
risk for recurrence of BCC.79 The factors described below comprise a lower risk. Lesions located on the 
central face, especially around the eyes, nose, lips and ears, are at higher risk of recurrence, this is also 
denoted as the H-zone. 
Location and size: 
I. < 6 mm in diameter in high-risk areas (facial H-zone) 
II. < 10 mm in diameter in other areas of the head and neck 
III. < 20 mm in diameter in all other areas (excluding hands and feet) 
Histology:  
I. Nodular or superficial histopathologic growth pattern  
II. Absence of perineural invasion 
Others:  
I. Primary BCC 
II. Well-defined clinical borders 
III. No history of radiation therapy at site 
IV. Immune competent patient 
 
In the Netherlands, the Rotterdam criteria for high risk BCC proposed by Flohil et al. in 2012 include 
indistinct clinical margins, aggressive histopathological subtype (e.g. sclerosing and morpheaform), 













Table 2. TNM staging categories for cutaneous melanoma according to the AJCC classification 2009 
T Tumor thickness Other prognostic parameters 
Tis  Melanoma in situ, no tumor invasion  Tis  
T1  1.00 mm  a: without ulceration, mitotic rate 
< 1/mm2 
: ith ul eratio  or itoti  rate  
1/mm2 
T2  1.01-2.00 mm  a: without ulceration  
b: with ulceration  
T3  2.01-4.00 mm  a: without ulceration  
b: with ulceration  
T4  > 4.00 mm  a: without ulceration  
b: with ulceration  
N  Number of metastatic nodes Extent of lymph node metastases  
N0 0 NA 
N1  1  a: micrometastasis1 
b: macrometastasis2 
N2  2-3  a: nodal micrometastasis  
b: nodal macrometastasis  
c: satellites or in-transit 
metastases without metastatic 
regional lymph nodes  
N3 > 4 LN, or matted lymph nodes or satellites or in-
transit metastases with metastatic regional 
lymph nodes 
 
M  Type of distant metastasis  Serum LDH  
M0 No distant metastasis NA 
M1a  Metastases in distant skin, subcutis or lymph 
nodes beyond the regional lymph nodes  
Normal  
M1b  Lung metastases Normal  
M1c  Distant metastases at other site or distant 




NA, not applicable. LDH, lactate dehydrogenase.1 Diagnosed after sentinel lymph node biopsy.2 









Table 3. Clinical stages for cutaneous melanoma according to the AJCC classification 2009 
Clinical 
stages 
T  N  M  Pathological 
stages 
T  N  M  
Stage 0 Tis N0 M0 Stage 0 Tis N0 M0 
Stage IA T1a N0 M0 Stage IA T1a N0 M0 
Stage IB T1b N0 M0 Stage IB T1b N0 M0 
 T2a N0 M0  T2a N0 M0 
Stage IIA T2b N0 M0 Stage IIA T2b N0 M0 
 T3a N0 M0  T3a N0 M0 
Stage IIB T3b N0 M0 Stage IIB T3b N0 M0 
 T4a N0 M0  T4a N0 M0 
Stage IIC T4b N0 M0 Stage IIC T4b N0 M0 
Stage III Any T N > N0 M0 Stage IIIA T1-4a N1a M0 
     T1-4a N2a M0 
    Stage IIIB T1-4b N1a M0 
     T1-4b N2a M0 
     T1-4a N1b M0 
     T1-4a N2b M0 
     T1-4a N2c M0 
    Stage IIIC T1-4b N1b M0 
     T1-4b N2b M0 
     T1-4b N2c M0 
     Any T N3 M0 














Table 4. TNM staging categories for cutaneous SCC according to the AJCC classification 2010 
Classification  
T Tumor  
TX  Primary tumor cannot be assessed  
T0  No evidence of primary tumor  
Tis  Carcinoma in situ  
T1  Tu or    i  greatest di e sio  with < 2 high-risk features 
T2  Tumor > 2 cm or a  size ith   high-risk features 
T3  Tumor with invasion of maxilla, mandible, orbit, or temporal bone 
T4  Tumor with invasion of skeleton or perineural invasion of skull base 
High risk features  
Depth/invasion >  2 mm thickness 
Clark le el  IV 
Perineural invasion 
Anatomic location Primary site ear 
Primary site hair-bearing lip 
Differentiation Poorly differentiated or undifferentiated 
N Lymph nodes  
NX  Regional lymph nodes cannot be assessed  
N0  No regional lymph node metastasis  
N1  Regional lymph node metastasis a single ipsilateral lymph node,  3 cm  
N2 a: metastasis in a single ipsilateral lymph node, > 3 cm but  6 cm;  
b: multiple ipsilateral lymph nodes  6 cm;  
c: bilateral or contralateral lymph nodes  6 cm 
N3 Metastasis in a lymph node > 6 cm 
M  Distant metastasis  
MX  Distant metastasis cannot be assessed  
M0  No distant metastasis present  
M1  Distant metastasis present  
MX  Distant metastasis cannot be assessed  










Table 5. Clinical stages for cutaneous SCC according to the AJCC classification 2010 
Clinical stages  T  N  M  
Stage 0  Tis  N0  M0  
Stage I  T1  N0  M0  
Stage II T2  N0 M0 












Stage IV  T1 N2 M0 
T2 N2 M0 
T3 N2 M0 
Any T N3 M0 
T4 Any N M0 
Any T Any N M1 
 
Prognosis 
Melanoma stage and gender influence the overall survival significantly. Men have a significant higher 
mortality rate than females. The 5-year survival rate is 90% in case of stage I disease but decreases to 
40% in case of regional disease (stage III) and only around 10% when metastases are present. In that 
case the median survival is around 9 months.81 
The relative survival rates of basal cell carcinoma are excellent since BCC grows slow and is mainly 
locally invasive. This however causes significant morbidity and disfigurement. Metastases are very rare 
and the prevalence ranges between 0.0028%-0.55% based on published cases.14,82 The 5-year survival 
rate for a primary cutaneous SCC is over 90%,83 and the yearly overall mortality rate is estimated to be 
less than 4%.84,85 Rates of metastasis from primary SCC are reported to be around 2-5%, and the risk is 
significantly correlated to tumor size and depth.85–87  
Treatment  
Melanoma 
The primary melanoma is excised with a 2 mm standard margin and the diagnosis is confirmed 
histologically. In addition a total body examination looking for a second primary melanoma and 
cutaneous or nodal metastases must be performed. The Belgian Association for Dermato-Oncology 
(BADO) recommends a local wide excision if there is no evidence for metastasis.88 The margin is based 




itoti  rate  / 2 is present (pT1b or more) a sentinel node biopsy can be performed at the same 
time. If in-transit metastases are present or lymph nodes are invaded the patient is diagnosed with 
stage III melanoma and should be surgically treated with complete lymph node dissection. Adjuvant 
treatment with interferon-alpha has shown to improve relapse free survival.89 Metastatic melanoma 
(stage IV) has a 5-year survival rate of around 10% and is still considered as incurable. Four main 
treatment approaches are currently available: chemotherapy (dacarbazine), radiation therapy, 
targeted therapies (BRAF, MEK and c-KIT inhibitors) and immune therapies targeting CTLA4 and PD-1. 
Although some argue that dacarbazine has no clear role in treatment of metastatic melanoma since 
the development of the newer treatments. In addition it never achieved a significant survival benefit 
in stage IV melanoma patients.90  
Basal cell carcinoma  
A variety of treatment options are available for basal cell carcinoma, and these are reviewed in extend 
by Telfer et al.91 The most important factors influencing treatment choice and efficacy are tumor size 
(>2 cm versus 2 cm), primary or recurrent BCC, histologic subtype, and the tumor location (low-risk 
or high-risk site for recurrence). Surgery is considered the main treatment option and standard 
excision has a 5-year recurrence rate of only 2-10% for primary BCC.92–96 A margin of 3-5 mm is 
recommended depending on the presence of risk features (size > 10 mm, recurrent or infiltrative 
BCC).97 Mohs micrographic surgery with microscopic margin control during surgery is only indicated 
for high risk BCC in the facial area, since it is labor intensive and has a higher cost. The 5-year cure rate 
is up to 100%.98 Non-surgical treatments (imiquimod, 5-fluorouracil,  photodynamic therapy (PDT)) are 
indicated for low-risk superficial BCC. Destructive techniques such as curettage and cautery, 
cryosurgery and carbon dioxide laser have varying effectiveness and only low quality evidence is 
available. Recurrent (non radiation induced) BCC or patients not indicated for surgery can be treated 
with radiation therapy. The small-molecule inhibitor of Smoothened (SMO) receptor, vismodegib is a 
new treatment option for metastatic or locally advanced disease not amenable to surgery or 
radiotherapy. 
Squamous cell carcinoma  
Several treatment options are available for SCC, depending on the risk factors of loco-regional 
recurrence or the risk for lymph node involvement of metastases. These include standard surgical 
excision or Mohs surgery, radiation therapy, topical therapy  (5-fluorouracil or imiquimod) and PDT. 
However, systematic reviews could not retrieve enough high quality evidence for general conclusions 
about the comparative effectiveness of the available treatments.99–101 In case of aggressive or nodal 




nodal disease.102,103 Systemic chemotherapy or monoclonal antibodies that target the epidermal 
growth factor receptor (EGFR) are indicated for patients with distant metastases or locally advanced 
disease that cannot be managed with surgery or radiation.104–109 
Follow-up  
Follow-up is necessary for all types of skin cancer mainly for two reasons: to detect disease 
progression or recurrence early, and to detect subsequent primary lesions. For NMSC no international 
evidence-based consensus exists concerning their follow-up. The latest European guidelines propose 
that ideally all patients presenting with BCC should be offered a lifelong follow-up yearly. Since this is 
not feasible for all public health care systems, follow-up every 6-12 months for 3-5 years is 
recommended especially for patients at high risk for recurrences or had recurrent BCC, and patients 
with multiple BCC.110 In Belgium, an initial 6 monthly follow-up the first 3-5 years and afterwards a 
yearly check-up is standard. The same schedule is followed for local SCC in healthy patients, however a 
recent study showed that patients with high risk for metastases (depending on tumor thickness, 
immunosuppression, localization at the ear and large horizontal size) should be evaluated every 3 or 4 
months for 4 years by clinical investigation and ultrasound of the regional lymph nodes.86 For 
melanoma the follow-up also differs between countries, and the Belgian Association of Dermato-
Oncology proposed the guidelines below (Table 6).88 In stage I and II melanoma the main purpose is to 
detect loco-regional recurrence, and depending on Breslow thickness, clinical examination or 
radiologic imaging is suggested. In stage III melanoma ultrasound and radiologic follow-up is suggested 
the first years to detect distant metastases. It is uncertain whether the intense follow-up schedule for 
stage I melanoma produces any survival benefit, in addition, it results in a significant cost.111 Leiter et 
al. concluded that the follow-up visits for stage IA melanoma can be yearly, based on the hazard rates 
for recurrent and secondary melanoma of a large cohort of 33 384 melanoma patients.112 These 











Table 6. Follow-up of melanoma according to the BADO guidelines 
 Stage IA Stage IB Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IIIC 
Year 1-2        



























Year 3-5        

























Year > 5        


































PREVENTIVE LANDSCAPE   
Preventive medicine can be organized at three levels (Figure 6). Primary prevention is addressed to 
healthy individuals with the goal of preventing or reducing the risk of skin cancer. Secondary 
prevention aims at individuals in preclinical or early stage with the goal of detecting lesions early and 
ameliorating the outcome of the disease. Secondary prevention involves screening and early detection 
methods. Primary and secondary prevention strategies can be aimed at the entire population, or 
specific risk groups. The individual often does not have any impairment at the time of the intervention, 
in contrary to tertiary prevention, that is addressed at diagnosed patients where therapy is given to 
prevent local relapses, invasion and metastasis.114  
 
 
Figure 6.  Different levels of preventive medicine, early detection and screening.  
 
The WHO defined a set of criteria in 2008,115 based on the criteria of Wilson and Jungner116 to address 
the question whether a healthcare problem is amenable for early detection. These are summarized 
below. First of all the disease has to be an important health care problem, its natural history is known 
and there has to be a safe, simple and inexpensive screening test that is acceptable to the population. 
In addition there should be a treatment for early disease that is more effective than treatment for 
later disease and all means for diagnosis and treatment should be available. In Flanders, a specific 
committee named Vlaamse Werkgroep Bevolkingsonderzoek , authorizes population-based screening 
and advises on this subject based on a set of criteria.117 These state that the expected health benefits 
to the target group as a result of the screening should be scientifically substantiated, the effectiveness 
of the screening is justified in a context that is relevant for Flanders, the screening should reach all 
individuals of the target group and provide them the opportunity to participate, and that it is shown 




or other actions resulting from the screening. In addition, the committee advises in name of the 
Flemish government on the choice of the screening tool and the definition of the target group.  
 
The ten WHO criteria for early detection and screening:  
I. The disease should be an important health problem 
II. A generally acceptable method of treatment must be available 
III. The policy for treatment must be clear 
IV. Provision for diagnosis and treatment must be available 
V. The disease must have a detectable latent stage 
VI. A suitable screening method must be available  
VII. The screening method must be accepted by the target population  
VIII. The natural course of the disease must be known 
IX. The program is cost-effective 



















For any health care intervention it is crucial to examine not only the efficacy (=produce beneficial 
effect under ideal circumstances) and effectiveness (=produce beneficial effect in daily practice) but 
also the cost-effectiveness: measuring the effect of the intervention in relation to its costs.118 Health 
economic research and cost-effectiveness studies have the main objective to adequately allocate the 
available financial means in order to gain as much health as possible.119 The benefit that is produced 
can be expressed as quality of life (QOL) by influencing morbidity and mortality in individuals and also 
the population as a whole. 
Health costs 
The perspective that will be applied in an economic study is important since it will determine which 
costs and effects of the intervention will be taken in account. It is recommended to analyze from the 
societal perspective, which is the most comprehensive. This includes the direct health care costs to 
the government and patients, as well as direct non-health care costs and costs due to productivity loss 
(= indirect non-health care costs). The KCE report for Belgian health economic (HE) evaluations states 
that direct medical costs paid by the federal go er e t s a d the o u ities  health are udget, 
as ell as the patie ts  o-payments need to be included in the basic analyses . This is the perspective 
of the health care payer.120 A broader perspective can be applied, but needs to be differentiated from 
the reference case. Table 7 summarizes the different types of costs to include in HE assessments (non-
exhaustive list of examples).   
 
Table 7. Health care costs in HE assessments (adapted from the KCE report120) 
 Health care costs Non-health care costs 
Direct Medications 
Hospitalizations 
Medical services, including procedures 









To have an indicator for the health gain of a specific intervention or health state, several units have 




years in responder group. However these units focus on numeric life years or days gained, not on the 
life quality added to the years. In other words a unit combining quantity of the years gained with the 
QOL experienced in these years is more accurate. For this reason the disability-adjusted life years 
(DALY) and quality-adjusted life years (QALY) measures were developed. The KCE recommends 
reporting all outcomes using the QALY measure,121 for this reason the following text focuses solely on 
the latter.   
The QALY, developed in 1976 is frequently used in HE assessments since it combines QOL of life and 
the quantity in one concept. To determine the QALYs, an index to determine the health related QOL 
(HRQOL) needs to be calculated (Y-axis, between 0 and 1). One would mean perfect health and 0 
represents death. This number, ranging from 0 to 1 is called the utility. The x-axis would represent the 
time (in years) that a person spent at that level of QOL (or utility). The area under the curve would 
then represent the number of QALYs. For example, a patient receiving standard care lives 10 years at 
an HRQOL index of 0.7. This would mean a total of 7 QALYs are achieved. In contrast a new treatment 
that ameliorates the patients QOL to an index of 0.8 during those same 10 years, would produce 8 
QALYs. A gain of health effect corresponding to 1 QALY could thus be produced. One could however 
also gain health by increasing the life expectancy of the patients, or both HRQOL and life expectancy. 
In reality however the level of the index value is not constant. Figure 7 represents a situation that is  
closer to daily practice.  
 
 
Figure 7. QALY concept explained, an index 1 value indicates perfect health and 0 represents death. 
The x-axis represents the time in years that a person spent at that level of utility index. The area under 





To generate these HRQOL indexes or utilities, different techniques and tools can be used. The 
EuroQOL 5 dimensions questionnaire (EQ-5D) and health utilities index are the most frequently used 
generic instruments that provide utilities. Some other methods are: the short form health health 
survey (SF-36), the WHO quality of life assessment, short form-6 dimension questionnaire or visual 
analogue scales. The international and Belgian guidelines encourage the use of the EQ-5D since this is 
a useful instrument in a broad range of health problems.120,122 In addition an EQ-5D valuation set is 
available for Belgium.59 Although it has to be noted that the EQ-5D may sometimes be less sensitive to 
pick up certain subtle changes in contrast to a disease-specific instrument. In the case of skin cancer 
however no validated disease specific instrument is available.  
The EQ-5D is a European questionnaire asking patients about five domains; mobility, self-care, daily 
activities, pain or discomfort and anxiety or depression.124 A 3 and 5 level multiple choice answer is 
available, respectively EQ-5D-3L and EQ-5D-5L. Based on the answer profile of the patient the utility 
can be designated according to the value sets provided by the EuroQOL. It is important to realize that 
these value sets are dependent on the patie ts  country, since the relative weight given to certain life 
dimensions (for example mobility) is culturally determined. A VAS can be incorporated at the end of 
the questionnaire, in order to score their general wellbeing. This is a scale from 0 (meaning the worst 
possible health one can imagine) to 100 (best possible health one can imagine). This can be used in 
addition to the time trade-off or standard gamble method for valuing HRQOL weights.125 
Incremental cost-effectiveness ratio and threshold  
Cost-effectiveness analyses produce a central outcome that is called the incremental cost-
effectiveness ratio (ICER). It expresses a cost per QALY gained, and is calculated as follow:  
 
ICER= 
Total costs (new intervention) - Total costs (current standard) 
QALY (new intervention) – QALY (current standard) 
 
When comparing two medical interventions based on the costs and effects 4 possible scenarios can 
occur. These are illustrated according to the cost-effectiveness plane (Figure 8). The current standard 
(or comparator) is located in the center, the x-axis denotes the incremental effect and the y-axis the 
incremental cost. In case the new intervention is more effective and less costly (situation A), this 




(situation D) than the current standard, is not cost-effective and will be excluded. When the new 
intervention however is less costly and less effective (situation C) one could debate about its 
acceptance, especially when the new intervention is only a bit less effective and costs significantly less. 
In most cases the new intervention will be located in plane B of this figure and a threshold for cost-




Figure 8. The cost-effectiveness plane. When comparing two medical interventions based on the costs 
and effects 4 scenarios can occur (A, B, C or D). The current standard (or comparator) is located in the 
center (white dot).  
 
The threshold at which an intervention should be considered as cost-effective is dependent on the 
gross domestic product (GDP) per capita according to the WHO.126 If the ICER is below the GDP per 
capita, it is assumed to be very cost-effective; in case of 1-3 x GDP per capita, it is cost-effective; and in 
case it exceeds 3 x GDP per capita the new intervention is considered not to be cost-effective. The 
gross do esti  produ t at urre t pri es per head of populatio  for Belgiu  i   as €  .127 
However in a recent KCE report it clearly states that no country uses one single ICER threshold value 




Excellence state two threshold values of £20 000 to £30 000 per QALY, and for other countries 
thresholds are deducted from previous positive or negative recommendations. ICER threshold values 
or ranges were proposed for the United States (US) ($50 000/QALY), New Zeeland (NZ$20 000/QALY), 
the Netherla ds €  /QALY  a d Ca ada CAN$   - $100 000/QALY).129–132 In general one 
could say that the probability of a new intervention being accepted is higher when having a lower 
ICER, but no exact cut-off is available to date. The reimbursement process is not seldom an interactive 
decision making process evaluating on a case-by-case basis. In addition to the ICER the budget impact 
analyses are indispensable.  
Markov modeling  
The ICER is calculated using a Markov model. This is a decision-analytic model that consists of different 
disease states.120 These are in fact all possible disease events that are representative both clinically 
and economically for the disease that need to be modeled. When defining the states one basic 
assumption is important: the patient can only be in one health state or the other. Figure 9 illustrates a 
simplified Markov model for melanoma skin cancer. The circles represent the disease states and 
arrows the different transitions with their associated probabilities (tp). At all states it is possible to die 
from a natural cause (tpND), but in case of patients diagnosed with melanoma stage IV this is added 
up to the probability of dying from melanoma stage V disease (tpDM). In addition there are different 
probabilities for melanoma progression (tpPMI, tpPMII, tpPMIII, tpPMIV). Patients can stay in the 
same health state during different cycles of the model (arrows returning), and death is called to be an 
absorbing state, of which patients are unable to leave. This figure does not completely represent 
clinical practice, and in reality the Markov Model will be more complex. For example, adding different 
health states for undetected, diagnosed melanoma (I to IV), treatment and follow-up would resemble 
current knowledge more closely, since it is possible for a patient to be diagnosed as stage II melanoma 







Figure 9. Simplified Markov model disease state for malignant melanoma. TpND: transition probability 
to natural death state; tpMD: transition probability to death as a direct result of melanoma stage IV; 
tpPMI: transition probability from stage I to II; tpPMII: transition probability from stage II to III; tpPMIII 
transition probability from stage III to IV.  
 
For every health state a utility (0-1) and cost is assigned. Depending on the patients in the state and 
the runtime of the model an ICER can be calculated when the costs and QALYs are summed over a 
large number of model cycles. Other parameters required for running the Markov model are cycle 
length (for example 6 months), time horizon (total runtime of the model), age of patients entering the 
model and of course the effect of the new intervention. In addition several general adjustments need 
to be considered. First of all it is important to include discount rates in the model for utilities and 






Discounting means recalculating future values to values at current time. In this way a net present 
value can be calculated for cost of outcomes that are adjusted for different timings of occurrence. The 
following formula is used: 
Net present value = 
Value time 
(1 + discount rate)time 
 
Since there is uncertainty around almost all variables sensitivity analyses are essential.133,134 There are 
several statistical techniques to assess the sensitivity of the ICER. Probabilistic sensitivity analysis or 
PSA  is performed by running the model a large number of times, each time selecting a random value 
in the confidence interval (CI) of the specific distribution of the input variable (for example cost, utility, 
transition probability or effect of new intervention). A scatter plot of all these Monte Carlo simulations 
is then presented in the cost-effectiveness plane around the base case ICER. Cost-effectiveness 
acceptability curves are a graphic way to illustrate the probability that a certain intervention is cost-
effective, or in other words a statistical alternative to calculate the CIs for the ICER. These probabilities 
(y-axis) are plotted for a ra ge of λ x-axis, which is the maximum acceptable threshold for the 
decision-maker). In fact this probability is simply the proportion of scatter plot points that will fall 
elo  the slope of λ dotted li e, Figure 8) in the B quadrant of the cost-effectiveness plane.135 One-
way sensitivity analyses are less complex, and illustrate the effect of variance around a single input 
variable, when all other variables remain constant. A tornado graph is used to illustrate this.  
Budget impact analyses (BIA) are important for policy makers since they estimate the net cumulative 
cost of the new intervention (including consequent care, follow-up and examinations). This outcome 
can be obtained using the disease specific Markov model.136 
Cost of illness studies 
Cost of illness studies are health economic studies only taking the cost of a specific disease in account. 
These studies give information, depending on the applied perspective, on the total cost society is 
spending on a certain disease and can demonstrate the different cost components (direct versus 
indirect, health care versus non-health care related). In addition the percentages of costs that are paid 
by the government versus these by patients are identified. Two prevalence based methods are 
described; a bottom-up and top-down protocol to calculate the total annual cost of a disease. The 
bottom-up approach estimates costs by calculating the average cost of disease state and multiplying it 
by the prevalence. In a top-down cost of illness studies the health expenditures serve as a fixed 




cost of illness studies are mainly performed to indicate areas of high expenditure, but fail to provide 
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The alarming global increase in incidence of MM and NMSC, partly due to the aging of the population 
and altered sun seeking behavior, obliges us to investigate preventive measures in this domain. Due to 
the consequent growing epidemic, the related health care costs are rising significantly. In addition to 
the augmenting direct costs, recent studies showed that young females are increasingly affected by 
skin cancer, resulting in important societal indirect costs due to productivity loss.5–7 Current opinion 
states that the health care spending is not sustainable in future, so studies with a focus on estimating 
current expenditures and innovative ways to improve cost-effective health care are needed.8 Despite 
the growing awareness of the magnitude of the skin cancer burden, the detection by visual inspection, 
and its known relation to either natural or artificial UV radiation, studies as such are rare.  
 
OUTLINES 
I. Evaluation of the current and future burden of skin cancer in Belgium 
Starting with knowledge on the exact magnitude of the health problem in terms of prevalence and 
economic burden was needed. Several studies in Australia and the United States mapped the 
expenses directed towards skin cancer, most however focusing on MM and the direct costs only.9–13 
Few European studies estimated the costs of both MM and NMSC, but were performed in Sweden, 
Germany, Denmark and the UK, and only up to 2010.14–17 No data on the current and future 
epidemiology, nor cost of skin cancer were available for Belgium.  
II. Evaluation of the cost-effectiveness of primary prevention strategies  
Primary prevention is assumed to reduce the burden of skin cancer. All cost-effectiveness studies on a 
SunSmart campaign or sunbed regulation have been performed in Australia, resulting in considerable 
cost-savings.18–21 Because of the substantial epidemiological and environmental disparities, we 
simulated the cost-effectiveness and budget impact of primary prevention, being a hypothetical UV 
protection campaign and a total ban on sunbed use in the Belgian setting.  
III. Clinical and cost-effectiveness of two skin cancer screening methods  
At this point, no evidence exists that mass population-based screening by means of whole body 
examination in asymptomatic persons is cost-effective22, although the experience in Germany suggests 
that such screening is feasible.23 Several early detection initiatives focus on MM and/or specific high 





group setting.24 The current cost-effectiveness studies performed in the United States and Australia, 
only focused on MM screening and were aimed at individuals at risk because of a positive family 
history, skin type and/or age.25,26 We examined the feasibility and effectiveness of a secondary 
prevention strategy for skin cancer in Belgium. We evaluated the clinical, as well as cost-effectiveness 
of a new lesion-directed screening method compared to a general standard total body examination.  
IV. The early detection of BCC  
Most early detection efforts focus on MM, in view of its mortality and the deduction that earlier 
detection would lead to a reduction in melanoma deaths. We questioned whether it is worthwhile to 
include BCC in a skin cancer screening in healthy individuals. In other words, whether early detection 
of BCC has a beneficial effect in terms non-survival endpoints. This matter was reviewed using the 
WHO criteria.27 
V. Effectiveness and clinical utility of dermoscopy in early detection of skin cancer  
A reliable and acceptable screening test is important when evaluating screening methods. 
Dermoscopy has been proven to increase diagnostic accuracy for melanoma over naked-eye-
examination in experienced users.28–30 On the other hand, dermoscopy is also known to be helpful in 
detecting NMSC,31–33 and in this way dermoscopy could reduce the number of unnecessary excisions. 
Although broadly used by dermatologists, the benefit of using dermoscopy in skin cancer screening, 
including NMSC has not been investigated. In addition, most of the studies examining the accuracy of 
dermoscopy are performed in a high prevalent setting with highly trained experts, which is known to 
influence accuracy of the technique.34 We examined the sensitivity, specificity and the number needed 
to excise using dermoscopy in the hands of the screening physician in a setting resembling screening 
practice.  
 
STRUCTURE OF THE DISSERTATION 
We addressed these aims systematically in the following chapters. In chapter 3, the direct and indirect 
cost of skin cancer in Belgium is described to indicate the magnitude of the problem. In addition the 
future prevalence and cost due to aging of the population were estimated. The evaluation of a primary 
prevention strategy and a ban on sunbed use is also presented in this chapter. Chapter 4 describes the 
clinical results of two skin cancer screening methods. The results concerning the cost-effectiveness of 
these secondary prevention methods, including the budget impact analyses can be found in chapter 5. 
In addition, we investigated whether the early detection of BCC could potentially be useful. We have 
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addressed this question in chapter 6. Chapter 7 describes the diagnostic accuracy of the main 
technique used for the early detection and diagnosis of skin cancer daily practice, dermoscopy. 
Chapter 8 consists of a general discussion and conclusion on the results and we end this thesis with 
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Background:  Skin  cancer  is  one  of  the  most  rapidly increasing  cancers  worldwide.  In order to 
inform policy decision makers, this study analyzed the current and future economic burden and cost-
effectiveness of primary prevention of skin cancer in Belgium.            
Methods:  A  retrospective  bottom-up  cost-of-illness  study  was  performed,  based  on  patient 
questionnaires with questions on the consumption of care,  quality of life and absenteeism. Patients 
were included from 1st March 2015 until 30th June 2015 when visiting dermatologists and  
oncologists  working  in general  and  university  hospitals,  small  (<  200  beds),  medium  (200-400  
beds)  or  big  (>  400  beds) hospitals, as well as private practices. At the end of the patient recruiting 
period, 287 completed questionnaires from Belgian skin cancer patients were received.  A  Markov  
model  with  a  latent  period  of  20  years  and  a  time horizon  of  50  years  analyzed  the  cost-
effectiveness  and  the  budget  impact  analysis  of  a  nation-wide  population-based  strategy  
promoting  UV  protective  behavior  and  a national  ban  on  sunbed use.  
Results: Information  from  these  questionnaires  was  used in the  Markov model,  analyzing  the  
health  economic  impact  of  skin  cancer  prevention in  the  Belgian  adult population (about 8.8 
million people).  The  total  economic  burden  of  skin  cancer  in  2014  in  Belgium  was estimated  at 
€107 million, with a cumulative cost of €3 billion in 2034. The majority of this total cost was due to 
melanoma (65%). Over  a  period  of  50  years,  both prevention  programs  would  lead  to  a  gain  in  
quality-adjusted  life-years  and  cost-savings,  making them  dominant  strategies. The budget impact 
analysis revealed that for every euro invested in the prevention campaign, €3.6 would be saved on the 
long-term for the health care payer. 
Conclusion:  A  nation-wide  population-based  strategy  promoting  UV  protective  behavior  and  a 
national  ban  on  sunbed  use  can lead  to a positive  health  and  economical  benefit  from  a  health 
care payer as well as societal point of view. The results from this study can aid policy makers and 












Skin cancer is increasing globally1–4, and affects nearly one out of five persons in Belgium. It is related 
to ultraviolet exposure, either naturally from the sun or artificially through solarium use.5–7 Several 
epidemiologic studies show an alarming global increase in incidence of melanoma skin cancer (MM) 
and non-melanoma skin cancer (NMSC) - defined as basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC)-, due to the increasing age of the population, but also to altered risk seeking 
behavior.1,8–11 Although NMSC is less aggressive than MM, it has an important impact on the health 
expenditures because of the high prevalence.12 Consequently to this epidemic, the related health care 
costs are rising significantly. The first objective of this study was to calculate the current and future 
health and economic burden of MM and NMSC in Belgium. The second objective was to assess the 
cost-effectiveness and budget impact of primary prevention of skin cancer, being a hypothetical 
prevention campaign and a total ban on sunbed use. 
 
METHODS 
Burden of skin cancer 
The health-related burden of skin cancer was estimated based on the registered prevalence of skin 
cancer lesions being in treatment, in intense follow-up or in long-term follow-up.13,14 The prevalence 
of undiagnosed skin cancer was calculated based on the yield of a screening trial performed in Belgium 
in 201415, divided by the sensitivity of the dermoscopy.16  In order to estimate the total economic 
burden of skin cancer on society, we conducted a bottom-up cost-of-illness study based  on  
retrospective  information  from  Belgian  patient  questionnaires  being gathered  from  1st  March  
2015  until    30th  June  2015. Dermatologists  and  oncologists  working  in general  and  university  
hospitals,  small  (<  200  beds),  medium  (200-400  beds)  or  big  (>  400  beds) hospitals, as well as 
private practices were recruited in December 2014. These physicians were asked to give  skin  cancer  
patients  the  information  about  the  study  and to  hand  out  the  questionnaires  to the  patients.  
Eligible  patients  were  those  who  were  18+,  had  a  diagnosis  of MSC, BCC  and  SCC maximum ten 
years ago and who presented to a participating physician. Patients were asked questions about their 
medical consumption for their skin disease during  the  last  six  months,  as  well  as  productivity  loss  
and  quality  of  life.  Questions  concerned  the number  of  consultations, hospitalizations, 
transportation, number  and  type  of  examinations,  drug  use,  number  of  days  absent  from work, 
informal care  and  health-related  quality  of  life  (based  on  the  EQ-5D-5L questionnaire). Based on 
the resource utilization patterns derived from these patient questionnaires for patients with MM, BCC 
or SCC and official Belgian unit costs17, we calculated the cost per skin cancer type per 6 months, 
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separately for the phases diagnosis and treatment, intense follow-up and long-term follow-up. The 
current total societal cost was calculated by multiplying the medical cost per cancer stage with 
prevalence of detected skin cancer (defined as patients in treatment as well as patients in follow-up) 
and by multiplying the cost per day absenteeism18 with the number of days absent from work due to 
skin cancer (based on the patient questionnaires). In order to calculate the future health and 
economic burden of skin cancer in Belgium, a Markov model was composed (Microsoft Excel® 2013), 
with a time horizon of 20 years. The model projected the current prevalence to 2034, taking into 
account the rising trend in incidence3,11,19. All costs were computed at the 2014 EURO price level and 
expressed separately as costs for the health care payer (i.e. government), costs for the patient (co-
payment) and costs due to productivity loss.  
Health economic evaluation of primary prevention 
A Markov state-transition cohort model was developed, examining the economic impact and the cost-
effectiveness of a sensitizing prevention campaign and a total ban on sunbed use in reference to the 
current situation. A Markov model is a type of decision model based on a series of states that a person 
can occupy at a given point in time.20 MM as well as NMSC were included in the model, consisting of a 
lesion-free state and several disease states: undiagnosed skin cancer, diagnosis & treatment, intense 
follow-up, long-term follow-up and death (Figure A1). All states were separated according to skin 
cancer stage. All cohort members started the model in one of the model states, according to the 
current prevalence of BCC, SCC and MM. Transitions between the disease states were possible every 
six months. Health effects and costs of a cohort of Belgian adult males and females were simulated 
from a societal perspective, during a time horizon of 50 years. This time horizon included an induction 
period (i.e. the period between risk factor exposure – being UV exposure or sunbed use - and the 
onset of skin cancer) of 20 years (based on expert opinion). Main outcomes of the health economic 
evaluation included the incremental cost-effectiveness ratio (ICER), the total economic societal impact 
as well as the impact on the health care budget, and the mortality reduction. The ICER was calculated 
by dividing the net costs by the net health benefits of the prevention program. In order to calculate 
the total economic burden and the budget impact over 50 years, the model allowed for annual new 
entrance of 18-year olds each cycle in the lesion-free state, who were subjected to the natural skin 
cancer progression. The same model design has been used before to estimate the cost-effectiveness 
of skin cancer screening. More information on the design of the model can be found in Pil et al.21 
 
 





Prevention campaign reducing risk of sunburn  
The hypothetical prevention campaign was defined as a comprehensive program such as the SunSmart 
campaign in Australia. SunSmart is a public education program which has been running in Australia 
(especially in the state Victoria) since 1987. The impact of a campaign on skin cancer was modeled 
through an effect on being sunburned. Published literature has shown the impact of ever being 
sunburned on the risk of MM to be preventable by means of comprehensive prevention campaigns. 
Hill et al.22 evaluated the SunSmart campaign in Australia two years after its implementation and 
found an effect on reducing sunburns by 41% (RR 0.59). The risk on developing MM was estimated to 
be 59% higher for persons ever being sunburned during lifetime in reference to those never being 
sunburned (RR 1.59; 95%CI 1.37-1.83; Table 1).23 No evidence was found for the impact of sunburns 
on SCC24 or BCC. As there is no evidence on the duration of the effect, in our analysis the prevention 
campaign was implemented annually. Based on these relative risks, a comprehensive prevention 
campaign would result in a relative risk reduction in MM of 14.2%. 
 
Table 1. Input parameters related to the impact of primary prevention on health 
Parameter Mean (SE) Source 
Prevalence of ever sunburned, Belgium 90% Expert opinion 
RR on sunburn if prevention campaign 0.59 (0.11) 22 
RR on skin cancer if ever sunburned   
MM 1.59 (0.12) 23 
SCC 1 25 
BCC 1  
Prevalence of ever used sunbed, Belgium 47% 26 
RR on skin cancer if ever used sunbed   
MM 1.25 (0.09) 27 
SCC 1.93 (0.43) 24 
BCC 1 28 
RR: Relative risk.  
 
Ban on sunbed use   
Boniol et al. found in their meta-analysis –based on 18 cohort studies- a relative risk on MM of 1.25 
(95%CI 1.09-1.43) for people who have ever versus those who have never used sunbeds (Table 1).5 
The relative risk on SCC was 1.93 and for BCC no evidence on excess risk was found.24,28,29 In this way, 
a ban on sunbed use would result in a relative risk reduction of 9.6% in MM and 27.8% in SCC. 




The comparator strategy is the situation without such a comprehensive prevention campaign and 
without a total ban on sunbed use. As our cost-effectiveness analysis is an incremental analysis, it is 
assumed that only the extra costs of the strategies evaluated are considered in the analysis. It is 
assumed that the current local fragmented initiatives would still exist in case of a national 
comprehensive prevention campaign.  
Input data 
Prevalence of diagnosed MM (excl. in situ) was derived from the Belgian cancer registry13 and of NMSC 
from the Dutch cancer registry14, since NMSC is more accurately registered in the Netherlands. A 
correction factor was applied to adapt the NMSC figures to Belgium, based on the ratio between the 
MM incidences of both countries. Prevalence of undiagnosed skin cancer derived from the screening 
trial.15 Information on the probability of natural progression can be found in Appendix I. All-cause 
mortality risk was applied to all persons in the model (based on Belgian life tables), whereas mortality 
from skin cancer was possible only for MM and SCC skin cancer patients stage III and IV.30  All 
epidemiologic and clinical input data are depicted in Table A1. The study was performed from the 
societal perspective, including direct medical costs as well as costs related to productivity loss because 
of morbidity and early mortality. Travel costs of patients were not included. The cost for the 
prevention campaign was calculated according to the study of Shih et al.31 who estimated the annual 
future cost for the SunSmart intervention to be €0.17 per capita. Applied to the Belgian population, 
this would imply a total cost for the prevention campaign of €1 525 998 per year. The possible 
associated costs of implementing a sunbed ban and financial consequences for the industry are not 
taken into account. Health effects of the primary prevention were defined as the impact on quality-
adjusted life-years (QALYs) and skin-cancer related deaths. Stage-specific QALYs were based on EQ-5D 
utilities derived from the Belgian patient questionnaires in combination with literature data (Appendix 
I + Table A2). Following Belgian guidelines, health effects were discounted at 1.5% and costs at 3%.18 
Scenario and sensitivity analysis 
In base case we assumed an induction period of 20 years. However, since the duration of this period is 
not well documented, we varied it between 10 and 30 years. A second scenario consisted of a 
combination of both a prevention campaign and a ban on public sunbed use. A one-way sensitivity 
analysis assessed the impact of variation in the key parameters one by one (according to the CI), or 
increased or decreased by 30% of their original value in case the CI was not available) in order to take 
into account uncertainty in the input variables. A probabilistic sensitivity analysis (PSA) created 
credibility intervals around the deterministic ICER by running 5 000 (Monte Carlo) simulations 




according to the distribution of the parameters. Utilities and probabilities were varied according to 
beta-distributions and costs according to a gamma-distribution. 
 
RESULTS 
Burden of skin cancer 
Sample characteristics  
In total 16 dermatologists, nine oncologists and one general practitioner, employed in 10 different 
hospitals and six private practices participated in the study. In total, we received 287 completed 
patient questionnaires in a time span of four months. Response rates were 82.8% in dermatology 
patients and 71.9% in oncology patients. The sample consisted of 56% women and 44% men. The 




Table 2. Stage distribution of study population  
  D&T Intense FU Longterm FU Total 
BCC <1cm 19 17 15 51 
BCC 1-2cm 26 10 3 39 
BCC>2cm 8 1 0 9 
BCC agressive histology 6 4 3 13 
SCC 0-I-II 7 11 10 28 
SCC III 0 2 0 2 
SCC IV 0 0 0 0 
MM 0-I 15 43 42 100 
MM II 5 7 3 15 
MM III 8 8 3 19 
MM IV 2 8 1 11 
Total 96 111 80 287 
D&T: Diagnosis and treatment, FU: follow-up. Duration D&T: BCC, SCC0-II, MM 0-I-II: 6 months (1 
cycle) SSC III-IV, MM III-IV: 1 years (2 cycles), Duration intense FU:BCC, SCC0-II, MM 0-I-II: 1.5 year (3 
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Epidemiology of skin cancer 
The model estimated the total number of skin cancers in 2014 in Belgium to be 137 117, of which the 
greatest part (70%) were BCC cases (95 871), 18.5% were SCC cases (25 345) and 11.5% were MM 
cases (15 902). There were more female than male skin cancer patients, with a ratio of 1.13 to 1. This 
current prevalence is estimated to have tripled by 2034, to 397 213 skin cancer cases, of which 66% 
BCC,  21.2% SCC and 12.8% MM.  
Cost of skin cancer 
Table 3 shows the cost per skin cancer stage, expressed per six months. As already stated in previously 
published studies32,33, it is clear from the table that costs increase with tumour stage. There were 
almost no costs due to productivity loss in NMSC patients. The total economic burden of skin cancer 
on society in 2014 in Belgium was estimated at €107 million, with direct costs being €78 million and 
indirect costs being €29 million (Table 4). The majority of this total cost was due to MM (65%). Total 
cumulative cost over a period of 20 years (up to 2034) was estimated at €3.2 billion and over 50 years 
€8 billion. The Markov model simulation over 50 years showed that of the total cumulative societal 
burden (including direct and indirect costs) of €8 billion, €228 million could be saved by a prevention 
campaign and €238 million by a total ban on sunbeds, which is respectively 2.8% and 2.9% of the total 
societal burden (Table 5). The budget impact analysis demonstrated that a prevention campaign could 
save €142 million (or 0.36%) of the health care budget (initial investment cost taken into account) and 
in case of a ban on sunbed use €167 million (or 0.42%). Every euro invested in the prevention 







Table 3.  Cost per stage per six months, separated according to phase 
  Diagnosis & treatment Intense FU Longterm FU 
  HC payer patient prod. loss HC payer patient prod. loss HC payer patient prod. loss 
BCC <1cm € 196 € 34 € 0 € 119 € 22 € 0 € 82 € 46 € 0 
BCC 1-2cm € 211 € 37 € 0 € 128 € 24 € 0 € 89 € 49 € 0 
BCC>2cm € 227 € 40 € 0 € 137 € 26 € 0 € 95 € 53 € 0 
BCC agressive hist. € 227 € 40 € 0 € 137 € 26 € 0 € 95 € 53 € 0 
SCC 0-I-II € 243 € 17 € 0 € 18 € 13 € 13 € 9 € 7 € 0 
SCC III € 1 396 € 217 € 0 € 91 € 24 € 24 € 45 € 12 € 0 
SCC IV € 1 659 € 262 € 0 € 91 € 24 € 24 € 45 € 12 € 0 
MM 0-I 
C0-I 
€ 1 891 € 161 € 2 663 € 385 € 71 € 1 872 € 231 € 41 € 26 
MM II € 2 119 € 244 € 1 213 € 318 € 60 € 1 872 € 258 € 43 € 26 
MM III € 4 737 € 200 € 6 591 € 1 082 € 72 € 11 864 € 822 € 72 € 3 401 
MM IV € 51 034 € 344 € 6 591 € 6 758 € 147 € 16 688 € 1 401 € 141 € 3 401 
Death* - - - - - - - - € 43 200 
















Table 4. Total current and future societal cost of skin cancer in Belgium (calculated with annual inflow) 
Total cost 2014 
Total 
cumulative cost  
2014-2034 
Total 
cumulative cost  
2014-2064 
  MALES FEMALES TOTAL (incl. death)     
  MM  NMSC MM NMSC MM NMSC TOTAL TOTAL TOTAL 
Health care payer € 17 574 784 € 12 791 731 € 20 289 465 € 13 983 486 € 37 864 249 € 26 775 217 € 64 639 466 € 1 909 776 064 € 5 243 814 688 
Patient € 893 220 € 5 102 829 € 1 293 760 € 5 683 730 € 2 186 979 € 10 786 559 € 12 973 539 € 341 834 700 € 993 608 874 
Productivity € 12 769 907 € 9 191 € 16 496 350 € 16 841 € 29 266 257 € 26 032 € 29 292 288 € 931 099 033 € 1 878 309 125 





Table 5. Results from the economic impact analysis showing cumulative costs over 50 years (calculated with inflow) 
 Cost of 
intervention 
Cost for health 
care payer 
Cost for patient Cost productivity 
loss 
Total cost Total extra cost 
from societal 
perspective 
Total extra cost 
from health care 
payer perspective 
Control € 0 € 5 243 814 688 € 993 608 874 € 1 878 309 125 € 8 115 732 687     
Prevention campaign € 39 219 386 € 5 062 395 121 € 987 492 778 € 1 798 897 062 € 7 888 004 347 -€ 227 728 340 -€ 142 200 181 














Table 6. Results from the cost-effectiveness analysis of primary prevention for skin cancer expressed per 1 000 persons (calculated without inflow) 
  





  males females males  females males  females males  females males  females 
No prevention strategy 18 876 20 856 € 669 861 € 977 368     
cost-saving 
Prevention campaign 18 877 20 857 € 654 587 € 959 957 1.39  1.39 -€ 15 273 -€ 17 411 
     (0.56-3.75)   (0.33-4.25) (-44 506-[-4209]) (-54 403 -[-2905]) 
Ban on sunbed use 18 881 20 862 € 649 975 € 956 984 4.81 5.94 -€ 19 886 -€ 20 384 
     (1.90 - 7.78) (2.63-8.49) (-49837 -[-6970]) (-57751 -[ -4403]) 








Health economic evaluation of primary prevention 
Impact on skin cancer mortality 
Based on the relative risks on skin cancer found in published literature (cf. supra), primary prevention 
of skin cancer would lead to a relative risk reduction in the prevalence of diagnosed SCC and MSC, by 
affecting the transition from ‘free of events’ to ‘undiagnosed lesion’. Our analysis showed that after 50 
years, the sensitizing campaign and the ban on sunbed use would lead to a reduction in the 
prevalence of diagnosed MSC stage I of 11.3% (absolute numbers: 10 954 in males and 15 053 in 
females) and 8.6% (absolute numbers: 9 491 in males and 11 335 in females) respectively. The ban on 
sunbed reduced the prevalence of SCC with 22.7% (absolute numbers: 35 934 in males and 52 565 in 
females). Due to this decrease in the prevalence of SCC and MSC, less tumors would progress to later 
stages, because of which a reduction in skin cancer mortality is to be expected. In our model, over a 
period of 50 years, 3 991 deaths were predicted to be avoided by means of an annual prevention  
campaign (1 593 in males and 2 398 in females) and 3 927 by means of a ban on public sunbed use (1 
602 in males and 2 329 in females). 
Cost-effectiveness and economic impact of primary prevention 
Table 6 shows the results of the cost-effectiveness analysis of both primary prevention programs. Both 
programs would lead to a gain in QALYs and cost-savings, making them dominant prevention 
strategies. The effect of a shorter or longer induction period was tested and showed that the strategy 
of a ban on sunbed use remained cost-saving in case of a 10 year or 30 year period. A one-way 
sensitivity analysis of both primary prevention strategies showed the most influencing parameters to 
be the utility of MM and SCC patients, the discount rate of costs and health effects, the direct cost of 
diagnosis and treatment of MM stage III-IV, the relative risk on sunburn in case of a prevention 
campaign, the relative risk on MM and SCC if sunbed use, the risk of dying from MM IV, the incidence 
of MM and the natural progression of MM (Figure A2). However, in all cases, the results remained 
cost-saving. The cost-effectiveness planes drawn based on the PSA represent all simulations (Figure 
A3). These planes show that all simulations are located in the south-east quadrant and hence are cost-










The analysis on the burden of skin cancer showed that if the rising incidence trend continues, the skin 
cancer health and economic burden in Belgium will triple in 20 years. In comparison, a recent study in 
the U.S. estimated MM incidence rates to double from 2011 to 2030.35 Tromme et al. have previously 
assessed the cost of MM treatment by means of 145 hospital bills and 253 patient questionnaires 
from one hospital (Cliniques Universitaires St-Luc).32 The cost they calculated for treatment of MM 
stage IV was lower than our result. Most probably, this has to do with the high cost of new treatment 
drugs for the management of melanoma stage IV, which were not yet used in the time Tromme et al. 
did their research. The current annual total cost for skin cancer in Belgium was estimated to be €107 
million in this study (for a population of 8.8 million Belgian adults), of which almost €65 million is to be 
paid by the health care payer (government), resulting in about 0.19% of the total health care budget in 
Belgium. The result is comparable to other European studies. A Danish study found that in 2010 direct 
skin cancer cost accounted for €33.3 million or 0.2% of the Danish health care budget.36 However, this 
study was performed some years ago, not yet taking into account the recent more expensive 
therapies to treat metastatic MM. According to our results, MM was responsible for 65% of the 
medical costs, in contrast to a study examining the hospitalization costs of skin cancer in Germany.12 
The latter study concluded that NMSC-related costs for hospitalizations are about twice the rates of 
MM. Nonetheless, in other studies the proportion of cost due to MM was similar to the Belgian 
proportion (resp. 68.7% and 59%, although the latter only included direct costs).36,37 However, since 
only the first NMSC is registered in the epidemiologic data from the Dutch cancer registry (IKNL), it is 
expected that the estimated total economic burden of skin cancer is an underestimation of the real 
cost of skin cancer. Projections to 2034 showed an estimated cumulative cost of €3.2 billion. To 
compare, in England a projection from 2008 to 2020 showed almost a doubling in the annual cost of 
skin cancer (106.4 pound to 190.5 pound).38  
The results at hand showed that an on average €155 million of the health care budget could be 
redirected to other diseases by implementing a skin cancer prevention campaign or a ban on sun beds 
in Belgium. Although a total ban on sunbed use would gain more health benefits, both interventions 
are cost-saving on the long term and thus dominant. A major challenge is to create the desired altered 
behavior by implementing a prevention campaign. Consequently, a total ban on sunbed use could be a 
relatively more easy way to achieve a specific behavior. The extra costs for the individuals as a 
consequence of the prevention campaign, such as extra sunscreen and sun-protecting clothing was 
not included in our model, since we do not have accurate information on these costs in the control 
group (i.e. without intervention). The sensitivity analysis revealed that the higher the medical costs of 
treating metastatic MM, the more cost-effective prevention would be, since the financial benefit of 




prevention would be higher. Recently, new expensive treatments for metastatic MM were introduced 
and it is expected that in the future treatment costs will continue to rise, which further favors 
preventive strategies for MM.  
Gordon & Rowell included seven studies in their review of the cost-effectiveness of primary 
prevention.39 Although all studies had different designs and context, they concluded that skin cancer 
primary prevention programs or policies are consistently cost-effective and may even be cost-saving 
for governments in the near future. A cost-effectiveness evaluation of the Australian SunSmart 
program demonstrated to reduce the burden of disease and to be highly cost-effective. Shih et al.31 
calculated a return of 2.3 AUD (= €1.5) for every dollar (AUD) invested in the campaign. In our study 
we estimated the return on investment to be €3.6.  
Some limitations of our analysis should be acknowledged. First, since for some skin cancer stages the 
sample of returned patient questionnaires was too small, we had to rely on expert opinions and 
literature data to calculate the medical costs for these groups. In addition, we cannot exclude a degree 
of selection bias, since sampling of the skin cancer patients was performed by the participating 
physicians. The indirect costs were derived from the small sample data and could therefore be partly 
biased. However, the prevention strategies remained cost-saving even without inclusion of 
productivity loss. Second, the simulation of the primary prevention programs is hypothetical; a trial-
based analysis may be beneficial. Therefore, we deduced the effect of a prevention campaign from the 
Australian SunSmart program. However, it is not known if such a campaign would have a similar effect 
on reduction of the relative risk of sunburn in Belgium. A German study evaluating the effectiveness of 
skin cancer information campaigns during the last 16 years found a relative risk of 0.68 for the risk on 
sunburn, which is lower than the relative risk in case of the SunSmart campaign in Australia.40 
However, the sensitivity analysis acknowledged this uncertainty and showed that the intervention 
would still be cost-saving in case of a lower effectiveness. Third, in Belgium there is no accurate 
registration of NMSC. Therefore, we relied on epidemiologic figures of the Dutch cancer registry, 
adjusted to Belgium. Lastly, knowledge on the natural history and progression of MM and NMSC is 
limited. Therefore, in our model, the natural progression was estimated based on calibration. For 
methodological reasons transition probabilities were assumed to be equal for all ages and gender, 









This analysis provides an accurate estimation of the current and future impact of skin cancer in 
Belgium and demonstrates that a nation-wide population-based strategy promoting UV protective 
behavior and a national ban on the use of sunbeds can lead to a positive health and economical 
benefit from a health care payer as well as societal point of view. The results from this study can aid 
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Background:  Skin cancer is at present the most frequent cancer type. The question remains if and how 
screening programs can be organized in a cost-effective manner.  Two screening strategies (systematic 
total body examination (TBE) and lesion-directed screening (LDS)) were compared as to their 
participation rate, effectiveness, adverse effects and costs.  
Methods: Population-based cross-sectional screenings by a team of 6 dermatologists were organized 
in two socio-demographically similar regions. The first population received a personal invitation for a 
standard TBE. In the second population people were invited for a LDS, if they had a lesion meeting one 
or more of the criteria listed: ABCD rule, ugly duckling sign, new lesion since more than 4 weeks, red 
non-healing lesions. The TBE was organized in a community of 9325 inhabitants older than 18 years 
(Wichelen, East Flanders, Belgium) during a five-day screening (March 2014). The LDS was organized in 
a socio-demographically comparable community (Nevele, East Flanders, Belgium) of 9484 adult 
inhabitants during a four-day screening (April 2014). 
Results: In total 1982 persons were screened and 47 (2.4%) skin cancers were confirmed histologically 
(0.45% melanoma, 1.9% basal cell carcinoma, 0.05% squamous cell or Bowen). The positive predictive 
value for all suspicious lesions was 56.6%. Participation rate was higher in the TBE group compared to 
the LDS group (17.9% versus 3.3%, P=<0.01). Detection rate did not differ significantly between the 
two groups per 100 participants (2.3 TBE versus 3.2 LDS, P=0.40). The diagnostic yield per 100 invitees 
for TBE was 0.42 and 0.08 for the LDS method (P<0.01).  LDS was 5.6 times less time-consuming than 
TBE. Participants in the LDS group had a significant higher baseline anxiety compared to the TBE group 
(3.7 versus 3.3 points, P<0.01). In screenees without a suspicious lesion anxiety significantly declined 
after screening. 
Conclusion: TBE yielded a higher absolute number of skin cancers, LDS has similar detection rate 
(3.2%) but was 5.6 times less time consuming. LDS by dermatologists can be an alternative screening 












The incidence of melanoma and non-melanoma skin cancer (NMSC) has been rising dramatically 
worldwide, and this increase is expected to continue with aging of the population.1 2 The cumulative 
lifetime risk of developing a basal cell carcinoma (BCC) is being estimated as high as 1 in 5 to 6 in the 
Netherlands.3 In the United Kingdom (UK), the lifetime risk of developing malignant melanoma is 1 in 
55 for men and 1 in 56 for women (UK cancer registry, Statistical Information Team at Cancer 
Research UK, 2012). Early detection is assumed to result in better cure rates and subsequently a more 
cost-effective treatment.4 5 Since skin examination is a simple, non-invasive technique, several early 
detection initiatives exist of which most focus on melanoma only. However, the majority of skin 
cancers are NMSC and these constitute the most important direct cost to public health.6-8 Mass 
population-based screening by means of total-body examination (TBE) in asymptomatic persons has 
not been proven cost-effective at this point,9 10 although a recent experience in Germany suggests that 
such screening is feasible and can reduce skin cancer burden.4 11 Most of the screening initiatives focus 
on specific high-risk groups,12-14 missing the great deal of skin cancers that occur outside this high-risk 
group setting. A reliable and acceptable test is an important tool in screening. Dermoscopy has been 
proven to increase diagnostic accuracy for melanoma over naked eye examination in experienced 
users.15 16  
As to date evidence for the cost-effectiveness of skin cancer screening by TBE is lacking, we conceived 
the idea to test a lesion-directed screening approach. As screenees can present with only a specific 
lesion of concern meeting certain pre-set criteria, we hypothesized that this technique could lower the 
threshold for screenees, increase the a priori probability of skin cancer and could be time-saving for 
the physician.  
In a pilot study evaluating lesion-directed screening (LDS) in 199 persons, a total of 25 suspicious 
lesions (12.6%) was detected and referred to the general practitioner (GP) or dermatologist for further 
care. When only the detected BCC, which can reliably be diagnosed clinically, and two histologically 
confirmed melanomas were included, this pilot study gave a detection rate of at least 8.5%. This is 10-
fold higher than the detection rate of the systematic population-based skin cancer screening program 
in the German state Schleswig-Holstein, in which 0.8% skin cancers were detected (0.5% BCC, 0.1% 
squamous cell carcinoma (SCC) and 0.2% melanoma).4 Based on estimated incidence rates in Belgium, 
the expected skin cancer yield would be less than 0.2% of the population. So screening people for 
selected lesions, meeting pre-defined criteria, could give a higher yield of relevant lesions than 
promoting a systematic whole body screening. This concept is new in the skin cancer screening world. 
Based on these data, we decided to perform a comparative effectiveness study.17  
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We compared dermatologist-conducted LDS screening to a standard TBE screening in 2 socio-
demographically similar regions with focus on participation rate, effectiveness, time and costs. As 
screening may induce unnecessary anxiety and depression,18 19 a visual analogue scale (VAS) to 
measure anxiety was included in the protocol. This is an accepted tool used in dental practice and for 
measuring fear perioperative.20 21 The VAS corresponds well to the STAI (Spielberger State-Trait 
Anxiety Inventory), a validated test quantifying anxiety.21 
 
MATERIALS AND METHODS 
Patients and screening 
Population-based cross-sectional skin cancer screenings were performed without randomization. The 
TBE was organized in a community of 9325 inhabitants (Wichelen, East Flanders, Belgium) during a 
five-day screening (March 2014). All inhabitants of 18 years and older received a personal invitation 5 
weeks in advance for a free of charge TBE, with the message that skin cancer incidence is an increasing 
health care problem.  
The LDS was organized in a comparable community in terms of genetic background, socio-economic 
status, culture and geographical area (Nevele, East Flanders, Belgium)  during a four-day screening 
(April 2014). The 9484 inhabitants where also invited by a personal letter 5 weeks in advance for a free 
of charge skin cancer check, if they had a lesion meeting one or more of the criteria listed: ABCD rule, 
ugly duckling sign, new lesion since more than 4 weeks, red non-healing lesions. A TBE was offered to 
all LDS participants at the end of the lesion screening. 
People were asked to pre-register in order to have an estimate on the number of participants and to 
organize the screening team. All aspects of the sensitization campaign and registration process were 
similar; only the specific messages given to the populations differed.  
The screenings were organized in a public place of the municipality. All participants were randomly 
allocated to one of the six dermatologists (LB, KV, KO, SDS, BB, SL) with similar expertise in skin cancer 
and dermoscopy. The screening was performed using both naked eye inspection and dermoscopy. In 
case of a suspicious lesion, a second opinion was asked to reduce inter-observer variability. Suspicious 
lesions were photographed and the patient received a referral letter for his GP or dermatologist. The 
study was approved by the Flemish government and by the medical ethical committee of the 
University Hospital Ghent. All participants provided written informed consent.  
 





The participants were interviewed using a standard questionnaire to collect information on 
demographics and risk factors. Anxiety for skin cancer was evaluated using a visual analogue scale 
from 0 (no fear) to 10 (highest possible fear) before and immediately after screening irrespective of 
the outcome.  
During clinical examination, the following features were recorded; skin type according to Fitzpatrick,22 
solar lentigines, actinic keratosis (AK), number of nevi and presence of atypical nevi. All melanocytic 
lesions on exposed skin (except genitalia) were counted, and atypical melanocytic nevi were defined 
as previously described by Garbe et al.23 24 The duration of the clinical examination was registered. This 
was defined as the time needed for the patient to get fully undressed (TBE) or to show the specific 
lesion (LDS), added up to the time needed for the dermatologist to examine the body (TBE) or the 
lesion (LDS) with naked eye and dermoscopy.  
When a suspicious lesion was detected during one of the screenings, the patient was referred to their 
GP or dermatologist for biopsy/excision and treatment. The clinical suspicion rate was defined as the 
number of referrals divided by the number of participants. The pathological outcome of the lesion was 
retrieved and considered to be the final diagnosis and yield.  
Outcomes  
Four primary outcomes were evaluated. First, the participation rate, defined as the total number of 
participants divided by the total number of invited inhabitants. Secondly, the detection rate, defined 
as the number of histological confirmed skin cancers on the total number of participants and the 
operational effectiveness, defined as the overall yield in the invited population. Thirdly, the impact of 
the screening on anxiety was evaluated by comparison of the VAS score before and after the 
screening. Finally, the cost, expressed as the direct costs per detected lesion, was calculated for the 
two methods. For calculation of the costs, the measurement and valuation of the costs was consistent 
with the perspective of the Belgian health care budget and in accordance with the 2014 National 
Institute for Health reimbursement guidelines. For these costs of the screening program, the 
subsequent treatment- and indirect cost were not taken into account. In addition, time spent per 
screening was also assessed in order to better understand the screening capacity of both methods. 
Mortality was not included as an endpoint.  
Statistical analysis 
All categorical variables were compared using Pearson’s chi-squared test or Fisher’s exact test in case 
the conditions for Pearson’s chi-squared test were not met. The independent or paired sample T-test 
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was used for continuous variables. Differences are expressed with a 95% confidence interval (CI).  All 
statistical tests were two-tailed and P-values <0.05 were considered statistically significant. The 
analyses were conducted in SPSS version 21.0 (IBM, Armonk, NY, U.S.A).  Sample size calculation of the 
number of invitees was based on participation rate and effect size of published data and the pilot 




A total of 1982 persons were screened in this study. Participation rate was significantly higher in the 
TBE group (17.9%) compared to the LDS group (3.3%, P<0.01) (Table 1). Gender distribution was 
comparable, with a modest female predominance of 56%. There was no difference in median age. 
Educational level was higher in the LDS group; there were more participants with a university degree 
(16% versus 9.9%, P<0.01).  
As expected, the main reason for people participating in the TBE screening was to have a total skin 
check (77.3%) whereas in the LDS group 75.8% consulted for a specific lesion. However 6.6% of the 
screenees in the TBE group consulted because of concern about a specific lesion, and 17.8% (n=56) of 
the screenees in the LDS group had no specific lesion of concern but consulted for a total skin 
examination. In total 283 participants (90.1%) of the 314 participants in the LDS group agreed to a 

















Table 1. Demographics of participants, participation rate, motivations to participate, and previous skin 
checks 
 Overall TBE LDS P-valuea 
Sex     
Females 1113 (56.2) 936 (56.1) 177 (56.4)  
Males  869 (43.8) 732 (43.9) 137 (43.6) 0.93 
Total  1982 1668 314 - 
Participation rate,  %  17.9 3.3 <0.01 
Educational level     
Primary school  208 (12.6) 37 (12.1)  
High school  757 (45.8) 119 (38.9)  
Higher education  526 (31.8) 101 (33.0)  
University degree  163 (9.9) 49 (16.0) <0.01 
Personal history of skin cancer  40 (2.4) 6 (2.0) 0.84 
Familial history of skin cancer  179 (11.2) 41 (14.0) 0.17 
Motivation to participate     
“I just wanted to be checked”  1280 (77.3) 56 (17.8) <0.01 
“I have many moles”  131 (7.9) 1 (0.3) <0.01 
“I have one/ more suspicious skin 
lesions” 
 109 (6.6) 238 (75.8) <0.01 
“A family member/friend advised me”  5 (0.3) 4 (1.3) 0.06 
“A doctor advised me”  59 (3.6) 2 (0.6) 0.01 
“Other”  71 (4.3) 13 (4.1) 0.99 
At least one previous skin check  634 (38.3) 123 (40.2) 0.29 
N (%) presented unless otherwise stated. Numbers do not always add up to the total due to missing 
data. SD, standard deviation; TBE, Total body examination; LDS, lesion directed screening; IQR, 
interquartile range. a Pearson’s chi-squared test unless otherwise stated. b Wilcoxon Rank Sum Test. 
 
 
Clinical findings  
The clinical findings are illustrated in Table 2. Participants in the two groups did not differ significantly 
with regard to Fitzpatrick skin type, total nevus count, presence of AK or atypical nevi. A positive 
personal or family history of skin cancer and the number of participants who received at least 1 
previous skin check was similar in both groups (38.3% in the TBE - and 40.2% in the LDS group). 
The clinical suspicion rate was 4.4% (n=73) in the TBE group and 3.2% (n=10) in the LDS group 
(P=0.66). BCC was the most frequent clinical diagnosis. Several screenees had more than one clinically 
suspicious lesion especially multiple BCCs (10 (n=1), 9 (n=1), 3 (n=1), 2 (n=6)) and more than one 
Bowen’s disease (3 (n=1), 2 (n=3)).  
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Table 2. Clinical findings and risk factors in the participants 
 Overall TBE LDS  P-valuea 
Number of participants 1982 1668 314 - 
Skin type     
I 123 (6.4) 107 (6.5) 16 (5.7)  
II 1143 (59.0) 965 (58.4) 178( 62.9)  
III 637 (32.9) 551 (33.3) 86 (30.4)  
IV 26 (1.3) 24 (1.5) 2 (0.7)  
V 6 (0.3) 6 (0.4) 0 (0.0)  
VI 1 (0.1) 0 (0.0) 1 (0.4) 0.23b 
Nevus count      
<25 1108 (57.3) 944 (57.1) 164 (58.0)  
25-50 567 (29.3) 483 (29.2) 84 (29.7)  
50-100 194 (10.0) 168 (10.2) 26 (9.2)  
>100 66 (3.4) 57 (3.4) 9 (3.2) 0.96 
Presence of AK 152 (7.8) 130 (7.9) 22 (7.6) 0.90 
Presence of solar lentigines  1264 (65.3) 1051 (63.6) 213 (75.0) <0.01 
Presence of atypical nevi 298 (15.4) 249 (15.1) 49 (17.3) 0.33 
Screenees with suspected skin cancer of any 
type 
83 (4.2) 73 (4.4) 10 (3.2) 0.66 
Screenees with suspected melanoma  10 (0.5) 9 (0.5) 1 (0.3)  
Screenees with atypical nevi referred for 
excision 
17 (0.8) 17 (1.0) 0 (0)  
Screenees with suspected BCC  47 (2.4) 40 (2.4) 7 (2.2)  
Screenees with suspected SCC/Bowen 8 (0.4) 6 (0.4) 2 (0.6)  
Screenees with other suspected skin cancer c 1 (0.05) 1 (0.1) 0 (0)  
n (%) presented unless otherwise stated. Numbers do not always add up to the total due to missing 
data. TBE, Total body examination; LDS, lesion directed screening; AK, actinic keratosis; BCC, basal cell 
carcinoma; SCC, squamous cell carcinoma. a Pearson’s chi-squared test unless otherwise stated. b 
Fisher’s exact test has been used because conditions for Pearson’s chi-squared test have not been 
met. c Merkel cell carcinoma.  
 
Skin cancer detection rate  
The histological diagnosis of one participant in the LDS group and 12 participants in the TBE group 
could not be retrieved. In the LDS group a lesion suspicious for Bowen’s disease had disappeared 
spontaneously when the participant presented for biopsy at the dermatology office. In the TBE group 
one participant died before referral, 4 persons have chosen not to have an excision or biopsy and 7 
have postponed the excision or biopsy because of other health problems.  
In total 1982 persons were screened and 47 (2.4%) skin cancers were confirmed histologically. No 
suspicious lesions were found in screenees younger than 35 and the calculated skin cancer detection 




rate in the age group >35 was 3.0%. Melanoma was detected in 9 (0.45%) screenees, 37 (1.9%) had 
confirmed BCC and 1 (0.05%) SCC or Bowen. Of the pathologically confirmed melanomas, 3 were in 
situ and 6 melanomas were invasive. The predictive value of a positive screening test for melanoma 
was 50% (95% CI 0.24 - 0.76), compared to a positive predictive value (PPV) of 72.3% (95% CI 0.58 - 
0.83 ) for BCC. The PPV of a positive screening test for SCC or Bowen was only 12.5% (95% CI 0.01 - 
0.49). The overall predictive value of a positive screening test for skin cancer was 56.6% (95% CI  0.46 - 
0.67)  (Table 3).  
Detection rates between the two screening methods did not differ significantly (TBE 2.3% versus LDS 
3.2%,  P=0.40), but in the population invited for TBE significantly more skin cancers were detected 
given the higher participation rate  (TBE 0.42% versus LDS 0.08%, P=<0.01) (Table 4).  
In total 283 (90.1%)  participants in the LDS group agreed to have a total skin check. Only 1 skin cancer 
at a non-examined site was detected if the initial index lesion was not suspicious. In the subgroup of 
10 participants where the presented lesion was suspicious, additional malignant lesions were revealed 
by total skin check in 3 persons (confirmed BCC in two, confirmed Bowen in one). In the 66 
participants in the LDS group that did not consulted for a specific lesion, only one skin cancer was 
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Table 3. Histological findings  
 Overall TBE LDS P-valuea Difference TBE-
LDS % (95% CI) 
Number of participants 1982 1668 248g - - 
Skin cancer detection rate 47 (2.4) 39 (2.3) 8 (3.2) 0.40 -0.89 (-3.96,0.90) 
Melanoma detection rate  9 (0.45) 8 (0.5)b 1 (0.4)  0.87f 0.08 (-1.78, 0.65) 
Positive predictive value 
for melanoma 
5/10 (50) 4/9 (44.4)b 1/1 (100) 0.99f  
BCC detection rate  37 (1.9) 30 (1.8)c, e 7 (2.8)d 0.28 -1.02 (-3.96,0.61) 









SCC/Bowen detection rate  1 (0.05) 1 (0.06) e 0 (0) 0.99f 0.06 (-1.47, 0.34) 
Positive predictive value 
for SCC/Bowen 
1/8 (12.5) 1/6 (16) e 0/2 (-) - - 
Missing histology reports 13 12  1 - - 
n (%) presented unless otherwise stated. Numbers do not always add up to the total due to missing 
data. TBE, total body examination; LDS, lesion directed screening; BCC, basal cell carcinoma; SCC, 
squamous cell carcinoma; CI confidence interval.  a Pearson’s chi-squared test unless otherwise stated. 
b Four melanomas were detected in participants referred for excision of an atypical nevus, four 
melanomas were detected in participants referred for excision of a lesion suspicious for melanoma. c 
Two BCCs were detected in participants with suspicion of Bowen’s disease. d One BCC was detected in 
a patient with a lesion suspicious for SCC. e For calculation of the detection rate and positive predictive 
value (PPV) only the first BCC and Bowen were taken in account. f Fisher’s exact test has been used 
because conditions for Pearson’s chi-squared test have not been met. g A total of 248 participants in 
the LDS group presented with a specific lesion, participants presenting for a standard skin check were 























Table 4. Detection rate and operational effectiveness 
 Detection rate (per 100 participants) 
TBE (n=1668) LDS  (n=248) P-valuea Difference TBE-LDS % 
(95% CI) 
Skin cancer  2.3 (39) 3.2 (8) 0.40 -0.89 (-3.96,0.90) 
Melanoma  0.48 (8) 0.4 (1) 0.87b 0.08 (-1.78, 0.65) 
BCC  1.8 (30) 2.8 (7) 0.28 -1.02 (-3.96,0.61) 
SCC/Bowen  0.06 (1) 0 (0) 0.99b 0.06 (-1.47, 0.34) 
 Operational effectiveness (per 100 invitees) 
TBE (n=9325) LDS (n=9484) P-valuea Difference TBE-LDS % 
(95% CI) 
Skin cancer  0.42 (39) 0.08 (8) <0.01 0.33 (0.19, 0.49) 
Melanoma  0.08 (8) 0.01 (1) 0.02b 0.08 (0.01, 0.16) 
BCC  0.32(30) 0.07(7) <0.01 0.25 (0.12, 0.39) 
SCC/Bowen  0.01 (1) 0 (0) 0.99b 0.01 (-0.03, 0.06) 
Number in brackets are the actual numbers of individuals. Numbers do not always add up to the total 
due to missing data. TBE, total body examination; LDS, lesion directed screening; BCC, basal cell 
carcinoma; SCC, squamous cell carcinoma; CI confidence interval.  a Pearson’s chi-squared test unless 
otherwise stated. b Fisher’s exact test has been used because conditions for Pearson’s chi-squared test 
have not been met. 
 
Anxiety  
Participants in the LDS group had a significant higher baseline anxiety (3.7 points) compared to the 
TBE group (3.3 points, P<0.01). In screenees in whom no suspicious lesion was detected by screening a 
similar reduction in anxiety using the VAS was observed in both groups (reduction with 1.3 points, 
P<0.01). In screenees who were diagnosed with a suspicious lesion, a small rise in anxiety (0.3 points) 
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Table 5. Anxiety  
 TBE LDS P-valuea 
Anxiety rate before screening, mean (SD) 3.3 (2.5) 3.7 (2.8) <0.01b 
Anxiety rate after diagnosis, mean (SD)  2.1 (2.2) 2.5 (2.6) 0.01b 
Difference in anxiety before and after screening, mean (SD)  - 1.2 (2.2) - 1.2 (2.4) 0.69b 
Paired anxiety difference, mean (SD)     
No suspicious lesion - 1.3 (2.1) - <0.01  
Diagnosis of AK - 0.1 (2.8) - 0.57 
Diagnosis of suspicious lesion 0.3 (2.5) - 0.28 
Paired anxiety difference, mean (SD)     
No suspicious lesion - - 1.3 (2.2) <0.01 
Diagnosis of AK - - 0.2 (3.1) 0.80 
Diagnosis of suspicious lesion - - 0.45 (3.4) 0.57 
Mean (SD) presented unless otherwise stated, Difference = VAS after minus VAS before screening. 
Numbers do not always add up to the total due to missing data. TBE, total body examination; LDS, 
lesion directed screening  a Paired sample T-test unless otherwise stated. b Independent sample-T test. 
 
Time and costs  
The mean duration of the complete TBE examination was 3 minutes 52 seconds compared to 40.9 
seconds in the LDS group (SD 70.1 and SD 67.1 resp., P<0.01). In this way LDS is 5.6 times less time-
consuming than TBE. Analysis of the time needed to perform only the clinical examination, without 
taking the time to undress in consideration, revealed similar results (TBE 2 minutes 51.6 seconds (SD 
62.7), LDS 24.2 seconds (SD 31.8)).  
Reimbursement for clinical examination, excision and pathology are in accordance with the 2014 
National Institute for Health guidelines. The total estimated cost of screening per detected skin cancer 
was €931 for the LDS method and €1012 for the TBE method. A Markov model will be designed to 













We present in this paper the results of a study comparing two different screening methods for skin 
cancer by dermatologists in 2 similar populations as to participation rate, effectiveness and cost. The  
effect of screening at decreasing advanced skin cancer stage was not included as an endpoint and no 
conclusions can be drawned based on the current study design. However, 1982 persons were 
screened by this initiative and 47 (2.4%) skin cancers were histologically confirmed (0.45% melanoma, 
1.9% BCC, 0.05% SCC or Bowen).  No skin cancers were detected in the age group <35 (n=434), hence 
for the subgroup aged >35 detection rate was 3.0%. In addition the positive predictive value was at 
least 56.6%. In 13 lesions definitive histological diagnosis was missing, meaning that the number of 
false positives, an important side effect of screening, ranged between 27.7 and 44.6%.  
These detection rates and PPV were high compared to other screening initiatives. The largest 
European study to date is the screening in Schleswig-Holstein (Germany) reporting a histological yield 
of 0.8% malignant lesions (0.5% BCC, 0.1% SCC and 0.2% melanoma) and a false positive rate of 
74.3%.4 25 The use of/and experience in dermoscopy could have led to a higher diagnostic accuracy in 
the current study. It has been demonstrated that the odds for detecting melanoma increases by at 
least nine times over naked eye examination.16 The difference in overall yield could also be explained 
by study design. In this screening, a team of dermatologists highly experienced in skin cancer and 
dermoscopy were involved, whereas in Germany non-dermatologists could also participate in the 
screening after an 8-hour course. As a result it is possible that the false negative rate was higher in the 
German study because some patients with suspicious lesions may not have been referred correctly to 
the dermatologist resulting in an overall lower yield. 
Data from the Euromelanoma campaigns rarely report complete histologic follow-up for NMSC. The 
yield for histological confirmed melanoma varies in different European countries; in the 2009 and 
2010 campaigns the total detection rate was 0.35% among all participating countries. Only one 
campaign in Switzerland included NMSC histology, resulting in a detection rate of 0.38% for BCC and 
0.15% for SCC.26-28 During the 2009 Euromelanoma campaign in Belgium, 2652 participants were 
screened and 12 melanomas were found resulting in a detection rate of 0.45% similar to our 
findings.28 The PPV for melanoma in this setting was 22.2% compared to 50% in our study, although 
dermoscopy was used in 94.4% of the examinations. 
LDS has a lower operational effectiveness, since TBE detects five times more skin cancers present in 
the population. The detection rate within the participant groups was not significantly different 
between the two screening methods (2.3% TBE versus 3.2% LDS, P=0.40). LDS was 5.6 times less time-
consuming and resulted in a lower cost per detected skin cancer. The effectiveness of LDS can be 
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increased if a whole body screening is offered in case of a suspicious index lesion that was the reason 
for participation. A large two-step screening study, offering a TBE after dermatologists performed 
inspection of problem and uncovered area, found that if a skin tumor is a reason for consultation (OR 
3.8 (95% CI 2.0 - 4.8)) or the presence of a suspicious lesion on the problem or uncovered area (OR 6.8 
(95% CI 5.2 – 9.0)) the risk of missing a skin cancer significantly increased when no additional total skin 
examination was performed.29  It is also known that a large proportion of patients with BCC develop 
multiple BCCs over time, and a proportion of these patients present with multiple BCCs 
synchronously.30 In our study 3 out of 10 patients had a second confirmed BCC or Bowen after 
presenting with a confirmed malignant lesion on LDS screening. TBE seems to be the most complete 
skin cancer screening that can be offered to a population, but health care systems today are faced to 
specific challenges of scarcity in budget and medical staff resulting in waiting lists, the LDS method 
might be an viable alternative.  
Participation rate in the TBE group is comparable to the participation rate of 19.1% in the German 
SCREEN project.31 The almost 5 times lower participation rate in the LDS group can only be explained 
by the specific message on the invitation or the stated conditions to participate, since all other aspects 
of the sensitization were similar and the 2 areas that were socio-economically comparable according 
to the official statistics. In the TBE group, 109 participants (6.6%) attended the screening because they 
were worried about one or more lesions, in contrast to 238 persons in the LDS group (75.8%). The 
message was thus correctly interpreted by the majority of participants in the LDS group, probably 
resulting in a general lower participation rate. In screening, higher education levels lead to higher 
participation. Our data showed a significantly higher level of education in the LDS group:  49.0% of the 
participants had higher education or university degree compared to 41.7% in the TBE group. This 
finding could be related to the more complex and selective message in LDS group and deserves 
attention since lower socio-economic class is an important risk factor for non-participation in health 
care programs and more advanced cancers at diagnosis.32 33 The effect of increasing the participation 
rate in the LDS group by means of sensitization using TV, social media and extra reminders should be 
examined to fully exploit the benefits of the LDS method and increase its overall yield. Introduction of 
a preventive health care pathway managed by the GP could benefit the current socio-economic 
discrimination in screening campaigns.  
Although melanoma is one of the most aggressive of all skin cancers, the screening cost per melanoma 
detected in our study is high, raising the question whether it can be cost-effective to focus only on 
melanoma. In this study the screening cost per melanoma detected varied between €4631 and €7449. 
NMSCs have a higher direct cost on the health care budget. Their early detection can help to reduce 




this cost since the different treatment options, when applied to early stage disease, are less costly and 
more effective.34  
To our knowledge, no studies evaluating anxiety in skin cancer screening have been published so far 
and this adverse effect is frequently used as an argument contra skin cancer screening. The literature 
suggests defining the high-anxiety state at 1 standard deviation above the normative mean, or a STAI 
>45.35 This correlates to a cut-off in VAS of >2 with a sensitivity of 76,7% and specificity of 64.9%.21   
Our results show that the mean anxiety significantly drops after a negative screening in both groups 
with 1.2 points (P<0.01). In case of a positive screening anxiety did not increase significantly. It is 
possible that anxiety was induced by the personal invitations send out 5 weeks in advance, resulting in 
a return to baseline afterwards. A measurement before sending out the invitation would give a more 
accurate effect from the intervention.  Anxiety pre-screening was 0.4 points higher in the LDS group 
(P<0.01). This effect is most probably due to the information about lesions alarming for skin cancer on 
the LDS invitation. The mean anxiety of 109 participants presenting with a specific lesion of concern in 
the TBE group was comparable to pre-screening LDS anxiety (mean 3.7, P=0.95). Overall, it is thus not 
only the specific message on the invitation, but also the invitee’s reason for participation that 
influences their anxiety of having skin cancer.  
 
CONCLUSIONS 
In general this study reached a high skin cancer detection rate and PPV compared to other screening 
initiatives. There was also high male participation compared to other screenings. Community-based 
sensitization and personal invitation for screening, as well as a screening team with experienced 
dermatologists using dermoscopy could be important factors in establishing this. 
TBE yielded a higher absolute number of skin cancers in the invited population, LDS has similar 
detection rate of 3.2% and is 5.6 times less time consuming. LDS by dermatologists can be an 
alternative screening method especially in health care systems with limited budget and/or waiting 
lists. However the effectiveness of this method by non-dermatologists warrants further study. It is 
important to increase participation rate in LDS and thus the absolute number of skin cancer detected, 
paying attention to any differences in educational level and skin cancer awareness. Only one skin 
cancer was found by total skin examination in the LDS group if the lesion of concern was not 
malignant. This suggests that a total skin examination would mainly be indicated in case the 
participant presents with a suspicious lesion.   
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Background:  Several  epidemiologic studies  show  an  alarming  global  increase  in  incidence  of  
melanoma  and  non-melanoma  skin  cancer. Consequently  to  this  epidemic, the related  health care 
costs are  rising  significantly. Two strategies (systematic total body examination (TBE) and lesion-
directed screening (LDS)) were compared as to their participation rate, effectiveness, adverse effects 
and costs.  
Methods: A Markov  model  with  a  latent period  of  20  years  and  a  time  horizon  of  50  years  
analysed  their  cost-effectiveness and  budget impact in Belgium. In total 1982 persons were screened 
and 47 (2.4%) skin cancers were confirmed histologically (0.45% melanoma, 1.9% basal cell carcinoma, 
0.05% squamous cell or Bowen). TBE yielded a higher absolute number of skin cancers, LDS had a 
similar detection rate but was 5.6 times less time consuming. The cost  per  quality-adjusted  life-year  
of  the  two strategies,  and the net costs for the health care payer over 50 years was measured.  
Results: Both screening strategies produced a gain in QALYs, resulting in incremental cost-
effectiveness ratios of €33 072/QALY in males and €18 687/QALY in females for TBE and €34 
836/QALY in males and €19 470/QALY in females for LDS. The budget impact analysis demonstrated 
that over a period of 20 years a one-time screening would induce an extra cost for the health care 
payer of €36 million in case of TBE or €6 million in case of LDS, respectively €4.1 or €0.7 per adult.  
Conclusion: These results can be interpreted as cost-effective at a willingness-to-pay threshold in 
Belgium of €35 000/QALY. Based on these results a TBE in general adult population (especially in the 
females, in males the results were less explicit) is the most cost-effective strategy and is predicted to 














Although the worldwide incidence, prevalence, and economic burden of skin cancer is substantial1-7 
and despite the idea that early detection can lead to better cure rates and reduce the costs of disease, 
few clinical studies have assessed the cost-effectiveness of secondary prevention strategies.8 Investing 
in population-based prevention programs is challenging for policy makers, since the budget is 
challenged by many other major health challenges. Screening is a prevention strategy by which early 
detection changes the prognosis by a shift in stage distribution to earlier stages. However, few studies 
have analysed the cost-effectiveness of skin cancer screening up to now. Currently available studies 
mainly addressed melanoma skin cancer (MM)8-12, while non-melanoma skin cancer (NMSC) is also 
responsible for a large part of the direct medical health care costs of skin cancer5, In addition, some of 
these early detection campaigns specifically focused on high-risk groups13, but it is known that most 
skin cancers develop outside these groups. Moreover, most published cost-effectiveness models on 
skin cancer screening predict mortality reduction, while this had not yet been proved in observational 
studies. At this point, no evidence exists that population-based screening by means of whole body 
examination in asymptomatic persons is cost-effective.14 In this study we compared the cost-
effectiveness of two population-based screening strategies organized as a pilot study in Belgium: a 
standard total body examination (TBE) versus a lesion-directed approach (LDS).15 The LDS approach, in 
which screenees are seen with only a specific lesion of concern meeting certain pre-set criteria, was 
shown to result in lower participation rates but similar skin cancer detection rates. In reference to TBE, 
LDS was time-saving for the physician. As most of the cost-effectiveness studies of skin cancer 
screening up to now do not provide information on the financial impact of a skin cancer screening 
intervention on the health care budget8, we also performed a budget impact analysis. 
 
METHODS 
A decision-analytic Markov model was developed, examining the economic impact of a single TBE and 
a single LDS compared to the current situation (i.e. no screening program). Health effects and costs of 
a cohort of adult males and females were simulated from a societal perspective, over a time horizon 
of 20 years, with six-monthly cycles. Main outcomes included the incremental cost-effectiveness ratio 
(calculated as the net costs divided by the net health effects), the budget impact and the estimated 
mortality reduction. In order to calculate the budget impact, the model allowed new entrance of 18-
year olds each cycle in the lesion-free state, who were subjected to the natural progression of skin 
cancer. The budget impact analysis estimated the net cumulative cost of the screening program (and 
consequent examinations, treatment and follow-up) for the health care payer (i.e. government) over a 
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period of 20 years. Ethics committee approval  for this study and patient informed consents were 
obtained for the clinical screening trial. 
Screening strategies 
The modelled screening strategies were based on a skin cancer screening trial which has been 
organised in Belgium in 2014, comparing TBE to LDS in two socio-demographically comparable 
regions.15 The TBE was organized in a community of 9325 inhabitants during a 5-day screening (March 
14-18, 2014). All inhabitants 18 years and older received a personal invitation. The LDS was organized 
in a comparable community (April 22 and 25-27, 2014), of which the inhabitants were invited for a 
free-of-charge skin cancer check of a specific lesion meeting one or more of the following listed 
criteria: ABCD rule (A, asymmetry; B, borders; C, colours; and D, differential structures), ugly duckling 
sign, new lesion lasting longer than 4 weeks, or red non-healing lesions. All participants (1668 TBE and 
248 LDS) were screened by a team of six dermatologists. As expected, the participation rate was 
higher in the TBE region compared to the LDS region (17.9% versus 3.3%, P = < 0.01). Skin cancer yield 
did not differ significantly between both groups (2.3% TBE versus 3.2% LDS, P = 0.40). Further details 
on the design of this trial can be found in Hoorens et al.15 In the health economic model all Belgian 
adult males and females, except those who have had skin cancer before, were assumed to be invited 
for the single screening program. Modelled clinical outcomes of the screening were pathologically 
confirmed skin cancer, a (false) positive result or a (false) negative result. It was assumed that persons 
with an undiagnosed lesion who chose not to participate in the screening program or persons with a 
false negative result could have their lesion diagnosed by spontaneous clinical detection in the same 
cycle. Spontaneous clinical detection was also possible in the comparator (i.e. current situation).  
Model structure 
The Markov model was developed in Microsoft Excel® 2013 and incorporated MM as well as BCC and 
SCC. It consisted of different disease states: undiagnosed skin cancer, diagnosis & treatment, follow-
up and death (Appendix II), separated per skin cancer stage. The duration of the diagnosis & treatment 
phase was 6 months (= 1 cycle) for patients with BCC, SCC 0-II or MM I-II and 1 year for patients with 
SSC III-IV or MM III-IV.  To assign a higher probability of skin cancer death in the first years after 
diagnosis in case of SCC IV and MM IV, the follow-up phase was divided into intense- and long-term 
follow-up, which lasted for 4 years, after which one moved into long-term follow-up. Patients in 
follow-up remained in this state until the end of the model’s time horizon, or until they died. MM and 
SCC stages were determined according to the 7th edition of the Tumor-Nodes-Metastases-
classification for malignant tumours.16 Stages for BCC were defined as <1cm, 1-2cm, >2cm and 
aggressive histology. BCC and SCC patients were assigned higher risk to develop an MM lesion. Risk of 




a recurrent or subsequent similar lesion (for all cancer types) was only accounted for in the costs, 
since the effect of a subsequent lesion on the quality of life has not yet been described in current 
literature. All cohort members started the model in one of the model states, according to the baseline 
prevalence of BCC, SCC and MM.17;18 More information on the age- and gender-specific transitions, 
the epidemiological, economical and clinical data inputs and sensitivity- and scenario analyses can be 
found in appendix II. 
 
RESULTS 
Impact on skin cancer epidemiology 
Over a period of 20 years, the model estimated the one-time screening to result in a 4% decrease in 
the incidence rates of stage III&IV MM at population level. Moreover, both single screening programs 
were estimated to have a positive, although modest, impact on mortality from skin cancer, with an 
absolute reduction of 628 deaths in case of TBE (273 in males and 355 in females) and 118 in case of 
LDS (57 in males and 61 in females). This corresponds to a relative mortality reduction of about 5.6% 




Both screening strategies resulted in a gain in QALYs over a period of 20 years (Table 1). Health effects 
and costs are in good balance, leading to incremental cost-effectiveness ratios of €33 072/QALY in 
males and €18 687/QALY in females for TBE and €34 836/QALY in males and €19 470/QALY in females 
for LDS  which can be interpreted as a moderate cost-effective result regarding a willingness-to-pay 
threshold in Belgium of €35 000.19;20 The budget impact analysis presented in table 2, showed that 
over a period of 20 years a one-time screening would induce an extra cost for the health care payer of 











Table 1. Results of the cost-effectiveness analysis, over a period of 20 years, per 1 000 persons 
  Incremental QALYs (95% CI) Incremental Costs (95% CI) ICER 





€ 6 465 
(5521-7517) 
€ 6 383 
(5143-7450) 









€ 34 836 € 19 470 
TBE: total body examination; LDS: lesion-directed screening; QALY: Quality adjusted life year; ICER: 
incremental cost-effectiveness ratio. 
 
 
Table 2. Results of the budget impact analysis, over a period of 20 years 
  Cost of intervention Health care payer Total cost Total extra cost 
Control  € 0 € 1 909 776 064 € 1 909 776 064   
TBE  € 7 308 319 € 1 938 193 177 € 1 945 501 496 € 35 725 432 
LDS € 463 275 € 1 915 431 360 € 1 915 894 635 € 6 118 570 
TBE: total body examination; LDS: lesion-directed screening. 
 
 
Scenario- and sensitivity analysis 
Results from the scenario-analysis are displayed in Table 3. A one-time screening from the age of 18 
remained the most cost-effective strategy. Screening every two or five years had a lower cost-
effectiveness ratio, but since the time horizon was set at 50 years for this scenario -as 20-year time 
horizon would not capture the effect of screening in e.g. year 18 - it should be compared to the 
scenario of a one-time screening with a time horizon of 50 years. To evaluate the effect of possible 
overdiagnosis, a worst-case scenario analysis with the hypothetical presumption that 25% of all 
melanomas detected and treated during the screening would not have progressed, was performed on 
the base case scenario. The one-way sensitivity analysis showed the most influencing parameters to 
be the natural progression of MM, the utility related to MM, the direct cost of follow-up of BCC, the 
indirect as well as direct cost of MM III and IV, the direct follow-up cost of MM I-II, the discount ratio, 
the prevalence of BCC and the sensitivity of dermoscopy for MM, (Figure 1, tornado diagram shown 
for TBE). A higher value on these parameters led to a more cost-effective result, except for the cost of 
BCC (long-term follow-up), the discount ratio and the direct follow-up cost of MM I-II in which the 
effect was the opposite. In case of a worse value on the parameter (bars on the right side of the 
figure), ratios were higher than the €35 000 threshold, leading to a worse result. The cost of screening 
(TBE) in males remains cost-effective up to an increase of the screening cost of 50%, whereas 




screening (TBE) in females remains cost-effective up to a screening cost of 7 times higher. The 
probabilistic sensitivity analysis created credibility intervals around the deterministic result, which are 
depicted in Figure 2. The cost-effectiveness planes show that most simulations are located in the 
north-east quadrant and are below the willingness-to-pay threshold of €35 000/QALY, although for the 
simulation in males part of the values are situated above the threshold. The cost-effectiveness 
acceptability curves in appendix II show that regarding willingness-to-pay threshold of €35 000/QALY, 
the probability of screening being cost-effective is 79.7% and 59.9% for TBE and LDS in males and 
100% and 99.9%  in females. 
 
Table 3. Results of the scenario analysis 
  
TBE LDS   
(cost/QALY) (cost/QALY) 
  males females males females 
ICER base case € 33 072 € 18 687 € 34 836 € 19 470 
Screening from 40 years € 35 622 € 21 841 € 36 348 € 23 485 
Time horizon 50 years € 9 253 € 5 722 € 10 262 € 5 549 
Screening every 5 years*  € 11 811 € 6 060 € 12 758 € 5 671 
Screening every 2 years*  € 12 180 € 6 021 € 12 404 € 5 436 
Base case overdiagnosis € 58 388 € 29 897 € 59 948 € 32 561 
ICER probabilistic € 31 360 € 18 051 € 34 170  € 18 999 
(95% CI) (€ 23 251 – € 41 468) (€ 13 493-€ 23 019) (€ 25 586-€ 44 831) (€ 13 725-€ 25 139) 
TBE: total body examination; LDS: lesion-directed screening; QALY: Quality adjusted life year; ICER: 
incremental cost-effectiveness ratio* during 20 years, but with a time-horizon of 50 years; CI: 






















































Figure 1a. Tornado diagrams with results of the one-way sensitivity analysis (for TBE in males); MSC: 
melanoma skin cancer; BCC: basal cell carcinoma; SCC: squamous cell carcinoma; D&T: Diagnosis and 
treatment; FU: follow-up; Light grey bars: minimum value of parameter; Dark grey bars: maximum 
value of parameter. 
    
 
Figure 1b. Tornado diagrams with results of the one-way sensitivity analysis (for TBE in females); MSC: 
melanoma skin cancer; BCC: basal cell carcinoma; SCC: squamous cell carcinoma; D&T: Diagnosis and 
treatment; FU: follow-up; Light grey bars: minimum value of parameter; Dark grey bars: maximum 
value of parameter.  







Figure 2. Cost-effectiveness planes displaying the 5 000 simulations. Each point depicted in represents 
the value of one simulation performed from the distribution around each of the key variables in the 
model. Willingness-to-pay threshold of €35,000/QALY is displayed in the graphs. Figure 2A: Total body 
examination in males; Figure 2B: Total body examination in females; Figure 2C: Lesion-directed 
screening in males; Figure 2D: Lesion-directed screening in females. 




Given the health impact and economic burden of MM and NMSC21, developing and implementing 
cost-effective strategies for its early diagnosis and treatment is crucial. Over a period of 20 years, a 
one-time TBE leads to a gain of 2,380 healthy life-years in the total population (8.8 million) and LDS 
gains 397 healthy life-years. In addition, TBE was projected to reduce skin cancer mortality by 5% over 
20 years. However, currently no prospective studies support a reduction in skin cancer mortality due 
to screening. According to Boniol et al., the transient decrease in mortality in Schleswig-Holstein 
followed by return to pre-screening levels could reflect a temporal modification in the reporting of 
death causes.22,23 In addition, no decrease in MM mortality has been documented since the nation-
wide skin cancer screening was introduced in Germany in 2013.24 Due to the screening cost, and the 
extra costs for treatment and follow-up, implementing a one-time screening costs extra money for the 
health care payer. Nevertheless, the balance between costs and health effects is shown to be 
beneficial, both for TBE and LDS (ratio below the accepted threshold of €35 000), although in the case 
of males both screening strategies tend to this threshold limit. However, most simulations in the 
probabilistic sensitivity analysis for males were below the threshold (80% TBE and 60% LDS). The 
incremental cost-effectiveness ratio for TBE was better than for LDS, and LDS did not seem to have a 
high impact on increasing healthy life years and reducing deaths, which can be explained by the low 
participation rate in the LDS screening arm. Since the skin cancer detection rates were comparable in 
both screening arms and since LDS screening was time-saving, it could be worthwhile to investigate 
how participation in this type of screening could be increased. If the same participation rates of TBE 
would be attained in LDS, then LDS would be more cost-effective than TBE. Screening in females was 
clearly more cost-effective than in males, because of the higher prevalence and incidence of skin 
cancer in females in Belgium. Screening from the age of 40 instead of 18 only slightly deteriorated the 
cost-effectiveness result, probably because younger persons have a higher quality of life, which means 
that screening could gain more health benefits in younger persons, and because older persons have a 
higher risk to die from other causes than skin cancer, which disadvantages the beneficial effect of 
screening. Suppose the time horizon of the model would be extended to 50 years, then the cost-
effectiveness ratio would be better than with a 20-year time horizon, because the effect of the 
screening is estimated to still continue for an extra 30 years. The choice to implement the screening 
program repeatedly would be cost-effective, but a one-time screening would still be the most cost-
effective strategy. 
The model found that the ICER is just below the Belgian willingness-to-pay threshold. However, the 
PSA suggests that, given the parameter uncertainty modeled, the ICER is likely to be between € 23 251 
- € 41 468 per QALY gained for TBE in males. In addition, the one-way sensitivity analyses demonstrate 




that natural progression is the most detrimental parameter in the overall uncertainty around the 
outcome. When a variation is applied of 30% the ICER exceeds € 60 000 per QALY gained. And since, 
the transitions and melanoma pathway are methodological assumptions, we need to underline the 
need for long term observational data to accurately evaluate these health and economic effects. 
Other important influencing parameters were the cost of MM III and IV (for diagnosis and treatment), 
and the sensitivity of the dermoscopy for MM. It is possible that the cost for treating MM III and IV will 
keep on rising due to new (combinations of) drugs and other technologies, which would result in 
screening becoming more cost-effective. Furthermore, since a better sensitivity of dermoscopy leads 
to a better cost-effectiveness result, training initiatives for dermoscopy are strongly recommended. 
Incidence of MM did not affect the result to a great extent, which shows that even in case of good 
primary prevention programs for skin cancer, screening would still be cost-effective. Other studies on 
the cost-effectiveness of skin cancer screening have been conducted especially in the U.S. and 
Australia and only included MM. Most of these studies expressed the cost-effectiveness of MM 
screening to no screening in cost per life-year saved. These studies showed that screening men over 
50 years biennially by general practitioners resulted in an ratio of $12 137/life-year saved (AUD).9 A 
one-time screening by dermatologists in a self-selected population resulted in $51 481/life-year saved 
(USD)25 and in a high-risk population in $39.600/life-year saved (USD).11  One study calculated the cost 
per QALY of a visual one-time screening from the age of 50 to be $10 100/QALY (USD) (~ €9 
256/QALY).10 When implemented biennially the ratio rose to $80 700/QALY  (~ €73 882/QALY) and if 
annually to $586 800/QALY (~ €537 220/QALY). Our results supports this latter result of better cost-
effectiveness in case of one-time screening. However, it is difficult to compare studies because of 
different screening setting (visual screening versus dermoscopy screening, composition of the 
screening team), different epidemiological backgrounds (cf. incidence of MM higher in United States 
and in Australia than in Belgium) and different model design. 
The major strength of this study is that it is based on a large population-based screening trial. This  is 
the first time that the costs and benefits of a skin cancer screening program have been analyzed in 
detail. Not only the benefits of screening were captured in the model, but the impact of a false-
positive screening result on quality of life in terms of psychological harms was included as well. 
However, in our model, the screening examination itself did not have an impact on the quality-of-life. 
The study of Collins et al.26 showed that screening (in general) does not appear to have an adverse 
emotional impact in the longer term and they stated that up to now too few studies have assessed the 
short-term emotional impact of screening. The study of Hoorens et al. 27 questioned the anxiety of the 
screenees right after the screening, but baseline levels were not available so no conclusions on the 
quality-of-life right before and after the screening could be deducted from this study.  
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Some limitations of our analysis should be addressed. Firstly, in Belgium there is no accurate 
registration of NMSC. Therefore, we relied on epidemiologic results of the Dutch cancer registry, since 
they have a more systematic registration of NMSC. Secondly, accurate information on the natural 
progression of skin cancer is not available. Therefore, in our model, the natural progression was 
estimated based on calibration. This is generally a more reliable approach than making assumptions 
on parameters based on limited studies. In addition, the transition probabilities were assumed to be 
equal for all ages and gender, although for MM these are known to be gender and age-specific. 
Traditionally, a 95% CI is recommended to capture the uncertainty. Since  the current study used 
several deducted estimations and calculations the 95% CI was not known; and  for several input 
parameters a 30% interval was applied which is determined by convention. Lastly, it may be noted 
that screening parameters such as participation rate, diagnostic performance of the screening team as 
well as unit costs of detection, treatment and follow-up are context-specific limiting the generalization 
and transferability of the results across different countries. However, we believe that our results can 
inform policymakers worldwide about the potential efficiency of skin cancer screening.  
 
CONCLUSIONS 
In terms of policy implications skin cancer screening proved to be cost-effective at a willingness-to-pay 
threshold of €35 000/QALY. Based on these results a total-body examination in the general adult 
population (especially in the females, in males the results were less explicit) is the most cost-effective 
strategy and projected to result in a significant reduction of mortality over 20 years. The study 
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Background:  The incidence of BCC has been rising 3- to 4-fold, and is expected to increase with aging 
of the population. Although BCC has a good prognosis, it causes significant morbidity for the patient 
and has an important impact on the public health budget due to direct costs related to the treatment.   
Methods: Based on the existing data we systematically checked the WHO criteria on screening 
whether earlier detection of BCC could reduce morbidity and cost of disease.  
Results: BCC slowly increases in size with time with a median increase in diameter of 0.5 mm over 10 
weeks. There seem to be important delays in diagnosis with a mean time from appearance of the skin 
lesion to seeking medical attention ranging from 19.79 to 25 months. In several studies size of BCC is 
an important determinant for cost of treatment, surgical complexity influencing defect size, 
reconstruction technique and the exact surgical procedure followed such as MMS for BCC located in 
the face and more specifically around peri-orificial areas (H-zone). One study estimated that size also 
seems to affect the cost per treatment for other non-surgical options. The use of vismodegib, an 
inhibitor of the hedgehog pathway, is confined to unresectable or metastatic BCC. Delay in diagnosis 
and appropriate treatment are the most important underlying causes in the occurrence of giant BCC 
and/or BCC with metastasis. Although the latter represent only a very small fraction of all BCCs, the 
majority of them is located in the face region.  
Conclusions: The available data point to a slow increase in size of BCC over time. This size is one of the 
major determinants in the choice of an effective treatment and the associated cost especially for facial 
BCC. Therefore current data supports early detection and adequate management of BCCs mainly 














Basal cell carcinoma (BCC) is the most common cancer in humans and represents 80% of all NMSC. 
The incidence rates increased from 40 to 165/100.000 for males and from 34 to 157/100.000 for 
females in the last 30 years in the Netherlands.
1
 This approximately fourfold increase is similar in other 
European countries. 
2
 The lifetime risk of developing BCC is currently 1 in 5. The overall prevalence is 
5.4% for people older than 65 years, compared to 1.3% in patients aged 35-64 years and 0.06% in 
patients younger than 34 years.
1
 Although BCC is typically a disease of the elderly, the highest relative 
increase in incidence rates of BCC were found in woman below the age of 40 years.
1 3 4
  
The main risk factor for BCC development is UV-radiation, however the risk ratio observed in 
epidemiological studies is relative low (2 for 8000-10 000 cumulated hours in a lifetime, 1.8 for 3-10 
sunburns in a lifetime and 1.5 for 11+ sunburns in a lifetime)
5-8
 Evidence for the primary prevention of 
BCC by regular use of sunscreens is missing,
9
 in contrast to the effect in preventing melanoma, actinic 
keratoses and squamous cell carcinoma (SCC).
10-15
 Interventions reducing ultraviolet exposure are 
assumed to only result in small changes in BCC incidence.
16
 Chemoprevention with topical tretinoin 
0.1 % has not been successful for BCC, systemic retinoids and nicotinamide have only been examined 
in high-risk patients.
17-22
 Primary BCC is associated with an important delay in diagnosis ranging from 
19 to 25 months.
23-26
 Factors attributing to this late presentation are the patients age, denial and the 
important fact that BCC in early disease stage has little to no impact on the quality of life.
23 25 26
 In 
addition, the initial rather benign appearance of BCC to the patient can lead to treatment delay.
27
 
Information delivered to the population to promote cancer awareness and early presentation in 
routine health care does not seem to affect the delay.
28
 
The World Health Organization (WHO) criteria defined a health care problem amenable for screening 
if the disease is an important health care problem, its natural history of the disease is known and there 
is a safe, simple and inexpensive screening test that is acceptable to the population. In addition there 
should be a treatment for early disease that is more effective than treatment for later disease and the 
facilities for diagnosis and treatment should be available.
29
 Table 1 summarizes the more extensive 
WHO principles, these have only partially been reviewed for BCC. The main objective is to discuss the 
current evidence in which early detection and treatment of BCC could reduce the important morbidity 
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Table 1. WHO criteria for screening  
The ten WHO criteria for screening: 
1. The disease should be an important health problem 
2. A generally acceptable method of treatment must be available 
3. The policy for treatment must be clear 
4. Provision for diagnosis and treatment must be available 
5. The disease must have a detectable latent stage 
6. A suitable screening method must be available 
7. The screening method must be accepted by the target population  
8. The natural course of the disease must be known 
9. The program is cost-effective 
10. The treatment of early disease should favour the prognosis of the patients  
 
METHODS 
All applicable studies on the topic of the natural history of BCC, treatment, cost of treatment, cost-
effectiveness and cost-of illness have been included in this review. Studies were recovered from 
PUBMED, Cochrane and Medline database. The following (Medical Subject Headings (MeSH)) term 
combinations were used: skin cancer, non-melanoma skin cancer, basal cell carcinoma, growth, 
natural course, treatment, treatment cost, cost-of illness, societal cost, burden of illness, cost-
effectiveness. All English language abstracts were evaluated for inclusion in the review. A manual 
search of the bibliographies of retrieved articles was performed to ensure a comprehensive review. 
The study design, setting, intervention, data collection and patient population were evaluated. 
 
RESULTS 
BCC is an important health problem  
BCC is by far the most common cancer in Caucasians, and the incidence rates are rising worldwide.
1 2
 
The impact of BCC diagnosis, treatment and follow-up on the health care system and budget is 
becoming an increasingly important. Several factors influence this epidemic rise namely the aging of 
the population, altered sun seeking behavior and efforts to increase registration in cancer registries.. 
Furthermore, in contrary to other cancer types, BCC is known for its high risk of multiple primary 
lesions. The relative risk of developing a second BCC with a positive history is 17.4, and 40% of patients 
will develop a second BCC in the following 5 years.
30 31
  The large majority of the lesions are located in 
the head and neck area.
1
 Because of the high visibility of this region, as well as its anatomic complexity 
as to innervation, vasculature and delicate anatomic structures such as the lacrimal system, the orbit 




and its direct connection to the brain,  BCCs in this area may cause important functional and esthetical 
morbidity.  
Mortality of BCC is low (less than 0.1%) but morbidity causes a great burden for health care systems in 
Europe.
32-35
 The main cost drivers for NMSC are the direct treatment costs, in contrast to melanoma 
where an important indirect cost is related to sick leave and premature mortality.
36
 The total costs for 
NMSC are estimated to be twice the cost for melanoma in Germany.
37
 In addition to the costs, this 
growing group of BCC patients will represent an important burden on the limited specialized 
dermatological care in most European countries in terms of number of patients needing treatment 
and follow-up.  
The natural course of BCC must be known 
Ultraviolet induced p53 mutation is an acquired genetic change and has a key role in tumor initiation 
in 30 -70% of all BCC.
38 39
 Mutations in the patched gene and smoothened genes are a cause of 




BCCs are normally characterized by slow clinical growth as opposed to a fast cell cycle of 217 hours, 
which is comparable to normal epidermal cells.
43
  This discrepancy is explained by the fact that (1) only 
the external layer of BCC mass is actively proliferating (small growth fraction), and there is 
predominant cell death in BCC tumors (high rate of cell death). (2) Tumor regression may occur in 
response to host immune factors.
44-47
  
Few studies examined the effect of treatment delay on the natural evolution and size of BCC. Two 
small prospective studies show a median change in largest diameter of 0.5 mm over 10 weeks in facial 
BCCs and 0.7 mm over 8.7 weeks for head and neck tumors.
48 49
 Although it is generally stated that 
BCCs grow slowly, clinically some tumors have surprisingly fast growth. One study examining 115 peri-
orbital BCCs shows a mean growth of 0.75 mm per 4.2 weeks after shave or punch biopsy. In tumors 
that increased in size after biopsy a worrisome 1.46 mm increase in size was seen after one month. 




Several retrospective studies support these results. Delay of one year between initial diagnosis and 
surgical removal by MMS was associated with twice the size of a surgical defect.
51
 The largest 
retrospective study evaluating the size of 889 BCCs in relation to time confirms an increase in largest 
diameter of 10% at 2-8 months,  and 21% at 8-12 months. Independent factors found to be related to 
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BCC size or delay were male sex, having no physician checks, initial misdiagnosis, morpheaform or 
micronodular tumor histology, ulceration and scar tissue around the lesion.
51 52
  
A recent review on giant tumors (BCC of more than 5 cm that represent 2.27% of all BCC), showed 
that time between the first appearance of the lesion to diagnosis of giant BCC is directly correlated 
with tumor dimension.
53
 Most of these giant BCCs were located in the head and neck region (68.2%).  
Histology and aggressiveness 
BCCs may be categorized in several histological subtypes, and this is an important element in 
treatment options. Up to 66 BCC subtypes are described in the scientific literature. A recent study 
suggested a simplified classification to aid clinical decision-making in superficial, fibro-epithelial, 
nodular and infiltrative subtypes.
54
 Superficial BCC (sBCC) is considered to be the least aggressive 
subtype since they do not tend to invade deeply in the dermis. Although, when large and located in 
the facial area, treatment can be challenging and recurrences occur.
55-57
  Aggressiveness is mainly 
related to the risk of recurrence, being highest for the aggressive growth variants (e.g. 26.5% in 
infiltrative BCCs) and lowest in the indolent growth variants (e.g. 6.4% and 3.6% for nodular and 
superficial BCC, respectively).
56
 Nodular BCC, also known as solid BCC is the most common histologic 
pattern. Some rare variants such as basosquamous, keratotic, infundibulo-cystic and adenoid BCC are 
also described.
58
 In addition, 17.8% of BCC consist of a mixed histology, most often a combination of 
superficial and nodular histology.
59
  
A recent study hypothesized that BCC represents a histologic continuum and progresses in a multistep 
model from superficial to nodular to infiltrative.
60
 This hypothesis was based on the finding of specific 
epithelial, stromal and inflammatory patterns that correlate with individual tumor progression. 
Decreasing host response and gain of permissive tissue environment was seen when infiltrative BCCs 
compared to superficial BCC. This finding is supported by the increased incidence of BCC at young age 
only for the superficial subtype, and by the observed median age according to the histological subtype 




Metastatic BCC is extremely rare, with an estimated incidence of 0.0028% to 0.55% based on 
published cases from 1894-1980.
61
 A recent update of the literature reported 194 cases during the 
period of 1981 through 2011.
62
 The majority (64%) of these metastatic BCCs were located in the head 





 Currently size and delay in appropriate treatment seem to be the only independent risk 
factors for metastasis, with a median interval between onset of tumor to metastasis of 9 years.
61 62
 




Furthermore risk of metastasis is estimated to be 1–2% in lesions > 3cm, 20–25% in lesions greater 
than 5 cm, increasing up to 50% in lesions greater than 10 cm in diameter.
65
   
BCC has a detectable latent stage 
BCCs grow slowly with an estimated growth rate of 0.5 mm over 10 weeks in facial BCCs and 0.7 mm 
over 8.7 weeks for head and neck tumors as discussed earlier.
48 49
 In case of a linear growth pattern 
this would mean that a BCC would take 2.4-3.8 years to reach a size of 10 mm. Metastatic disease is 
rare, and several years precede the metastatic or giant stage.  
A suitable screening method is available and the method is accepted by the target population 





Dermoscopy has been a well established tool for diagnosis of BCC, regardless of its size.
68-70
 
Dermoscopy increases the diagnostic accuracy for BCC diagnosis from 58 to 84% over naked-eye 
examination.
71
 Currently, sensitivity ranges from 95%-97% and specificity 87%-96% for expert 
observers.
68
 Dermoscopy thus not only improves the diagnostic accuracy, but also reduces the number 
of unnecessary referrals, excisions or biopsies, an important side effect of screening.  
There is an acceptable method of treatment available for BCC, the policy for treatment is clear and the 
treatment of early disease favours the prognosis of the patients 
The major objective of screening is to reduce morbidity and mortality by detecting disease and 
implementing an effective treatment earlier in order to favor the outcome. Without this objective the 
early detection of BCC would be meaningless.  
Treatment options for BCC are evaluated in a large number of studies, and a Cochrane review was 
published in 2007.
72
 The British guidelines of 2008, defining the treatment of choice according to 
different factors are still applicable today.
73
 Tumor size (>20 mm versus <20 mm) is the most 
important determinant to select treatment. Others include: primary or recurrent BCC, histologic 
subtype, and the tumor location (low-risk or high-risk for recurrence). Lesions located on the central 
face, especially around the eyes, nose, lips and ears, are at higher risk of recurrence. 





 Standard excision (SE) is an effective treatment for all primary BCC 
with a 5-year recurrence rate of 2-10%.
77-82
 The best safety margins in terms of relative recurrence 
range from 3 to 5 mm.
83
 A 5 mm margin is advised in larger BCCs (> 10 mm), recurrent BCC or 
infiltrative BCC.  
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Mohs micrographic surgery (MMS) has the highest 5-year cure rate for primary BCC in the range from 
94 to 99%,
84-89
 but is an expensive technique.
90
 The absolute direct cost for treatment of one BCC in an 
outpatient setting with direct closure for SE versus MMS is estimated to be 1:3.
91
 Although MMS has 
proven to be cost-effective in high-risk tumors, in which the additional benefits of MMS outweigh its 
higher cost, earlier detection and adequate treatment of primary BCC might result in even more cost-
effective surgery.
90
  Flohil et al. concluded that size of the BCC larger than 20 mm and recurrent 
lesions were the strongest predictor for one versus multiple stages in facial lesions.
92
 MMS for primary 
BCC in the non-facial area is only appropriate for nodular lesions larger than 20 mm and aggressive 
lesions based on their histology of 6 mm in size or more.
93
 Non-surgical treatments including 5-
fluorouracil, imiquimod and photodynamic therapy (PDT) can be indicated for low-risk superficial BCC. 
Topical 5-fluorouracil and imiquimod creams are available in various concentrations. A recent RCT 
concluded that imiquimod is the first line local treatment of choice for primary superficial BCC (sBCC) 
in a non-facial area compared to 5-fluorouracil and PDT in terms of effectiveness.
94
 However a large 3 
year follow-up RCT, comparing imiquimod with SE for superficial and nodular BCC at low-risk sites  still 
showed inferiority of imiquimod (84% versus 98% clearance).
95
 And no clear difference was noted 
between groups in patient-assessed cosmetic outcomes. Furthermore, tumor thickness influences 
therapeutic efficacy of imiquimod. The median tumor thickness is 0.26 mm for non-recurrent lesions, 
while for recurrent cases the median tumor thickness is 0.57 mm. The cut-off value is 0.4 mm, where 
no recurrence occurred in contrast to a recurrence rate of 58% for lesions thicker than 0.4 mm.
96
 One 
small study examining the cost of treatment of sBCC smaller then 20 mm with imiquimod (with 
efficacy of 82%) versus surgical excision (efficacy of 97%) suggested that the savings per patient cured 
with topical imiquimod is 55 euro.
97
 T o RCT’s ha e sho n 5- to 10-fold higher cure rate with excision 
of nodular BCC (nBCC) than treatment by PDT. Nodular BCC clearance is half of that seen for sBCC.
77 98-
100
 Guidelines recommend if PDT is used it should also be limited to sBCC less than 1 mm to 2 mm 
thick. When comparing the cost-effectiveness of all non-surgical treatments together 
imiquimod and topical fluorouracil cream are more cost-effective than PDT for treatment of sBCC. 
101
 
Destructive techniques for treatment of BCCs include curettage and cautery, cryosurgery and carbon 
dioxide laser, but quality of the current evidence is low and results vary.
102-107
  For this reason these 
techniques are not recommended as a first line treatment.
73
 One RCT compared radiotherapy to SE for 
primary BCC and the 4-years recurrence rates where 10 times lower for SE (0.7%) versus radiotherapy 
(7.5%). Radiotherapy is indicated in the treatment of (non-radiation) recurrent BCC or patients 
unwilling or unable to undergo surgery.  
Recently a new treatment option for metastatic or locally advanced disease not amenable to surgery 
or radiotherapy became available with vismodegib, a small-molecule inhibitor of SMO.
108
 Most BCC 




contain a genetic alteration in the hedgehog signaling pathway, resulting in aberrant pathway 
activation and uncontrolled proliferation of basal cells. These alterations cause loss of function of 
patched homologue 1 (PTCH1), which normally acts to inhibit the signaling activity of smoothened 
homologue (SMO), a seven-transmembrane protein.
109 110
 In patients with metastases treatment with 
vismodegib showed 30% of partial response and no complete responses. Forty-three percent of 
patients with locally advanced BCC had complete or partial response during treatment.
111
 Frequent 
adverse effects, including muscle spasms, fatigue and severe hyponatraemia have been reported. In 
some patients severe weight loss, ocular disorders alopecia, anemia or SCC developed. A 12 month 
follow-up study showed that 72.1% of patients discontinued treatment mainly for other reasons than 
disease progression.
111 112
 In case of control of extensive local disease there is discussion how long the 
treatment should be continued.  
Provision for diagnosis and treatment of BCC must be available 
Diagnosis by means of naked-eye examination aided by dermoscopy and the different treatment 
options are available in most European countries. In some countries MMS is however not available 
(Greece, Malta, Poland and Romania).
74-76 113
 Table 2 gives an overview of the therapeutic options used 
for treating BCC in the Netherlands, Scotland, Finland and England. 
 
Table 2. BCC treatment in different European countries  









Surgical excision  83.6 87.2 57.1 86.0 
Mohs 1 1.5 2.4 0.4 
Cryotherapy 6.1 2.3 28.4 3.1 
Photodynamic 2.8 - 11.8 0.8 
5-fluorouracil 0.5 1.5 - 0.5 
Imiquimod 0.4 4.9 - - 
Diclofenac - 0.3 - - 
Curettage 0.7 - - - 
Tretinoin - - - - 
Radiotherapy - 0.3 - 1.7 
Expectative 0.2 - - - 
Missing 4.6 - 0.3 - 
Numbers stated in percent. 
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The screening program is cost-effective 
To our knowledge no studies examined the cost-effectiveness of screening programs for BCC. 
However, since the current screening method would detect all skin cancers, including melanoma and 
SCC, its cost-effectiveness can only be argued by an overall assessment for all skin cancers. Indirect 
evidence suggests that treatment of larger BCCs in the face is more costly and that the risk of 
recurrence is higher, which in turn increases treatment cost. Evidence for non-facial lesions is scarce.  
Rogers et al. calculated that the cost per primary treatment modality (MMS, SE, imiquimod, 
radiotherapy) increases with increasing lesional size for a hypothetical BCC lesion on the cheek of 6 
mm, 11 mm, 21 mm and 31 mm. 
116
 Size of the lesions can indirectly influence cost by its impact on 
different surgery setting (outpatient or inpatient basis) and complexity of the reconstruction 
technique. For excision of BCC on the ear a strong correlation between size and reconstruction 
technique has been demonstrated. Defects smaller than one fourth the vertical auricular size (15 to 20 
mm) can be treated by primary closure, larger defects required more complex reconstruction.
117
 
Comparison of cost for NMSC showed that tumor size >10 mm, tumors on the head and neck and 





In view of the high incidence of BCC, its predicted increase in the future and in the absence of 
mortality due to this type of skin cancer, this review addresses the question whether including BCC in 
skin cancer prevention campaigns could be worthwhile. In this respect we evaluated the WHO criteria 
for screening specifically adapted to BCC. Epidemiological data show that most BCCs develop in the 
head and neck area of older patients (> 65 years). Detection of BCC by visual inspection is a relatively 
simple, safe and non-invasive examination. Dermoscopy can increase diagnostic accuracy. On the 
other hand appropriate treatment strategies are available. Surgery remains the most effective 
treatment but some other non-surgical strategies have also proved to be effective and are currently 
used in daily practice.  
Size of BCC and the specific growth pattern seem to be very important determinants in treatment 
complexity and related cost, especially for the facial location. Data on the natural progression of BCC 
and the main drivers for histology are scarce. Available data point to a rather slow increase in size of 
BCC, creating a large time frame where BCC is amenable for early detection and treatment. Current 
evidence supports delay as the main underlying cause for a more aggressive clinical behavior, and no 
specific intrinsic biological factor has been identified so far.  




We conclude that it may be worthwhile for skin cancer screening initiatives to include BCC especially 
of the face region. Studies point out that complexity, effectiveness and cost of surgical procedures in 
this area is highly influenced by size of the lesion. A small increase in size might therefore lead to more 
extensive or complex surgery which may affect outcome of the patient (surgical defect), the risk of 
side effects due to the procedure, the frequency of follow-up visits and hence total cost in an 
important way.  
The appropriate selection of an adequate initial treatment seems to be of equal importance, since 
treatment failure will lead to disease recurrence, necessitating a second treatment with increased 
complexity and  cost.  
 
CONCLUSIONS 
We conclude that BCC in the facial area fulfills the majority of WHO criteria for screening. Early 
detection and adequate treatment of BCC could reduce treatment complexity and cost, and offers a 
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Background: The use of dermoscopy has benefit the diagnosis of skin cancer significantly in well-
trained dermatologists. However to evaluate its cost-effectiveness in daily practice, not only sensitivity 
but the excision rate is crucial. For this purpose we examined the diagnostic accuracy of cases derived 
from a population-based sample scored by Flemish dermatologists.  
Methods: 126 dermatologists were randomly assigned to 145 digital cases of patients presented with a 
lesion to a skin cancer screening. This resulted in 4655 case-evaluations using a web application. 
Accuracy of diagnosis and treatment was correlated to the histological diagnosis or expert opinion.  
Results: The larger part (89.7%) of dermatologists uses their dermatoscope daily. Dermoscopy 
dramatically increased sensitivity for skin cancer diagnosis from 70.6% to 84.6%, but this was 
associated with a small but significant decrease in specificity of 3.6%. To detect one skin cancer 5.23 
lesions with suspicion had to be excised. Dermoscopy significantly increased the certainty about 
aki g a orre t diag osis, a d this was ost the ase for se orrhei  keratosis, Bowe ’s disease a d 
melanoma.  
Conclusion: No significant reduction in the number of excisions could be demonstrated in this sample, 
the use of dermoscopy by Flemish dermatologists in daily practice significantly improves the sensitivity 

















The skin cancer epidemic has an important impact on health care budget in Europe. Early detection 
and treatment is assumed to give better cure rates and subsequently a more cost-effective treatment. 
Dermoscopy is a well-established tool for diagnosis of melanoma and non-melanoma skin cancer 
(NMSC). Several meta-analyses have shown that dermoscopy, in the hands of experienced 
dermatologists, is superior to naked-eye examination (NEE) to detect melanoma.
1-3
 Dermoscopy also 
significantly increases the diagnostic accuracy of NMSC diagnosis.
4
 For basal cell carcinoma (BCC) the 
diagnostic accuracy obtained by dermoscopy is up to 95-99%.
5-7
 It is known that the diagnostic 
accuracy of dermoscopy depends significantly on training of the examiners.
8
 In the hands of untrained 
practitioners, dermoscopy provides no better diagnostic accuracy for melanoma than NEE.
1
 Most of 
the studies on the additional diagnostic value of dermoscopy have been performed in a well-selected 
set of lesions, in which MM and other malignant lesions are usually overrepresented. Since skin cancer 
prevalence in real life setting is usually much lower, this can influence the number of false positives 
a d their related ost i  a  i porta t way Bayes’ theore . For this reason we examined diagnostic 
accuracy of NEE alone and of additional dermoscopy among dermatologists in a population-based 
sample in Belgium.  
 
METHODS 
Study design  
Cases and determination of reference diagnosis 
The cases were collected during a population-based lesion-directed skin cancer screening. Screenees 
could register for a free of charge skin cancer check, if they had a lesion meeting one or more of the 
criteria listed: ABCD rule, ugly duckling sign, and new lesion since more than 4 weeks, red non-healing 
lesions. All lesions presented by the screenees were photographed both clinically and dermoscopically 
(respectively Canon EOS 1200 D and DermLite Photo System). In total 248 lesions were presented for 
screening and 8 out of them were histologically proven to be skin cancers (3.2%). Further details on 
this screening initiative have been published elsewhere.
9
 In total 145 of the 248 cases (58%) were 
selected for a web application. Exclusion of cases was due to sub-optimal quality of the photographs 
or a missing clinical or dermoscopy photo. This study was approved by the Flemish government and by 
the medical ethical committee of the University Hospital Ghent. All screenees provided written 
informed consent.  
As a histological diagnosis was not available for most of the lesions the following surrogate reference 
diagnosis was used in a hierarchical order: diagnosis of the pathologist in case of excision or biopsy of 
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the lesion (n = 6, 4.1%), concordant diagnosis by 2 expert dermoscopists (KV, LB (n = 100, 67.0%));  in 
case of discordance in diagnosis by these 2 experts, a third independent expert dermoscopist (GA) was 
asked and the most concordant diagnosis was chosen (n = 39, 26.9%). The gold standard diagnosis of 
all cases are listed in Table 1.  
 
Table 1. Specific diagnosis lesions of the 145 cases  
Diagnosis Number Percent 
Melanoma  1 0.7 
BCC 4 2.8 
SCC/Bowen  1 0.7 
Actinic keratosis 3 2.1 
Angioma 5 3.4 
Dermatofibroma 4 2.8 
Atypical nevus 6 4.1 
Blue nevus 3 2.1 
Congenital nevus 6 4.1 
Benign nevus 53 36.6 
Solar lentigo 12 8.3 
Seborrhoic keratosis 40 27.6 
Other 7 4.8 
Total  145 100 
 
Recruitment of dermatologists 
A personal invitation to participate in this study was sent out to all 384 Flemish dermatologists. Only 
certified dermatologists could participate. Participating dermatologists were asked to register online, 
and to evaluate 1 or more series of 25 cases each. Case series were presented randomly to each 
registered dermatologist. Upon registration, information concerning their practice, previous training in 
dermoscopy and the frequency of use of dermoscopy in routine practice was asked. 
Case evaluation 
Each online case mentioned a brief clinical information (age, gender and location of the lesion). First 
dermatologists were shown the clinical photo and were asked to select a clinical diagnosis (multiple 
choice), to score the certainty of their diagnosis on a visual analogue scale (VAS) from 0 - 100%, and to 
choose the best treatment action (no treatment, biopsy, surgical excision, curettage, cryotherapy and 




other); after registration of these answers they were shown the dermoscopy photo and were asked to 
complete the exact same questions.   
Sample size calculation and statistical analysis 
A sample size of 1630 case-evaluations was required to achieve a power of 80% to detect a difference 
in specificity of 5% in the group of clinical evaluation compared to the group of additional dermoscopy 
evaluation with a significance level of 5%. A specificity of 85.4% for the clinical diagnosis was expected 
and an interclass correlation of 0.81 was assumed (based on pilot data). Sample size calculation was 
adjusted for the clustered nature of the design by applying the method described by Killip (2004).
10
 
Descriptive statistics were used to describe the cases and dermatologists participating. The related 
samples wilcoxon signed rank test was used for continuous variables. Due to the clustered nature of 
the data mixed logistic regression models were used to calculate sensitivity, specificity and number 
needed to excise (NNE) and their relation to experience and training of the dermatologist. All 
statistical tests were two-tailed and P-values <0.05 were considered statistically significant. The 
analyses were conducted in SPSS version 21.0 (IBM, Armonk, NY, U.S.A).   
Outcomes  
The primary outcome of this study was to evaluate the diagnostic accuracy of dermoscopy compared 
to NEE in a population-based setting. Furthermore we wanted to evaluate if dermoscopy can increase 




In total 126 dermatologists randomly evaluated 1 or more series of cases with a mean of 32.1 
evaluations per case. This resulted in 4655 case-evaluations. The majority of the participating 
dermatologists were female (80.2%). The median age was 45 (interquartile range (IQR) 38-52). The 
majority of dermatologists worked in a private practice (54.8%), 38.9% in a university center and 6.3% 
in a hospital setting. The reported median number of patients seen in their practice or hospital was 
100 per week (IQR 70-130). Dermoscopy was used at least once a day in 89.7%, once a week but not 
daily in 7.9%, once a week up to once a month 1.6% and not at all in 0.8%. Thirty-seven dermatologists 
(29.4%) use a non-polarized dermatosope. Training in dermoscopy varied among the participating 
dermatologists: only 3 dermatologists (2.4%) had no training in dermoscopy; whereas 25 (19.8%) had 
1-5 hours, 42 (33.3%) had 5-10 hours and 56 or 44.4% had more than 10 hours of training. 
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Diagnostic accuracy and certainty of diagnosis 
Dermoscopy dramatically increased sensitivity for skin cancer diagnosis significantly from 70.6% to 
84.6% (Binomial generalized linear mixed model, P<0.01; Table 2), and was associated with a small but 
significant decrease in specificity (96.9% for NEE versus 93.5% for dermoscopy, Binomial generalized 
linear mixed model, P<0.01; Table 2) (Figure 1). The sensitivity for the diagnosis of melanoma in 
specific increased from 76.0% to 94.3% (Binomial generalized linear mixed model, P=0.03). The odds 
for making a correct diagnosis of melanoma using dermoscopy was 5.38 (95%CI 1.22-23.81) compared 
to NEE. Dermoscopy also increased sensitivity for diagnosis of BCC and SCC/Bowen from 71.5% to 
74.6%, and 58.9% to 71.0% respectively, but this failed to reach statistical significance.  
 
Table 2. Diagnostic performance of dermoscopy according to level of training of the dermatologist 
 Clinical  Dermoscopy P-value
a 









 0.065  
b,c
<0.01 




0.085 0.774  0.861 
 
0.139 - 
5- 10 hours 0.702 0.921  0.079 0.829  0.885  0.115 - 
>10 hours 0.704 0.940 
 
0.060 0.852  0.887  0.113 - 
P- value
a
  0.49 0.61  - 0.42 0.53 -  
Sens, sensitivity; Spec, specificity; 
a 
Binomial generalized linear mixed models.  
 
A trend to increasing sensitivity/specificity was observed with increasing training level (figure 2). The 
confidence about a correct diagnosis significantly increased from a median of 70% (IQR 60-80) using 
NEE to 83.7% (IQR 70-90) with dermoscopy (Related samples wilxocon signed rank test, P<0.01). The 
increase was most pronounced for seborrheic keratosis, Bowe ’s disease a d ela o a. 
 





Figure 1. Sensitivity and and 1 minus specificity for a malignant diagnosis made clinically and using 
dermoscopy. Dermoscopy increased sensitivity for skin cancer diagnosis significantly from 70.6% to 
84.6%, but this was associated with a small but significant decrease in specificity (96.9% for NEE versus 
93.5% for dermoscopy). 
 
 
Figure 2. Sensitivity and 1 minus specificity for a malignant diagnosis according to level of training of 
the dermatologist. Sensitivity and specificity for skin cancer diagnosis raised with advanced level of 
training, although this failed to reach statistical significance. 
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Number needed to excise  
Dermoscopy resulted in 43 additional excisions for skin cancer and 252 extra excisions for benign 
lesions (on a total of 1765 excisions or biopsies performed) compared to the clinical evaluation  
without dermoscopy. This resulted in a NNE of 4.77 for clinical evaluation alone and 5.23 when using 
dermoscopy (Binomial generalized linear mixed model, P=ns). NNE did not seem to be influenced by 
training level (0-5 hours NNE 5.15, 5-10 hours NNE 4.89 and > 10 hours NNE 5.62, Binomial 
generalized linear mixed model, P=ns). Regarding to specific diagnoses (melanocytic lesions and BCC) 
the NNE also did not change significantly between clinical diagnosis and dermoscopy diagnosis. In 
addition, no significant difference in NNE using dermoscopy could be demonstrated associated with 
characteristics of the dermatologist (age, number of patients per week, work environment or the 
frequency of use).  
 
DISCUSSION  
In this study the additional value of dermoscopy use over clinical diagnosis by 126 dermatologists was 
evaluated in a population-based series of 145 cases. In the past a lot of similar studies have used very 
selected case series in which skin cancer is usually overrepresented. As the aim is to not miss skin 
cancer (high sensitivity), which is especially important in melanoma, the importance of not over-
diagnosing skin cancer (high specificity) may become more and more important in populations where 
skin cancer prevalence is low. In this study we therefore included a case series based on a skin cancer 
screening program, in which the skin cancer prevalence was 6/145 (4.1%). One hundred twenty six 
(32.8%) of all Flemish dermatologists evaluated at least 25 of the 145 cases. Cases were randomly 
presented to the dermatologists leading to a total of 4655 case-evaluations. In this way this study 
reflects the additional value of dermoscopy in the hands of Flemish dermatologists in a population-
based series. In this regard, the possibility that lesions with more clear visual and clinical features were 
included, owing to the design of the screening study must be mentioned. On the other hand, since the 
screening was an early detection initiative, it could have rendered relative smaller lesions more 
difficult to diagnose.  
The results of our study demonstrate that dermoscopy is frequently used in Belgian dermatology 
practice: almost 90% of the dermatologists use the dermatoscope daily. This is comparable to large 
studies performed in France and Australia (94.6-98%).
11 12
 We noted, in accordance with other studies, 
that dermoscopy significantly increases sensitivity for malignant lesions.
1-4 6
  However this results also 
in a small but significant decrease in specificity, thus increasing the number of false positives. In this 
study dermoscopy resulted in 43 additional excisions for skin cancer and 252 extra excisions for benign 




lesions over clinical diagnosis. The sensitivity/specificity tended to increase with increased level of 
training, confirming previous studies.
1-4 6
 Confidence about making a correct diagnosis was significantly 
higher usi g der os opy, a d ost i porta t i  ela o a, se orrhei  keratosis a d Bowe ’s 
disease. However this did not end up in a reduction of unnecessary excisions as the NNE did not 
significantly differ between clinical diagnosis and dermoscopy nor did it seem to be influenced by 
training. However the NNE of the experts in the real life setting on the screening (KV, LB) was clearly 
lower than the NNE reached in the online case evaluation.
9 
The use of both clinical and dermoscopical photographs with the added information of gender, age 
and lesion location to evaluate pigmented skin lesions remains somewhat artificial. In the absence of a 
total body inspection individual lesions may be interpreted in a different way, as it is for example 
known that one individual with multiple nevi usually displays similar lesions (signature nevi) and that 
there should be caution about lesions with a different pattern (ugly duckling sign). This was illustrated 
by 2 prominent nevi, that were considered non-suspicious by the 2 experts (KV, LB) on the screening 
and were scored as potential melanoma in the online case series by at least 2 of 3 experts. Digital 
follow-up of these lesions by means of new clinical and dermoscopy photographs about 20 months 
after screening demonstrated stability, suggesting that these lesions have a benign behavior. This 
illustrates that part of the false positive skin cancer diagnoses may be due to the artificial conditions in 
which the lesions are evaluated.   
Compared to previous studies the NNE of 1 out 6 is more effective than dermoscopy use by general 
practitioners. Evaluation of the large SCREEN campaign in Germany in a partially non specialized 
setting resulted 17 excisions of suspicious melanocytic lesions for the detection of one melanoma.
13
 
Our data is comparable to a large multi-centric study examining excision rates over a period of 10 
years in a specialized clinical settings, with a NNE of 6.8.
14
 
There was a trend towards increased sensitivity and specificity with increased training, however 
training of >10 hours did not reach statistically significant superior results. In the current guidelines 
the use of/and training in dermoscopy regarding melanoma has a grade A recommendation, however 
the NNE in this study is not influenced by the hours of training in dermoscopy.
15
 The required amount 
of training however is debated. It has been shown that despite the frequent use of dermoscopy 
training seems to be insufficient and that even among dermatologists who consider themselves 
experienced in dermoscopy, repeated training moments can increase diagnostic accuracy.
11,8
 In 
addition currently a lot of training courses in dermoscopy mainly focus on red flags (increase of 
sensitivity for melanoma). However when used in low prevalence populations it could be interesting to 
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put more focus on green flags (recognition of harmless lesions), thereby reducing the number of false 
positive diagnoses and hence unnecessary excisions. 
 
CONCLUSIONS 
The current study evaluated the additional value of dermoscopy in the hands of Flemish 
dermatologists in a population-based setting using a series of photos in a web application. These 
results demonstrate that dermoscopy clearly increases sensitivity for malignant lesions in a population 
based setting, at the expense of a small but significant decrease in specificity. Although dermoscopy 
significantly increased confidence about a diagnosis, especially in melanoma, seborrheic keratosis and 
Bowe ’s disease, this did not result in a reduction of NNE. There was a trend towards higher sensitivity 
and specificity according to training level (<5 hours, 5-10 hours or > 10 hours). We suggest that 
continuous training for dermoscopy may be needed and that training courses should also pay enough 
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EPIDEMIOLOGY AND SKIN CANCER COST 
In chapter 3, we estimated the current and future prevalence, and economic burden of MM and 
NMSC in Belgium. These results indicated that the prevalence of skin cancer will triple in the next 20 
years. In 2034, the total number of persons affected by skin cancer will be 397 213, of which 66% BCC, 
21.2% SCC and 12.8% MM. The rate of increment for MM, SCC and BCC was calculated respectively at 
3.2, 3.3 and 2.7. The total economic burden of skin cancer in 2014 was estimated at €107 million 
dire t osts €78 illio ; i dire t osts €29 illio , ith a u ulati e ost of € .  illio  i  . The 
majority of the total cost is due to MM (65%). The indirect costs due to productivity losses are mainly 
(>90%) due to MM. Melanoma and NMSC are both responsible for about half of the direct costs. To 
summarize, we found that MM is responsible for the majority of the costs; and NMSC affects the 
majority of patients.  
A limitation of the current epidemiological and economic studies, including ours, is that these future 
prevalence and costs are presumably underestimated, since few cancer registries collect correct data 
on NMSC. As most national registries are pathology based, tumors without histological confirmation 
will not be captured. The EPIDERM audit, performed in 4 European countries (Netherlands, Scotland, 
Finland and Malta), demonstrated that up to 24.1% of BCCs are diagnosed without histological 
confirmation.1 In addition, most registries only document the first NMSC per patient and do not 
differentiate SCC from BCC. For the current study, we had to rely on the Dutch cancer registry, 
likewise not including BCC without histological confirmation, nor multiple NMSCs. The latter also 
impacting the results significantly, since it is generally acknowledged that over a period of 10 years up 
to 30% of BCC patients develop a second or even third BCC.2  
Cost calculations were based on patient questionnaires gathered in different clinical settings; private 
practices, private hospitals and university setting. In contrast to the relatively large amount of 
physicians (16 dermatologists, nine oncologists and one general practitioner), only 287 patients were 
included using consecutive sampling. We tried to minimize recall bias by only questioning disease 
related costs and QOL over the last 6 months. Even under these circumstances, the bottom-up nature 
of our study has several advantages compared to top-down methods. Since the latter are more 
predisposed to misallocate direct and indirect categories of the costs. In addition, the design does not 
include informal costs, such as transport, informal care or other indirect costs which were included in 
our questionnaires. And given that elderly skin cancer patients have multiple pathologies, it can be 
difficult to attribute the exact part of, for example a hospitalization, to the disease of interest in a top-
down design.3  
 





UV prevention campaign and a total ban on sunbed use 
The impact of a SunSmart campaign was modeled in chapter 3. The effects of the intervention were 
expressed as a reduction in sunburns, since the risk of developing MM is 59% higher compared to 
those who have never been sunburned. We did not model an impact of reduced sunburn on SCC or 
BCC incidence.4 In addition, the effect of a total ban on sunbeds was modeled. Over a period of 50 
years, both prevention programs would lead to a gain in QALYs and cost-savings, being dominant 
strategies. It is clear that a ban on sunbed use would be the most cost-effective solution, because 
intervention costs are absent, and the strategy achieves a higher incremental QALY than a UV 
protection campaign. The budget impact analysis revealed that for every euro invested in the 
pre e tio  a paig , € .  ould e sa ed i  the lo g-term for the health care payer.  
In the absence of clear data on the tumor biology, lag-time of UV exposure and tumor initiation and 
promotion, an induction period of 20 years was applied.5  Repeated analyses with 10 and 30 years 
induction periods also resulted in dominant ICERs. Based on migration studies, it is shown that 
exposure to high levels of sunlight in childhood is a strong determinant of MM incidence and even 
mortality.6 In addition, a large meta-analysis demonstrated that the risk for developing MM is 1.91 
when ever being sunburned during childhood, compared to 1.44 during adult life.7 Our cohort 
included the adult Belgian population, and to appropriately capture the positive impact of the 
intervention in children, a longer induction period would be required. Nevertheless, a prevention 
campaign should focus on sun avoidance and wearing of protective clothing, especially in children 
based on the epidemiologic evidence.7 Additionally, the campaign teaches children responsible sun 
behavior, having an educational effect. For parts of the body not protected by clothing, the use of 
sunscreens with SPF in the range of 30 to 50 should be advised. These results indicate that policy 
makers are obliged to critically review the topic of a national UV prevention campaign and a sunbed 
ban. In Brazil and Australia, a national sunbed ban is currently in place.8,9 At present the Belgian 
Superior Health Council is preparing a report supporting a restriction on sunbed use in Belgium. 
Some methodological assumptions concerning the disease models are imperative to discuss. Since 
knowledge on the natural history of skin cancer is limited, generic progression rates were applied 
irrespective of age and gender, based on the large dataset of Leiter et al.10 and calibration for the 
natural progression of MM. It is known, however that females have a lower risk of melanoma 
progression (hazard ratio (HR) 0.68).11–13 In addition, age is an independent prognostic factor for 
melanoma survival and progression. Patients under the age of 20 years have better survival, and older 
age (> 70 years) is a negative prognostic factor.14,15 Because of the large amount of calculations 
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needed for validation and fitting the data, making a full age- and gender specific model would be 
impossible. On the other hand, the most important effect, namely the female advantage in survival 
was adopted in the disease model. Secondly, the model assumed that the effect of the SunSmart 
campaign would only affect sunburn and MM. A reduction of cumulative UV exposure was not 
incorporated because of the lack of data on this effect. In the ideal situation, a difference in incidence 
of MM and NMSC between to nearby regions, with one having a SunSmart campaign would be needed 
to model the true impact. No such data is available at the moment for Europe, and the only study 
performed in Australia showed that the incidence of only BCC had decreased (in age groups less than 
50 years old). These findings were based on surveys, and partly as a result of the primary prevention 
initiative. There was no impact on SCC incidence observed.16 Therefore, the effectiveness of the 
SunSmart program was measured by reduction in sunburn only, knowing that the overall UV exposure 
and risk for development of BCC and SCC would also decrease,17 benefiting the cost-effectiveness 
ratio. 
Challenges for primary prevention 
Effective primary prevention is faced with some important challenges; below we provide a non-
exhaustive overview. Behavioral changes, needed for successful primary prevention, are difficult to 
implement in the general population as shown by the Australian example. Its ell k o  Slip, slop, 
slap!’ campaign advises people to spend time in the shade between 11am and 3pm, cover up with a t-
shirt, hat and sunglasses and to use a sunscreen generously. Since 1980 there have been enormous 
efforts to promote sun safe behavior in Australia using multi-component and community-wide 
programs.18 Unfortunately, people enjoy being in the sun and tanned skin is still considered as a sign 
of beauty. And the visible negative effects of UV radiation, such as solar aging and development of skin 
cancer develop with a significant delay. Research on sun protection in schools and families in Australia 
indicates that despite the programs, the rates of sun protection remain unsatisfactory.19,20 More 
recently, however, a positive trend was seen with an increase in sunscreen use and a consistently high 
use of sunglasses; however seeking shade, staying inside and wearing protective clothing remained 
low.21 And exactly those measurements are known to be most protective; as some studies actually 
show that sunscreen use is associated with increased intentional tanning and a moderate increased 
MM risk.22,23  
Likewise, a change in mentality concerning the use of sunbeds is needed. In Belgium, 16% of the 
population stated to have had at least 1 tanning session in the past 12 months, with 8% stating that 
they use indoor tanning devices at least 5 times a year.24 The users are predominantly young females. 
The Belgian government recently introduced regulations banning those with a history of skin cancer, 




skin type 1 and minors, from using indoor tanning facilities.25 Unfortunately, more than 90% of the 
indoor tanning centers ignored these regulations, with half surpassing the intensity of 0.3 W/m2 UV 
radiation.26 Moreover, the industry makes false claims concerning possible positive effects of indoor 
tanning. These profess that indoor tanning will increase vitamin D production, improve bone 
structure, benefit the immune system and cure various skin diseases . Because of the failed self-
control by the industry and the carcinogenic effects, the Belgian government acknowledged the 
importance of this matter and gave it a prominent place on the policy agenda. 
A last factor interfering with effective primary prevention is, as mentioned above, the relation 
between UVB radiation and vitamin D metabolism. This vitamin is essential for calcium homeostasis 
and bone development, and vitamin D3 is synthesized in the skin under the influence of UVB radiation. 
Be ause seru  ‐h dro ita i  D le els are se siti e to a ou ts of vitamin D consumption and 
UVB e posure, the easure e t of seru  ‐h dro ita i  D le els is commonly used as a marker 
of individual vitamin D status. Several recent meta-analyses could not confirm the health benefits 
supposedly associated with increased ‐h dro ita i  D. Despite high doses of supplementation of 
≥  µg per da , administered to individuals with low vitamin D status before randomization, even on 
endpoints as osteoporosis, fractures or falls.27–29 The exposure to artificial or natural UV for increasing 
vitamin D is not more efficient than taking oral supplements of vitamin D, while it increases the risk for 
skin cancer. In the current climate of attention for vitamin D status and sunbed use or sun exposure, 




Because skin examination and dermoscopy is a simple non-invasive technique, several early detection 
initiatives exist, of which most focus on MM. However the majority of skin cancers patients suffer 
from NMSC, resulting in 35% of the total cost of skin cancer in Belgium. Based on the WHO criteria, we 
questioned the role for simultaneous early detection of BCC - in which the main outcome of mortality 
is absent - as an answer to the growing economic burden. In chapter 7, we found that BCC grows 
slowly and increases with a median diameter of 0.5 mm over 10 weeks. Delay in diagnosis and 
appropriate treatment are the most important underlying causes in the occurrence of giant BCC or 
metastasis. The early detection and initial adequate treatment of BCC seems to be crucial for BCC 
located on the face, more specifically in the H-zone, as small changes in size on this location can 
dramatically affect treatment options, their effectiveness and associated costs. Despite the above, it 
needs to be recognized that, the effectiveness of BCC screening can only be justified by the overall 
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benefit of skin cancer screening, since no method exists to date to solely detect facial BCC. On the 
other hand, our findings support the inclusion of BCC in screening initiatives, a topic in the prevention 
of skin cancer that was, to our knowledge, not addressed earlier. 
Clinical effectiveness of skin cancer screening 
Mass population-based screening by means of whole body examination in asymptomatic persons has 
not been proven cost-effective, although the experience in Germany seems to suggest that such 
screening is feasible and could reduce skin cancer burden.30 We proposed a new technique and 
compared it to the standard screening method in two socio-economical similar populations; these 
results are described in chapter 4. The novel lesion-directed approach implied that screenees were 
invited to present with a specific lesion meeting criteria listed on the invitation (ABCD rule, ugly 
duckling sign, new lesion since more than 4 weeks and/or red non-healing lesions). Based on a smaller 
pilot study we hypothesized that the lesion-directed screening (LDS) would increase the a priori 
chance of skin cancer and could be more efficient than a total body examination (TBE).  
Our work showed that a systematic screening initiative seems achievable in Belgium, and that 
participation rate is remarkably higher in TBE than in LDS (17.9% versus 3.3%). The TBE participation 
was comparable to the participation rate of 19.1% in the German state where the SCREEN project was 
organized.31 We observed a high male participation; 43.8% compared to 26.4% in Germany. Since our 
studies were conducted in Belgium we cannot exclude an effect of awareness resulting from the 
Euromelanoma initiative. This is an opportunistic early detection campaign that has been conducted 
annually in Belgium since 1999. The Euromelanoma day is now also organized in 31 European 
countries with the main objective to offer free screenings by dermatologists and inform on skin cancer 
and its prevention.32 In our study, 38.2% of the screening participants previously received a skin check. 
This high number could be explained by a combination of several factors; the rising awareness for skin 
cancer in general, healthy subject bias and effects of the Euromelanoma campaigns. In order to have 
as minimal contamination as possible, the longest duration feasible between the Euromelanoma 
campaign (launched in May) and our screening study was established (March/April).  
The two screening methods yielded the same number of skin cancer per 100 participants, though the 
diagnostic yield per 100 invitees was 5 times higher for the TBE method due to the significant 
difference in participation. As for the negative consequences, i.e. false positives or unnecessary 
excisions and anxiety; we reached a high positive predictive value of 56.6% compared to other 
screening initiatives (22.2% in the 2009 Euromelanoma campaign and 25.7% in the SCREEN 
project).33,34 I  additio , parti ipa t s a iet  easured efore and immediately after screening did 
not change significantly, which is a criticized undesired side effect of all screening initiatives. Since LDS 




had a similar detection rate of 3.2% as TBE, though 5.6 times less time-consuming, we hypothesized 
that LDS by dermatologists could be an alternative screening method, especially in health care systems 
with limited budget and, or waiting lists. In addition, only one skin cancer was found by total skin 
examination in the LDS group if the lesion of concern was not malignant. This suggests that a total skin 
examination is mainly indicated in case the participant presented with a suspicious lesion.  
Cost-effectiveness of skin cancer screening  
In contrast to our main hypothesis, we could not demonstrate an economic benefit from a lesion-
directed technique. This was mainly due to the significantly lower participation rate (17.9% versus 
3.3%) (chapter 5). Both screening methods ranged below the Belgian willingness-to-pay threshold. Our 
research findings did however demonstrate a clear benefit, in terms of cost-effectiveness for females 
over males for both methods ICE‘ fe ales €   -   ersus €   - 34 836 for males). 
Presumably, this finding can be attributed to the higher incidence of MM in females, and especially in 
the age group of 35 - 64 years (male/female ratio is 0.6).35  
The base case scenario (i.e. one time screening in the adult population) is most cost-effective. 
Screening from 18 years on seems to be more cost-effective than from 40 years. An argument for the 
latter is the more important gain in QOL and productivity in case of early detection in younger age 
groups. However, several scientific findings argue the opposite; in Germany the nation-wide screening 
is organized every 2-years from the age of 35 years, though this decision was solely based on 
observational results and a micro-simulation model examining MM mortality, not QOL; nor comparing 
different age-scenarios.36 To date no cost-effectiveness study using QALY as an outcome 
measurement, published different age-scenarios.37–40 The only study that included QOL, examined 
only a one-time screening scenario from the age of 50 years, and the result was clearly more cost-
effective than our screening strategy ($ 10 100/QALY).38 In this discussion, several methodological 
issues should be taken in account, and could explain the relative benefit of inviting the population 
from the age of 18 years old, observed in our study. To the best of our knowledge, the Markov model 
presented is the first to include NMSC, the indirect costs due to productivity losses, the cost of death 
and QOL. On the contrary, several studies demonstrate that in case the cost per life-years gained (LYG) 
is the only outcome of interest,39 prevalence of disease in participants is pivotal in the cost-
effectiveness ratio per LYG.37 
In accordance with the study of Losina et al., our research demonstrated that repeated screenings 
would be less cost-effective, presumed as a result of the rising intervention costs.38 When comparing 
two screening intervals during a period of 20 years with a time horizon of 50 years, the TBE strategy is 
most cost-effective for males every 5-years and females every 2-years. When organizing repeated 
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lesion directed screenings, this would be most cost-effective every 2-years compared to screening 
intervals of 5-years for both sexes, but differences are minimal (Table 1). Nevertheless, with the 
background knowledge that defining the interval and target population for cervix-, colorectal- and 
breast cancer screening in Belgium was a continuous process, the aforementioned findings need to be 
confirmed and corroborated in order to determine the most optimal target group and screening 
interval.41–43  
 
Table 1. Cost-effectiveness ratio of different preventive strategies and scenarios 
Intervention  Level  Cost-effectiveness (cost/QALY) 
  Males Females 
Ban on sunbed use Primary Cost-saving Cost-saving 
Prevention campaign Primary Cost-saving Cost-saving 
Screening time horizon 20 years    
TBE 18 years one time Secondary €   €   
LDS 18 years one time Secondary €   €   
TBE 40 years one time Secondary €   €   
LDS 40 years one time Secondary €   €   
Screening time horizon 50 years     
TBE 18 years one time Secondary €   €   
LDS 18 years one time Secondary €   €   
TBE every 2 years Secondary €   €   
LDS every 2 years Secondary €   €   
TBE every 5 years Secondary €   €   
LDS every 5 years Secondary €   €   
 
 
Patient specific data gathered in the prospective clinical trial, was inputted in the Markov model and 
was subjected to the corresponding uncertainty around each parameter. In practice, even for 
economic evaluations performed parallel to clinical trials, several input data needs to be synthesized 
from other studies in order to evaluate the cost-effectiveness with the best knowledge at hand. The 
one-way and probabilistic sensitivity analyses are, because of the above, as important as the main 
outcome since it allows to systematically investigate all influencing factors. The 95% CI for each input 
parameter is necessary to quantify the uncertainty. In deducted estimations and calculations, the 95% 
CI is not at one's disposal; and by convention a 30% interval is applied.44 This was the case for utilities 
and costs of skin cancer, as well as the progression rates. As mentioned earlier, we found an ICER just 
below the Belgian willingness-to-pay threshold, however the PSA suggests that, given the parameter 
uncertainty modeled, the ICER is likely to be between € 23 251 – €   per QALY gained for TBE in 




males. In addition, the one-way sensitivity analyses demonstrate that natural progression is the most 
decisive parameter in the overall uncertainty around the outcome. In case a variation of 30% is applied 
around the progression, the ICER clearly exceeds the threshold at € 60 000 per QALY gained. As 
discussed above, these transitions and MM pathway are methodological assumptions, and long-term 
observational data is needed to accurately calculate these input parameters. The sensitivity analyses, 
in this way, underline the importance of gathering additional knowledge on this crucial determinant in 
the evaluation of skin cancer screening.  
Challenges for secondary prevention 
Several important challenges and controversies concerning skin cancer screening and early detection 
need to be discussed. Arguments supporting early detection are that significant lower melanoma 
Breslow thickness has been demonstrated when melanomas were detected (i) during physician clinical 
examination compared to by patients or their family members.45–47 A mean reduction of 0.55 mm in 
thickness is seen when melanomas are detected by clinicians,47 and a TBE in the last 3 years prior to 
MM diagnosis is inversely associated with MM thickness.46 In the US, the incidence of all thickness 
MM is still increasing,48,49 and among patients of lower SES with limited access to care, the highest 
increases were seen for melanomas of 2.01 mm up to more than 4.01 mm thickness.50 (ii) by a 
dermatologist compared to other physicians,51,52 and (iii) using dermoscopy instead of a NEE.53 In 
addition to the above, the association between dying from MM and increasing tumor thickness has 
been demonstrated incontestable by several studies.54–61 Hazard ratios up to 32.6 for melanoma-
related mortality have been observed for Breslow thickness of 4.01 mm compared to 0.50 mm.55 
However, no prospective controlled studies could currently demonstrate a reduction in melanoma-
specific mortality due to screening, nor are there studies proving the contrary.  
Following the German SCREEN study in 2003-2004, including 360 288 adults, the proportion of thin 
melanomas increased significantly from 52 to 64% and a reduction in mortality was observed.30 Boniol 
et al. argue that this transient mortality decrease was observed to close to the screening and possibly 
due to bias in registration of the cause of death.62 To the present day, there is no consistent evidence 
that screening results in a decrease of disease-specific mortality; on the contrary some argue that 
early detection initiatives and awareness will induce overdiagnosis of lesions without malignant 
potential and only cause significant morbidity.63 On the other hand, it has been shown in a 
retrospective study of 2000 individuals, that in case the melanoma was detected by a dermatologist, 
this lead to improved survival.51 Older men (>60 years) living alone presented with more advanced 
stage at diagnosis and had a reduced MM specific survival.64 
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A limitation of the presented study is that the magnitude of overdiagnosis was not quantified, since 
knowledge on the exact proportion of patients diagnosed with a MM that will progress - or not - is 
missing. A worst-case scenario analysis, with the hypothetical presumption that 25% of all melanomas 
detected and treated during the screening would not progress, increased the ICER for the base-case 
screening scenario significantly up to €   – €   for fe ales a d €   – €   for 
males. In the above assumption of overdiagnosis, the ICER would thus exceed the willingness-to-pay 
threshold for males.  
An argument contrasting the above criticism of overdiagnosis, is the development of melanoma, 
which involves successive biologic phenomena, with cell cycle dysregulation, invasion of the dermis, 
which can ultimately lead to distant metastases. Some melanomas behave more aggressively and 
demonstrate events early that usually occur later in the process. As a consequence the concept of 
different subtypes of MM kinetics (slow-growing, medium-growing versus rapid-growing) is postulated 
by several authors.65–67 Presence of a BRAF mutation is not necessarily associated with rapid tumor 
growth,68 yet on the other hand melanomas that show initial fast growth seem to be prognostically 
less favorable, and a high mitotic index predicts a short-term relapse.69 Some believe that these rapid-
growing melanomas are the true killers, and therefore, without diagnosing these, early detection will 
not result in any survival benefit, but mainly overdiagnosis. The difficulty is also identifying risk factors 
associated with thick, fast-growing melanomas. Since this subtype does not develop in the typical 
high-risk groups, but often in older male patients with few solar lentigines and nevi. Clinically, these 
fast growing melanomas are often amelanotic symmetrical lesions, lacking typical clinical and 
dermoscopic features, which makes them more difficult to diagnose in an early phase.65 Such lesions 
would be missed by one-time or routine screenings, inherent to their fast growth in a number of 
weeks. However, the awareness and early detection of slow- or medium growing lesions may impact 
survival in a positive way. The most common histological subtype of MM, namely the superficial 
spreading melanoma, also develops a nodular and aggressive component, since more than 50% of 
metastatic patients had initially a superficial spreading MM.70 The authors conclude that as superficial 
spreading melanomas are growing over a longer period to become invasive and potentially metastatic, 
there might be a chance to focus prevention programs not only on fast growing tumors but also on 
slowly changing tu ors.  
It is argued that the increasing incidence of thin melanomas and the stable mortality are actually a 
result of a steady improvement in our ability to diagnose MM early, with a resulting continuous 
decline in the average thickness of melanoma at diagnosis. Following the aforementioned argument, 
the proportion of thick melanomas should also steadily decrease. Unfortunately, this is not the case 
and the absolute number of thick melanomas is not declining up to now.71 A combination of factors 




may explain the observed trend; increased awareness, diagnostic drift and overdiagnosis of in situ and 
thin melanomas as mentioned before, or as a third argument, the fact that thick melanomas are a 
continually smaller proportion of a continually increasing number of melanomas and lastly a changing 
tumor biology as suggested by the group of Autier et al. The authors studied cohort effects of 
melanoma mortality that support the drastic effect of UV exposure at young age in the MM biology. 
The group hypothesizes that melanomas will become gradually less aggressive and deadly since the 
importance of UV protection in children became highly recognized.72 Nevertheless, the beneficial 
effect of early detection of MM and NMSC must also be seen in the light of alternative non-survival 
outcomes, including reduced morbidity and enhanced QOL as suggested by Lewandrowski et al.73 Our 
research focused on the intermediary outcome of cost-effectiveness, taking all these alternative non-
survival benefits into account. We believe that in the current health economic climate such endpoints 
are of great importance to support the decision makers in their assessment of screening initiatives.  
Participation in screening is an important concern in all cancer screenings, and especially in individuals 
of lower socio-economic backgrounds. In Belgium, the health care system is organized around primary 
care by a general practitioner, holding a global medical record of the majority of his patients. Because 
of the latter, patients are encouraged to have a primary care physician that is the first contact in case 
of medical problems. Currently, a fee-for-service applies in Belgium for primary care, although it is 
known that this encourages over-servicing.74–76 A mixed payment incentive such as fee-for-service and 
specific payments to meet population health targets is known to effect providers behavior and 
increase quality, especially for chronic pathologies (such as diabetes and hypertension).77,78 In addition 
target-based prevention modules (i.e. screening for colon cancer, vaccination and other preventive 
measures) including for skin cancer, could increase the effectiveness and participation of population-
based prevention strategies significantly.  
Screening physicians and dermoscopy 
The presented clinical screening study was performed by dermatologists highly trained in dermoscopy. 
Because of the known interaction between the o ser er s training and accuracy of the technique, the 
diagnostic performance by Flemish dermatologists was examined. In chapter 7 we described our 
results based on the image analyses in a web-based application, demonstrating respectively clinical 
and dermoscopic photographs of the lesions presented at the LDS screening. A high sensitivity and 
specificity was observed of respectively 84.6 and 93.5%. Surprisingly, we could not demonstrate 
additional benefit of using dermoscopy in terms of NNE, the most important side effect of screening. 
Due to the method of case collection, we cannot exclude the possible inclusion of lesions with more 
clear visual and clinical features. On the other hand one could argue, because based on an early 
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detection initiative, relative smaller lesions, more difficult to diagnose were included. Dermoscopy 
however significantly increased the certainty about making a correct diagnosis, and this was mainly 
the ase for se orrhei  keratosis, Bo e s disease a d MM.  
Our findings suggest it would be  interesting to repeat this study among trained general practitioners 
to evaluate the diagnostic accuracy and its impact on the early detection of skin cancer in general 
practice, where according to some a need for diagnostic tools exists.79,80 In our opinion, the most 
representative study is performed in a real-life setting, since it is known that a digital evaluation and 
paucity of clinical information can influence performance in a negative way, namely improved 
sensitivity with decreased specificity. In addition, the adequate amount of training should be 
investigated, since significant differences are reported in literature, and it is acknowledged that the 
level of training needed to ameliorate sensitivity is relatively less than for improving specificity.81,82  
 
RECOMMENDATIONS FOR FURTHER RESEARCH 
Our findings inevitably led to several additional questions that are important to address in future 
research. Below, we provide a non-limitative overview of these questions and lacunas that arose in the 
setting of our analyses.  
Mortality as a result of NMSC is rare, though the disease influences QOL in a distinct way. The current 
generic instruments to measure the QOL are lacking in sensitivity to correctly calculate the impact. 
Since these tumors are frequently located in important esthetic units and demand surgery, BCC and 
SCC result in distinct functional limitations and cosmetic concerns not captured in the classical generic 
instruments such as the EQ-5D. Several dermatology-specific or disease-specific instruments have 
been studied in this respect; the dermatology life quality index (DLQI), Skindex-16 and skin cancer 
index (SCI).83–87 It seems that the SCI is the most sensitive and captured significant changes in all 
subscales as compared to the DLQI.88 Efforts should be made to generate utility weightings for these 
instruments to develop more robust cost-effectiveness analyses. In addition to more accurate QOL 
data, the main hazard remains the poor registration of NMSC in most countries, including Belgium. As 
only the first histological NMSC is registered, subsequent tumors are not included, and multiple 
tumors are not differentiated, we are continuously underestimating the true burden of NMSC. Flohil 
et al. performed an appreciable audit in Europe, demonstrating that up to 24.1% of the BCCs in 
Europe are not histologically confirmed.89 Registration of NMSC should be improved and consensus 
standards need to be developed. 
Unraveling the biology and natural progression of the different types of skin cancer would benefit 
preventive studies in a significant way. As mentioned before, the progression of BCC was determined 




as 1 cm per 3.8 years or 1.2 mm per 6 months, based on the results of Kirkup et al.90 The transition risk 
from SCC stage 0-II to stage III or IV was estimated as 0.5% per 6 months based on the estimation of 
Smoller et al. (1-2% per year).91 For MM we used a calibration method based on the total number of 
deaths annually, in the absence of accurate measurements. The one-way sensitivity analyses show 
that for skin cancer screening, natural progression and utilities of MM are the most important 
variables influencing the ICER. To more adequately assess the effect of prevention, efforts should be 
made to examine these parameters more thoroughly. In addition to the growth rate, identifying 
patients who are at risk for developing a more aggressive or deadly course of skin cancers by 
predictive risk factors or biomarkers would benefit the research field.92–94  
Knowledge about suitable interventions for permanently changing the populatio s behavior is 
needed. Several interventions use a multi-component approach that combines strategies aimed at 
individuals, mass-media campaigns, environment and policy. The yearly Euromelanoma campaign, a 
well-organized opportunistic early detection initiative, its main objective is to inform and raise 
awareness in the general population using varied media. Research and surveillance is needed to 
determine the contribution of individual components to help prioritize and maximize the use of 
limited resources. Current evidence suggests that intentional tanning is strongly associated with a 
preference for tanned skin and other appearance-focused behaviors; future messages could focus on 
the appearance-related harms of excessive UV exposure.95 To reduce harms from indoor tanning one 
could examine the use of topical, sunless tanning products, although the effect of dihydroxyacetone 
inhalation is unknown and the promotion of sunless tanning products does not address the underlying 
social norms that drive tanning behaviors.  
Randomized controlled trials documenting the effect of screening on mortality are absent. Studies 
with sufficient power and long-term follow-up are needed, though due to the relatively low incidence 
of MM and mortality such trials would take a long time and are costly.73 The first large European pilot 
study examining an organized population based screening was an ecological study organized in 2003-
2004 with a 19% participation rate.96 A reduction in mortality was observed in 2008-2009 for the 
entire state,97 however criticized to be too close to the intervention.62  Indeed, one could assume that 
since the lag-time for breast- and prostate cancer is respectively 10.7 years and 10.3 years before one 
death can be prevented per 1000 patients screened,96 definite consensus on the presence - or 
absence - of a reduction in mortality is still some years ahead. Especially, since the aforementioned 
estimations were estimated in a controlled group setting at higher incidence of disease. A feasibility 
study published in 2000, calculated that 560 000 adults should be randomized in an intervention and 
control group, to find a mortality reduction of 20% in 15 years.98 Overdiagnosis and increased 
treatment of clinically insignificant cancers should be a major focus, in order to accurately assess all 
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key aspects of skin cancer screening. Further research should be designed comparing screened versus 
unscreened individuals head-to-head. In addition, new techniques, that are less operator dependent 
such as digital image analysis systems, could offer interesting novel perspectives in the setting of skin 
cancer screening.  
As mentioned at the start of this dissertation, skin cancer prevention is currently a major subject of 
interest. The presented research was designed to examine the highly discussed interventions from a 
clinical and health-economical point of view. It is our firm hope that the presented results will help 
researchers in future studies to determine the most opportune and cost-effective strategy in 
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Cost-of-illness study based on patient questionnaires 
In order to estimate the total economic burden of skin cancer on society, we conducted a bottom-up 
cost-of-illness study, based on retrospective information from Belgian patient questionnaires being 
gathered from 1st March 2015 until  30th June 2015. Dermatologists and oncologists working in general 
and university hospitals, small (< 200 beds), medium (200-400 beds) or big (> 400 beds) hospitals, as 
well as private practices were recruited in December 2014. These physicians were asked to give skin 
cancer patients the information about the study and to hand out the questionnaires to the patients. 
Eligible patients were those who were 18+, had a diagnosis of MSC, BCC and SCC maximum ten years 
ago and who presented to a participating physician between 1st March 2015 and 30th June 2015. 
Patients were asked questions about their medical consumption for their skin disease during the last 
six months, as well as productivity loss and quality of life. Questions concerned the number of 
consultations, number and type of examinations, drug use, number of days absent from work and 
health-related quality of life (based on the EQ-5D-5L questionnaire). Ethics committee approval and 
patient informed consents were obtained.  
For some patient groups (all stages of SCC and the more severe lesions of MSC) the response rate was 
low. To increase the power of the study, we calculated the direct cost based on guidelines produced 
by EURODERM as well as dermatologist and oncologist expert opinions. For these groups with low 
sample, we constructed a care pathway that reflected current management patterns as accurate as 
possible. Also for large and aggressive BCCs, there was a low response rate, so from the cost of small 
BCC (<1cm) we calculated the cost of larger and aggressive BCCs based on the ratios reported by 


































                










































































































































































































































































































































             
Correction factor IKNL 
prevalence BCC/SCC 0.51 
Based on mortality 
(IARC) and 
incidence (2010) 
BE versus NDL 












18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
INCIDENCE                 
BCC M 0.001% 0.004% 0.013% 0.024% 0.053% 0.101% 0.107% 
3 
BCC F 0.002% 0.006% 0.024% 0.029% 0.055% 0.075% 0.078% 
3
 
SCC M 0.000% 0.000% 0.001% 0.005% 0.018% 0.053% 0.123% 
3
 
SCC F 0.000% 0.000% 0.002% 0.006% 0.017% 0.038% 0.076% 
3
 
MSC I M 0.002% 0.004% 0.007% 0.010% 0.013% 0.019% 0.017% 
4
 
MSC I F 0.005% 0.011% 0.017% 0.016% 0.015% 0.017% 0.009% 
4
 
           
NATURAL PROGRESSION          
BCC 12.5% 
5 
SCC stage 0-II => III 1.0% 
6 
SCC stage III => IV 7.0% calibration 
MSC I/II => II/III 0.8% calibration 
MSC I/II => IV 0.7% calibration 












18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
PROGRESSION TO METASTASES, AFTER TREATMENT          
SCC 0.23% 
7 
MSC stage I  => MSC stage III  0.07% 
8 
MSC stage I  => MSC stage IV 0.07% 
8 
MSC stage II  => MSC stage III  0.47% 
8 
MSC stage II  => MSC stage IV 0.47% 
8 
MSC stage III  => MSC stage IV 2.26% 
9 
         
  
RR OF DEVELOPING MSC AFTER DIAGNOSES OF NMSC         
  
MSC after BCC    3.28    
10 
MSC after SCC 3.62 
10 
           
MORTALITY RATES    
Mortality due to  skin cancer  (first year)          
MSC stage IV 26.66% 
11
 corrected for new therapies 
SCC stage IV 13.55% 
12 
Mortality due to  skin cancer  (follow-up)          
MSC stage IV M: 12.45%   F: 7.65% 
11
 corrected for new therapies 
SCC stage IV M: 6.33%   F: 9.71% 
13 
Mortality due to other causes          
M 0.04% 0.05% 0.12% 0.33% 0.76% 1.97% 3.85% Belgian life tables 2012 
F 0.01% 0.02% 0.04% 0.13% 0.30% 0.71% 2.46%   




Health-related quality of life: utilities 
Undiagnosed BCC, SCC stage 0-II and MSC stage 0-I were assigned the same utility as the population 
norm, which is 0.81.14 The utility for undiagnosed SCC stage III-IV and MSC stage III-IV was calculated 
as the average of the population norm and the utility for diagnosis and treatment. There were too few 
returned patient questionnaires for SCC and MSC stage II-III and IV to have sufficient sample power, so 
the utilities of these stages (diagnosed) were calculated based on the ratio of the utilities in these 
stages compared to stage I, as described by Tromme et al.15 The utility for BCC patients, who are in 
treatment or intense follow-up is derived from the study of Gaulin et al.16 The utility for patients in 
long-term follow-up for BCC, SCC 0-II and MSC 0-I and II was defined to be the same as the population 
norm, since we assume that once the lesion has been excised, the quality-of-life will return to baseline 
























Table A2. Utilities assigned to the model states 
Parameter Utility  Source 
General population 0.812 
14 
BCC undiagnosed 0.812 
 
D&T BCC  0.790 
16 
intensive FU BCC  0.790 
16 
longterm FU BCC  0.812 General population (assumption) 
SCC 0-II undiagnosed 0.812 General population (assumption) 
SCC III undiagnosed 0.631  
SCC IV undiagnosed 0.651  
SCC 0-II D&T 0.532 patient questionnaires (n=7) 
SCC III D&T 0.450  
SCC IV D&T 0.490  
SCC 0-II intense FU 0.707 patient questionnaires (n=11)
1
 
SCC III intense FU 0.620  
SCC IV intense FU 0.702  
SCC 0-II longterm FU 0.812 General population (assumption) 
SCC III longterm FU 0.617  
SCC IV longterm FU 0.699  
MSC 0-I undiagnosed 0.812  
MSC IIundiagnosed 0.812  
MSC III undiagnosed 0.672  
MSC IV undiagnosed 0.695  
MSC 0-I D&T 0.682 patient questionnaires (n=15)
1
 
MSC II D&T 0.575  
MSC III D&T 0.531  
MSC IV D&T 0.579  
MSC 0-I intense FU 0.701 patient questionnaires (n=43)
1
 
MSC II intense FU 0.695  
MSC III intense FU 0.609  
MSC IV intense FU 0.690  
MSC 0-I longterm FU 0.812 General population (assumption) 
MSC II longterm FU 0.812  
MSC III longterm FU 0.665  
MSC IV longterm FU 0.753  











Natural evolution of skin cancer 
Information on the natural evolution of undiagnosed melanoma tumours is lacking. Therefore, we 
applied model calibration by manually searching for the best combination of parameter values, as to 
match the modelled outputs to the observed evidence on the outputs, in this case the number of 
melanoma deaths. In Belgium, every year about 450 people die from skin cancer. Over 20 year this 
would mean about 9,000 deaths (without taking the rising trend in incidence into account). Since SCC 
lesions are under registered in Belgium, the actual number of deaths is estimated to be higher. The 
output of the model, in terms of number of skin cancer deaths after 20 year, was matched to this 
expected 9,000 deaths based on estimation of the natural progression. When this natural progression 
to MSC stage II or III was set at 0.8% and to stage III at 0.7% per six months, the output of the model 
showed 11,100 deaths over 20 years, which is in line with the estimated number of deaths in reality. 
Natural progression of BCC was derived from the study of Kirkup et al.5, showing an evolution of  1 cm 
per 3.8 years or 1.2 mm per 6 months. The transition risk from SCC stage 0-II to stage III or IV was 
estimated as 0.5% per 6 months based on the estimation of Smoller et al (1-2% per year).6 The 
probability of spontaneous clinical detection was defined as the average prevalence of diagnosed skin 





Figure A1a. visualization of the Markov model; BCC: Basal cell carcinoma; FU: Follow-up; D & T: 
Diagnosis and treatment. Light-colored states correspond to undiagnosed cancer *FU is divided in 






Figure A1b. visualization of the Markov model; SCC: Squamous cell carcinoma; FU: Follow-up; D & T: 
Diagnosis and treatment. Light-colored states correspond to undiagnosed cancer *FU is divided in 
intense FU (3 cycles) and long-term FU  ** FU is divided in intense FU (8 cycles) and long-term FU 










Figure A1c. visualization of the Markov model; MSC: melanoma skin cancer; FU: Follow-up; D & T: 
Diagnosis and treatment. Light-colored states correspond to undiagnosed cancer *FU is divided in 












Figure A2a: One-way sensitivity analysis: tornado-diagram showing the most influencing parameters 
on the cost-effectiveness of a prevention campaign in females. Dark-colored bars = maximum 
parameter value; light-colored bars = minimum parameter value  [range of variation in relative terms]; 





Figure A2b: One-way sensitivity analysis: tornado-diagram showing the 5 most influencing parameters on the 
cost-effectiveness of a total ban on sunbed use  in females. Dark-colored bars = maximum parameter value; 
light-colored bars = minimum parameter value [range of variation in relative terms]; D&T: diagnosis & 










Figure A3: Cost-effectiveness planes displaying the results of the 5,000 simulations. Each point depicted in 
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Natural evolution of skin cancer 
Information on the natural evolution of undiagnosed melanoma tumours is lacking. Therefore, we 
applied model calibration by manually searching for the best combination of parameter values, as to 
match the modelled outputs to the observed evidence on the outputs, in this case the number of 
melanoma deaths. In Belgium, every year about 450 people die from skin cancer. Over 20 year this 
would mean about 9 000 deaths (without taking the rising trend in incidence into account). Since SCC 
lesions are underregistered in Belgium, the actual number of deaths is estimated to be higher. The 
output of the model, in terms of number of skin cancer deaths after 20 year, was matched to this 
expected 9,000 deaths based on estimation of the natural progression. When this natural progression 
to MSC stage II or III was set at 0.8% and to stage III at 0.7% per six months, the output of the model 
showed 11,100 deaths over 20 years, which is in line with the estimated number of deaths in reality. 
Natural progression of BCC was derived from the study of Kirkup et al.1, showing an evolution of  1 cm 
per 3.8 years or 1.2 mm per 6 months. The transition risk from SCC stage 0-II to stage III or IV was 



























18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
PARTICIPATION RATE                 
TBE males 8.8% 13.6% 14.2% 20.5% 24.1% 18.3% 5.4% 
3 
TBE females 14.5% 20.1% 20.3% 24.0% 27.1% 18.6% 4.6% 
3 
LDS males 1.5% 2.1% 2.2% 3.8% 5.9% 3.7% 2.6% 
3 
LDS females 1.8% 3.3% 3.7% 2.7% 5.5% 2.7% 0.9% 
3 
           
 
TEST CHARACTERISTICS          
 
sensitivity dermoscopy BCC 83% (73%-93%) 
4 
SCC 83% (73%-93%) 
4 
MSC 74% (62%-86%) 
4 
specificity dermoscopy BCC 86.5% (85%-88%) 
4 
SCC 86.5% (85%-88%) 
4 









18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
PREVALENCE UNDIAGNOSED LESIONS                 
 BCC <1cm  M 0.015% 0.135% 0.377% 0.699% 1.528% 3.022% 3.809% 3 
 BCC <1cm  F 0.035% 0.150% 0.633% 0.799% 1.419% 2.033% 2.275% 3 
 BCC 1-2cm M 0.008% 0.075% 0.209% 0.387% 0.846% 1.674% 2.109% 3 
 BCC 1-2cm F 0.019% 0.083% 0.350% 0.443% 0.786% 1.126% 1.260% 3 
 BCC >2cm M 0.002% 0.021% 0.059% 0.109% 0.238% 0.470% 0.592% 3 
 BCC >2cm F 0.005% 0.023% 0.098% 0.124% 0.221% 0.316% 0.354% 3 
 BCC agr. hist. M 0.011% 0.101% 0.282% 0.522% 1.141% 2.257% 2.844% 3 
 BCC agr. hist. F 0.026% 0.112% 0.472% 0.597% 1.059% 1.518% 1.699% 
3 
 SCC stage 0-II M 0.000% 0.001% 0.002% 0.013% 0.048% 0.268% 0.967% 
3 
 SCC stage 0-II F 0.001% 0.002% 0.010% 0.033% 0.095% 0.222% 0.419% 
3 
 SCC stage III M 0.000% 0.000% 0.000% 0.001% 0.006% 0.031% 0.112% 
3 
 SCC stage III F 0.000% 0.000% 0.001% 0.004% 0.011% 0.026% 0.049% 
3 
 SCC stage IV M 0.000% 0.000% 0.000% 0.000% 0.001% 0.007% 0.026% 
3 
 SCC stage IV F 0.000% 0.000% 0.000% 0.001% 0.003% 0.006% 0.011% 
3 
 MSC stage I M 0.065% 0.173% 0.328% 0.527% 0.805% 1.156% 1.132% 
3 
 MSC stage I F 0.128% 0.311% 0.488% 0.543% 0.704% 0.767% 0.502% 
3 
 MSC stage II M 0.019% 0.049% 0.094% 0.151% 0.230% 0.331% 0.324% 
3 
 MSC stage II F 0.029% 0.070% 0.109% 0.122% 0.158% 0.172% 0.112% 
3 
 MSC stage III M 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
3 
 MSC stage III F 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
3 
 MSC stage IV M 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
3 
 MSC stage IV F 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
3 
             
Correction factor IKNL prevalence BCC/SCC 0.51 
Based on mortality (IARC) and 












18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
INCIDENCE                 
BCC M 0.001% 0.004% 0.013% 0.024% 0.053% 0.101% 0.107% 
5 
BCC F 0.002% 0.006% 0.024% 0.029% 0.055% 0.075% 0.078% 
5 
SCC M 0.000% 0.000% 0.001% 0.005% 0.018% 0.053% 0.123% 
5 
SCC F 0.000% 0.000% 0.002% 0.006% 0.017% 0.038% 0.076% 
5 
MSC I M 0.002% 0.004% 0.007% 0.010% 0.013% 0.019% 0.017% 
6 
MSC I F 0.005% 0.011% 0.017% 0.016% 0.015% 0.017% 0.009% 
6 
         
  




SCC stage 0-II => III 1.0% 
2 
SCC stage III => IV 7.0% calibration 
MSC I/II => II/III 0.8% calibration 
MSC I/II => IV 0.7% calibration 










18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
PROGRESSION TO METASTASES,  FU          
SCC 0.23% 
7 
MSC stage I  => MSC stage III  0.07% 
9 
MSC stage I  => MSC stage IV 0.07% 
9 
MSC stage II  => MSC stage III  0.47% 
9 
MSC stage II  => MSC stage IV 0.47% 
9 
MSC stage III  => MSC stage IV 2.26% 
9 
         
  
RR OF DEVELOPING MSC AFTER DIAGNOSES OF NMSC         
  
MSC after BCC    3.28    
11 
MSC after SCC 3.62 
11 
           
MORTALITY RATES    
Mortality due to  skin cancer  (first year)          
MSC stage IV 26.66% 
12
, corrected for new therapies 
SCC stage IV 13.55% 
13 
Mortality due to  skin cancer  (follow-up)          
MSC stage IV M: 12.45%   F: 7.65% 
12
, corrected for new therapies 
SCC stage IV M: 6.33%   F: 9.71% 
14 
Mortality due to other causes          
M 0.04% 0.05% 0.12% 0.33% 0.76% 1.97% 3.85% Belgian life tables 2012 










Table A3. Cost input parameters: Direct costs per 6 months, per stage and phase  
DIRECT COSTS diagnosis & treatment intense FU longterm FU 
  HC payer patient HC payer patient HC payer patient 
BCC <1cm € 196 € 34 € 119 € 22 € 82 € 46 
BCC 1-2cm € 211 € 37 € 128 € 24 € 89 € 49 
BCC>2cm € 227 € 40 € 137 € 26 € 95 € 53 
BCC agressive histology € 227 € 40 € 137 € 26 € 95 € 53 
SCC 0-II € 243 € 17 € 18 € 13 € 9 € 7 
SCC III € 1,396 € 217 € 91 € 24 € 45 € 12 
SCC IV € 1,659 € 262 € 91 € 24 € 45 € 12 
MSC I € 1,891 € 161 € 385 € 71 € 231 € 41 
MSC II € 2,119 € 244 € 318 € 60 € 258 € 43 
MSC III € 4,737 € 200 € 1,082 € 72 € 822 € 72 











Table A4. Cost input parameters: Indirect costs due to productivity loss per 6 months, per stage and phase  
INDIRECT COSTS diagnosis & treatment intense FU longterm FU 
  transport prod. loss transport prod. loss transport prod. loss 
BCC <1cm € 43 € 0 € 7 € 0 € 6 € 0 
BCC 1-2cm € 17 € 0 € 5 € 0 € 45 € 0 
BCC>2cm € 76 € 0 € 30 € 0 € 0 € 0 
BCC agressive histology € 21 € 0 € 18 € 0 € 38 € 0 
SCC 0-II € 55 € 0 € 8 € 13 € 42 € 0 
SCC III € 317 € 0 € 40 € 24 € 208 € 0 
SCC IV € 377 € 0 € 40 € 24 € 208 € 0 
MSC I € 102 € 2 663 € 30 € 1 872 € 33 € 26 
MSC II € 69 € 1 213 € 12 € 1 872 € 32 € 26 
MSC III € 98 € 6 591 € 34 € 11 864 € 81 € 3 401 
MSC IV € 274 € 6 591 € 152 € 16 688 € 106 € 3 401 
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The main objective of this dissertation was to gain more insight in the preventive landscape of skin 
cancer in Belgium. We examined the 3 most common forms of skin cancer, malignant melanoma 
arising from the melanocytes, and non-melanoma skin cancer (NMSC) that originate from 
keratinocytes (basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)). Prevention can be 
aimed at the healthy population resulting in primary prevention strategies, or trying to detect a 
disease at an earlier state, being secondary prevention. We started mapping the current health as 
economic burden of melanoma as well as NMSC in Belgium.  
In Chapter 3 the results of the cost-of illness study are presented; the  economic  burden  of  skin  
cancer  in  2014  in  Belgium  was estimated  at €107 million (direct costs: €78 million; indirect costs: 
€29 million), with a cumulative cost of €3.2 billion in 2034. The majority of this total cost was due to 
melanoma (65%). We found that the prevalence of skin cancer in Belgium will triple in the next 20 
years. A model examining the effects of a UV protection campaign and ban on sunbeds showed that 
both would  lead  to  a  gain  in  quality-adjusted  life-years (QALY) and  cost-savings,  making them  
dominant  strategies. The budget impact analysis revealed that for every euro invested in the 
prevention campaign, €3.6 would be saved on the long-term for the healthcare payer. 
In addition to primary prevention, we examined the clinical effectiveness of two population based skin 
cancer screening methods in Chapter 4. We compared a lesion-directed screening method (LDS) to a 
standard total body examination (TBE). Participation rate was higher in the TBE group compared to 
the LDS group (17.9% versus 3.3%). Detection rate did not differ significantly between the two groups 
per 100 participants (2.3 TBE versus 3.2 LDS), but the diagnostic yield per 100 invitees for TBE was 
0.42 and 0.08 for the LDS method. LDS was as hypothesized 5.6 times less time-consuming than TBE. 
For this reason we concluded that LDS by dermatologists could be an alternative screening method in 
health care systems with limited budget and/or long waiting lists. 
In Chapter 5 we compared these two screening methods as to their cost-effectiveness using Markov 
Models. We found that both screening strategies produced a gain in QALYs, resulting in incremental 
cost-effectiveness ratios (ICERs) of €33 072/QALY in males and €18 687/QALY in females for TBE and 
€34 836/QALY in males and €19 470/QALY in females for LDS. These ICERs are moderately cost-
effective at a Belgian willingness-to-pay threshold of €35 000/QALY. We concluded that a TBE in 
general adult population (especially in females) is the most cost-effective strategy and is predicted to 







Several screening initiatives focus on melanoma, but as demonstrated in chapter 3, NMSC and 
especially BCC also produce a large cost and burden for the health care system. For this reason in 
Chapter 6 we addressed the question if it is useful in to screen for BCC – in which no effect of 
mortality is absent – in addition to melanoma and SCC. We examined this question based on the WHO 
criteria for screening and found that BCC slowly increases in size with time with a median increase in 
diameter of 0.5 mm over 10 weeks. There seem to be important delays in diagnosis with a mean time 
from appearance of the skin lesion to seeking medical attention ranging from 19.8 to 25 months and 
size is one of the major determinants in the choice of an effective treatment and the associated cost 
especially for facial BCC.  
The final part of this thesis describes the results of an observational study examining the main 
diagnostic aid in detecting skin cancer being dermoscopy. We questioned all Flemish dermatologist 
about their use an examined the diagnostic accuracy. The majority (89.7%) of dermatologists uses 
their dermatoscope daily. The study showed that dermoscopy dramatically increased sensitivity for 
skin cancer diagnosis from 70.6% to 84.6%, but also with small but significant decrease in specificity of 
3.5%. To detect one skin cancer 5.23 lesions with suspicion had to be excised. Dermoscopy 
significantly increased the certainty about making a correct diagnosis, and this was most the case for 
seborrheic keratosis, Bowen’s disease and melanoma. However, surprisingly we could not 
demonstrate a significant reduction in the number of excisions in daily practice using dermoscopy.  
In conclusion primary prevention is cost-saving and a missed opportunity to control the skin cancer 
epidemic. Secondary prevention offering a total body examination, including BCC screening is 












































De hoofddoelstelling van dit proefschrift is inzicht te verwerven in het preventieve landschap van 
huidkanker in België. We hebben hierbij de 3 meest voorkomende vormen van huidkanker onderzocht 
met name maligne melanoom, uitgaande van de melanocyten en de niet-melanome huidkanker die 
ontstaan uit de keratinocyten (basaalcel- en spinocellulaire carcinomen). Preventie kan gericht zijn 
naar gezonde individuen en wordt dan onder de noemer van primaire preventieve gedefinieerd, of 
preventieve interventies kunnen het doel hebben de ziekte vroegtijdig op te sporen en behandelen. 
Deze laatste interventies, zoals ook screening, vallen onder secundaire preventie.  
In hoofdstuk 3 hebben we getracht de huidige impact van huidkanker in België in kaart te brengen. 
Deze kostenstudie heeft aangetoond dat de totale kost van huidkanker in 2014, €107 miljoen 
bedraagt (directe kosten: €78 miljoen; indirecte kosten: €29 miljoen), met een cumulatieve kost van 
€3.2 miljard in 2034. De meerderheid (65%) van deze kost werd veroorzaakt door melanomen. Verder 
zagen we dat de prevalentie van huidkanker in België zal verdrievoudigen over de volgende 20 jaar. 
Het modelleren van 2 primaire preventiecampagnes toonde aan dat zowel UV protectie maatregelen 
als een totaal verbod op zonnebanken een netto besparing zou opleveren. Voor iedere euro die 
geïnvesteerd wordt in de campagnes zal op lange termijn €3.6 uitgespaard worden.  
Naast deze primaire preventiestrategieën hebben we de klinische effectiviteit van 
huidkankerscreening in België onderzocht. Hiervoor werden 2 screeningsmethoden in een 
populatiegebaseerde setting vergeleken, deze resultaten zijn terug te vinden in hoofdstuk 4. Een 
letselgerichte screening werd hiervoor vergeleken met een standaard totale huidinspectie. De 
participatie was duidelijk hoger in de totale huidinspectie groep (17.9% versus 3.3%), de detectie ratio 
was niet significant verschillend per 100 deelnemers (2.3 TBE versus 3.2 LDS). Wanneer de 
operationele effectiviteit vergeleken werd, is het duidelijk dat een totale huidinspectie de meeste 
maligne letsels detecteert in de uitgenodigde populatie (0.42 versus 0.08) per 100 genodigden. De 
letselgerichte screening was 5.6 maal meer efficiënt wat betreft tijdsbesteding, en op basis van deze 
resultaten konden we concluderen dat letselgerichte screening een alternatieve en meer kosten-
effectieve screeningsmethode kan zijn, vooral in een gelimiteerde gespecialiseerde zorg.  
In hoofdstuk 5 werd de kosteneffectiviteit van deze twee screeningsmethoden onderzocht en 
vergeleken aan de hand van Markov modellen. Beide screeningsstrategiën resulteerden in een winst 
aan ‘quality-adjusted life years’ (QALY) en een incrementele kosten-effectiviteitsratio (IKER) voor een 
totale huidinspectie van €33 072/QALY voor mannen en €18 687/QALY voor vrouwen. De IKER voor 




resultaten kunnen we interpreteren als matig kosteneffectief gezien de drempel voor 
aanvaardbaarheid in België €35 000/QALY is. Een totale huidinspectie in de algemene volwassen 
populatie (en voornamelijk vrouwen), lijkt de meest kosteneffectieve methode.  
De huidige screeningsintitiatieven focussen voornamelijk op melanomen, maar zoals aangetoond in 
hoofdstuk 3 zijn de niet-melanome vormen van huidkanker, en vooral de basaalcel carcinomen 
verantwoordelijk voor een belangrijk deel van het gezondheidszorgbudget. In hoofdstuk 6 hebben we 
onderzocht of het nuttig is basaalcel carcinomen op te nemen in screeningsinitiatieven, gezien er geen 
effect op mortaliteit verwacht kan worden. Aan de hand de WHO criteria werd systematisch de 
huidige evidentie bestudeerd; deze toonde dat basaalcel carcinomen traag groeiende tumoren zijn 
met een mediane toename in diameter van 0.5 mm over 10 weken. Er is een belangrijke latentie 
tussen het verschijnen van het letsel en de diagnose, die varieert van 19.8 tot 25 maanden. De huidige 
literatuur toont ook aan dat tumordiameter een van de belangrijkste determinanten is in de keuze van 
de behandeling, de effectiviteit en geassocieerde kosten. Dit is voornamelijk zo voor tumoren 
gelokaliseerd in het gelaat, meer specifiek de H-zone. Het verband tussen tumor grootte en 
behandelingsoutcome voor basaalcel carcinomen gelokaliseerd op het lichaam is minder overtuigend.  
In het laatste hoofdstuk beschrijven we de resultaten van een studie over de diagnostische 
accuraatheid van dermoscopie. Door middel van een webapplicatie werden alle Vlaamse 
dermatologen uitgenodigd om deel te nemen aan deze observationele studie. De meerderheid van de 
dermatologen (89.7%) gebruikt dermoscopie in hun dagelijkse praktijk. We vonden een significante 
stijging in sensitiviteit (70.6% naar 84.6%), bij het gebruik van dermoscopie tov. de klinische evaluatie 
van letsels verdacht voor huidkanker. Dit gaat gepaard met een kleine, maar significante daling in 
specificiteit van 3.5%. Om één huidkanker te detecteren moeten 5.23 letsels geëxciseerd worden. 
Dermoscopie verhoogt significant de zekerheid bij het maken van de correcte diagnose, en dit vooral 
de diagnose verruca seborrhoica, ziekte van Bowen en melanomen. We konden echter geen daling in 
het aantal excisies aantonen als gevolg van het gebruik van dermoscopie.  
Als besluit kunnen we stellen dat op heden, primaire preventie de meest kosten-effectieve vorm van 
preventie is om de huidkankerepidemie te bestrijden. Screening door middel van totale huidinspectie, 












































Niets gebeurt tweemaal en niets zal tweemaal gebeuren. 
Wislawa Szymborska (Roepen naar Yeti, 1957) 
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